

Scientific Programme

Wednesday, 06 November 2019

Industry sponsored session
08:00 - 12:00

Boston 1-3

Industry sponsored session

(For more details, please visit the conference website)

Scientific Programme

Pre-conference workshop/course
09:30 - 16:00

Singapore

EACS pre-educational course

Convener: EACS

Access to the webcasted session:

[Introduction](http://resourcelibrary.eacs.cyim.com?mediald=77962)
[Zzzzzzz: Sleep issues beyond efavirenz: Clinical case](http://resourcelibrary.eacs.cyim.com?mediald=77963)
[Zzzzzzz: Sleep issues beyond efavirenz: Overview](http://resourcelibrary.eacs.cyim.com?mediald=77965)
[Zzzzzzz: Sleep issues beyond efavirenz: Questions](http://resourcelibrary.eacs.cyim.com?mediald=77966)
[Non-AIDS respiratory issues: Clinical case](http://resourcelibrary.eacs.cyim.com?mediald=77969)
[Non-AIDS respiratory issues: Overview](http://resourcelibrary.eacs.cyim.com?mediald=77974)
[Non-AIDS respiratory issues: Questions](http://resourcelibrary.eacs.cyim.com?mediald=77975)
[Dermatology in the modern era of HIV: Clinical case](http://resourcelibrary.eacs.cyim.com?mediald=77986)
[Dermatology in the modern era of HIV: Overview](http://resourcelibrary.eacs.cyim.com?mediald=77987)
[Dermatology in the modern era of HIV: Questions](http://resourcelibrary.eacs.cyim.com?mediald=77988)
[Chem sex: East and West; Eastern European perspective](http://resourcelibrary.eacs.cyim.com?mediald=77989)
[Chem sex: East and West: Western European perspective](http://resourcelibrary.eacs.cyim.com?mediald=77990)
[Chem sex: East and West: Questions](http://resourcelibrary.eacs.cyim.com?mediald=77991)
[Using new ARVs in real life: Clinical case + Overview](http://resourcelibrary.eacs.cyim.com?mediald=77994)

[Using new ARVs in real life: Questions](http://resourcelibrary.eacs.cyim.com?mediald=77995)

[YING Session](http://resourcelibrary.eacs.cyim.com?mediald=78001)

[EACS Educational programme and opportunities Intro/background to YING](http://resourcelibrary.eacs.cyim.com?mediald=77997)
[Introduce YING Faculty and panel discussion: Q&A](http://resourcelibrary.eacs.cyim.com?mediald=77998)
[Close](http://resourcelibrary.eacs.cyim.com?mediald=78000)

Chairs:

Tristan Barber, United Kingdom
Laura Waters, United Kingdom

Coffee break

09:30 - 10:00

Introduction

Tristan Barber, United Kingdom
Laura Waters, United Kingdom

10:00 - 10:10

Zzzzzzz: Sleep issues beyond efavirenz

Scientific Programme

Clinical case Nina Vora, United Kingdom	10:10 - 10:30
Overview Hugh Selsick, United Kingdom	10:30 - 10:50
Questions Panel	10:50 - 11:00
Non-AIDS respiratory issues	
Clinical case Jochen Schneider, Germany	11:00 - 11:20
Overview James Brown, United Kingdom	11:20 - 11:40
Questions	11:40 - 11:50
Lunch break	11:50 - 12:20
Dermatology in the modern era of HIV	
Clinical case Tala Ballouz, Switzerland	12:20 - 12:40
Overview Stefan Esser, Germany	12:40 - 13:00
Questions Panel	13:00 - 13:10
Chem sex: East and West	
Eastern European perspective Magdalena Ankiersztejn-Bartczak, Poland	13:10 - 13:30
Western European perspective Dominic Rowley, Ireland	13:30 - 13:50
Questions Panel	13:50 - 14:00
Tea break	14:00 - 14:20
Using new ARVs in real life	
Clinical case Rocio Montejano Sanchez, Spain	14:20 - 14:40
Overview Jose Arribas, Spain	14:40 - 15:00
Questions Panel	15:00 - 15:10
YING session	
EACS Educational programme and opportunities Sanjay Bhagani, United Kingdom	15:10 - 15:30

Scientific Programme

Intro/background to YING Tristan Barber, United Kingdom	15:30 - 15:40
Introduce YING Faculty and panel discussion/Q&A Laura Waters, United Kingdom	15:40 - 15:55
Close Tristan Barber, United Kingdom Laura Waters, United Kingdom	15:55 - 16:00

Pre-conference workshop/course
10:00 - 13:00

Sydney

WAVE workshop - Women against viruses in Europe

Convener: EACS

Access to the webcasted session:

[SESSION 1 - If women are more mature... - menopause and ageing](http://resourcelibrary.eacs.cyim.com?mediald=77970)
[SESSION 1 - WAVE 2017-2019 report including WWC](http://resourcelibrary.eacs.cyim.com?mediald=77971)
[SESSION 1 - Menopause: Patient's perspective](http://resourcelibrary.eacs.cyim.com?mediald=77972)
[SESSION 1 - Clinical cases #1 and 2: Menopause and ageing](http://resourcelibrary.eacs.cyim.com?mediald=77976)
[SESSION 1 - Menopause: Everything we know or not about women living with HIV](http://resourcelibrary.eacs.cyim.com?mediald=77977)
[SESSION 1 - Discussion](http://resourcelibrary.eacs.cyim.com?mediald=77978)
[SESSION 2 - PrEP for women in Europe](http://resourcelibrary.eacs.cyim.com?mediald=77982)
[SESSION 2 - Clinical case #3: Breastfeeding](http://resourcelibrary.eacs.cyim.com?mediald=77981)
[SESSION 2 - Discussion](http://resourcelibrary.eacs.cyim.com?mediald=77980)
[Patient's view on breastfeeding](http://resourcelibrary.eacs.cyim.com?mediald=77983)
[How to counsel and manage women living with HIV who are breastfeeding?](http://resourcelibrary.eacs.cyim.com?mediald=77984)
[Wrap up + Plan 2019-2021](http://resourcelibrary.eacs.cyim.com?mediald=77985)

SESSION 1 - If women are more mature... - menopause and ageing Chairs:

Yvonne Gilleece, United Kingdom
Antonella d'Arminio Monforte, Italy
Justyna Kowalska, Poland

Welcome remarks Karoline Aebi-Popp, Switzerland	10:00 - 10:05
WAVE 2017-2019 report including WWC Karoline Aebi-Popp, Switzerland Sonia Ganai, United Kingdom	10:05 - 10:15
Menopause: Patient's perspective Sophie Strachan, United Kingdom	10:15 - 10:25

Scientific Programme

Clinical cases #1 and 2: Menopause and ageing	10:25 - 10:35
Lesia Ostapiuk, Ukraine Umbelina Caixas, Portugal	
Menopause: Everything we know or not about women living with HIV	10:35 - 11:00
Shema Tariq, United Kingdom	
Discussion	11:00 - 11:20
Networking	11:20 - 11:35
SESSION 2 - If women are missing clear guidelines... - PrEP and breastfeeding Chairs:	
Fiona Mulcahy, Ireland Karoline Aebi-Popp, Switzerland	
PrEP for women in Europe	11:35 - 11:45
Ben Collins, United Kingdom	
PrEP for women: Facts and figures	11:45 - 12:00
Yvonne Gilleece, United Kingdom	
Discussion	12:00 - 12:05
Clinical case #3: Breastfeeding	12:05 - 12:10
Marta Lipińska, Poland	
Patient's view on breastfeeding	12:10 - 12:20
Franziska Borkel, Germany	
How to counsel and manage women living with HIV who are breastfeeding?	12:20 - 12:35
Christian R Kahlert, Switzerland	
Discussion	12:35 - 12:45
Wrap up + Plan 2019-2021	12:45 - 13:00

ePosters
12:45 - 20:00

Exhibition hall

Access to and models of care

PE1/1	Barriers in TB services for people living with HIV and overcoming them according to the health care workers opinion in the TB facilities in Russia (sociological study) Zinaida Zagdyn, Russian Federation
PE1/2	Investigating the impact of peer counseling intervention on access and use of sexual and reproductive health services in women Living with HIV in Nepal: a prospective cohort study Khem Pokhrel, Nepal
PE1/3	Health care delivery for HIV-positive people with tuberculosis in Europe Adrian Bentzon, Denmark
PE1/4	A survey of physicians on circumstances and factors influencing testing for HIV in Lithuania Raimonda Matulionyte, Lithuania

Scientific Programme

- PE1/5 **Experiences of forgiveness and unforgiveness of HIV-specific offenses among people living with HIV/AIDS in Ghana**
Judith A. Osae-Larbi, Ghana
- PE1/6 **Time to antiretroviral therapy: service model adaptation during an outbreak of HIV in people who inject drugs (PWIDs)**
Harrison Stubbs, United Kingdom
- PE1/7 **HIV infection hospital-based active case finding in Sardinia, Italy: results from the SHOT project**
Maria Sabrina Mameli, Italy
- PE1/8 **Retention activities based on home visits as a tool of return and keeping in care of low adhered patients. Results of work 2016-2019 Krasnoyarsk AIDS clinic**
Konstantin Kandlen, Russian Federation
- PE1/9 **Pilot project of shared assistance with primary care for patients with HIV infection**
Adrián Ferre, Spain

ePosters
12:45 - 20:00

Exhibition hall

Antiretroviral observational studies

- PE2/1 **A study of the effect of antiretroviral therapy on sexual risk behavior in a high-risk cohort of Congolese women**
Samuel Bitá, Congo, the Democratic Republic of the
- PE2/2 **Coagulation system and HIV infection: a review**
Nnamdi Nwachukwu, Nigeria
- PE2/3 **Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-naïve HIV-1 infected patients - 24-month results from the German TAFNES cohort study**
Hans-Jürgen Stellbrink, Germany
- PE2/4 **"Attracting men" - extended clinic hours as differentiated model of care in an urban Malawian cohort**
Sam Phiri, Malawi
- PE2/5 **HIV care in India: a systematic review of barriers to anti-retroviral therapy adherence**
Charu Kohli, India
- PE2/6 **Comparing NRTI-sparing dual regimens using data from the Swiss HIV cohort study**
Jim Young, Switzerland
- PE2/7 **Physicians' opinions on generic antiretroviral drugs and single tablet regimen (STR) de-simplification for the treatment of HIV infection: a multicentre survey in Spain**
Inés Suárez-García, Spain
- PE2/8 **Simplifying salvage regimens with darunavir-based dual therapy in HIV-infected individuals harboring multidrug-resistance**
Pilar Vizcarra, Spain
- PE2/9 **Clinical outcomes among HIV-infected Africans with advanced disease in Spain**
Adrià Ramírez-Mena, Switzerland

Scientific Programme

- PE2/10 **The Treatment of Primary HIV (TopHIV) cohort: a prospective multicenter cohort in Germany**
Melanie Stecher, Germany
- PE2/11 **No decrease in CD4/CD8 ratio after 36 months therapy in patients who were switched to two dual regimens containing rilpivirine**
Cecilia Tortajada, Spain
- PE2/12 **Clinical experience of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in real life practice: data from the Turkish HIV-TR cohort**
Volkan Korten, Turkey
- PE2/13 **Real world utilisation of raltegravir 1200mg once daily (The RETRO Study)**
Christine Mackay, United Kingdom
- PE2/14 **Effectiveness, persistence and safety in treatment-naïve and treatment-experienced HIV-1 infected patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) - 12-month evaluation of the French TARANIS cohort**
Jean-Luc Meynard, France
- PE2/15 **24-month evaluation of the German TAFNES cohort - Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF + 3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-experienced HIV-1 infected patients**
Heribert Knechten, Germany
- PE2/16 **Effectiveness, safety and tolerability of bicitgravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected adult patients in routine clinical practice - 6 months results of the BICSTaR cohort**
Stefan Esser, Germany
- PE2/17 **Short-term increase in Body Mass Index and systolic blood pressure elevation in treatment naïve persons starting INSTI-based antiretroviral therapy**
Ronald Galdamez, Spain
- PE2/18 **Baseline characteristics in JUNGLE, a German observational cohort study of Juluca as 2-drug Regimen in virologically suppressed patients, compared to the phase-3 SWORD 1 & 2 study populations**
F. Schabaz, Germany
- PE2/19 **Examining the efficacy in clinical practice of the dual antiretroviral therapy regimen of boosted protease inhibitors with maraviroc**
Abhishek Katiyar, United Kingdom
- PE2/20 **Good efficacy but side effects including hypercholesterolemia and body weight gain after switching to dolutegravir plus booster protease inhibitor regimen among treatment experienced HIV-positive patients**
Yu-Lin Lee, Taiwan, Republic of China
- PE2/21 **Rates of DTG/ABC/3TC discontinuation in a real-life setting: no surprises found in reported adverse events**
Ana Gorgulho, Portugal
- PE2/22 **Low baseline HIV viral loads with a history of PrEP use - how should these patients be managed?**
Victoria Tittle, United Kingdom
- PE2/23 **Lamivudine-based maintenance 2-drugs regimens: an algorithm for the estimation of 2-years risk of virological failure in clinical practice**
Alberto Borghetti, Italy

Scientific Programme

- PE2/24 **Adding raltegravir to a bPI failing regimen was not associated with higher virologic suppression**
Monica Maria Gomes-da-Silva, Brazil
- PE2/25 **Neuropsychiatric tolerability of bictegrovir combined with FTC/TAF in clinical practice**
Christian Hoffmann, Germany
- PE2/26 **Real-world clinical outcomes of patients switched from complex multi-tablet regimens to TAF-based single-tablet regimens plus a boosted protease inhibitor**
Charlotte-Paige Rolle, United States
- PE2/27 **Dual therapy with fixed dose combination of darunavir/ritonavir plus raltegravir in HIV-infected patients in Argentina**
Diego Martin Cecchini, Argentina
- PE2/28 **Detectability of HIV residual viremia despite therapy is highly associated with treatment with protease inhibitor**
Gilles Darcis, Belgium
- PE2/29 **Prediction of virological failure in patients with low level HIV-1 viremia using a joint latent class model**
Enrique Bernal, Spain
- PE2/30 **Comparing effectiveness and tolerability of emtricitabine/tenofovir alafenamide (F/TAF) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV-1 infected adult patients in routine clinical practice: a cross cohort analysis**
Stefan Esser, Germany
- PE2/31 **Effectiveness of Dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients**
Rakan Nasreddine, Belgium
- PE2/32 **Characterizations of weight gain following antiretroviral regimen initiation in treatment-naïve individuals living with HIV**
Ricky Hsu, United States
- PE2/33 **How to RESPOND to modern challenges for people living with HIV: a new cohort collaboration**
Bastian Neesgaard, Denmark
- PE2/34 **ART simplification: use of dual therapy for HIV in a public health reference center (CRT-DST/Aids) in São Paulo, Brazil**
Roberta Schiavon Nogueira, Brazil
- PE2/35 **Simplification to dual (2D) antiretroviral therapy (ART) with lamivudine and dolutegravir in HIV-infected patients with solid organ transplantation (SOT): a preliminary single-center experience**
Juan Ambrosioni, Spain
- PE2/36 **Comparable effectiveness of Raltegravir-based dual therapy versus other regimens in patients switched for maintenance**
Karen Martin, Germany
- PE2/37 **Comparison of a two-drug regimen (dolutegravir/rilpivirine) to standard three-drug regimens in virologically suppressed, treatment experienced individuals in the real world**
Gerald Pierone, United States

Scientific Programme

- PE2/38 **Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir in treatment-experienced patients: a multicentre cohort study**
Inés Suárez-García, Spain
- PE2/39 **High persistence of dolutegravir-containing 2-drug regimens in routine clinical care**
Sebastian Noe, Germany
- PE2/40 **Virologic, immunologic and clinical outcomes in antiretroviral treatment (ART) naïve individuals in the RESPOND cohort collaboration**
Amanda Mocroft, United Kingdom
- PE2/41 **A retrospective analysis of the EuResist data set assessing HIV dual therapy success in a real-life context**
Michael Böhm, Germany
- PE2/42 **The real-world impact of switching to tenofovir-alafenamide (TAF) on metabolic co-morbidities in PLWH aged over 60s**
Ming Jie Lee, United Kingdom
- PE2/43 **Effect of simplification to INSTI-based dual therapy on residual inflammation and viral reservoir**
Giulia Marchetti, Italy
- PE2/44 **Changes in LDL after switch from TDF to TAF in the U.S.**
Paddy Mallon, Ireland
- PE2/45 **A retrospective analysis of the EuResist data set assessing if NRTI resistance impairs INSTI based treatment with NRTI backbone**
Michael Böhm, Germany
- PE2/46 **Impact of archived M184V/I mutations on the effectiveness of switching to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide among virologically suppressed HIV-positive patients**
Chien-Ching Hung, Taiwan, Republic of China
- PE2/47 **Central nervous system (CNS) side effects and viral blips post cART switch from atazanavir boosted with ritonavir (ATZ/r) to atazanavir boosted with cobicistat (ATZ/c)**
Stephanie Tyler, United Kingdom
- PE2/48 **Quantitation of cellular HIV-1 DNA levels by droplet digital PCR in virologically-suppressed patients switching to dolutegravir plus lamivudine: a prospective study**
Francesca Lombardi, Italy
- PE2/49 **Evaluation of weight gain in incarcerated individuals living with HIV/AIDS after switching to a raltegravir-based regimen**
Melissa Badowski, United States
- PE2/50 **Determinants of viral non-suppression among people living with HIV (PLHIV) in rural setting, Neno: a retrospective cohort study**
Potiphar Damiano, Malawi
- PE2/51 **Risk of developing HIV resistance in patients with low level viraemia in a large London cohort**
Naomi Fitzgerald, United Kingdom

Scientific Programme

- PE2/52 **Virological outcomes of first line regimens in women living with HIV from Icona cohort: comparison with clinical trial data**
Cristina Mussini, Italy
- PE2/53 **Well-being in people living with HIV/AIDS (PLWHA) according to cART exposure: data from IOCONA cohort**
Antonella Cingolani, Italy
- PE2/54 **Body composition changes in HIV: do INSTI matter?**
Giovanni Guaraldi, Italy
- PE2/55 **Dolutegravir-based regimens are associated with weight gain over two years following ART-initiation in ART-naïve people living with HIV (PLWH)**
Heidi Crane, United States
- PE2/56 **Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in combination with boosted darunavir (DRV) in treatment experienced patients with HIV**
Lucas Hill, United States
- PE2/57 **Real world data of using Triumeq (dolutegravir/abacavir/lamivudine; DTG/ABC/3TC): final outcomes of the 3-year German TRIUMPH cohort show good virologic effectiveness and safety in clinical routine**
Nils Postel, Germany
- PE2/58 **The effectiveness of E/C/F/TAF in treatment-naïve (TN) or treatment-experienced (TE) adult HIV-infected patients in a real-world setting, results from southern Turkey**
Dilara Inan, Turkey
- PE2/59 **Comparison of efficacy and safety of a switch to fixed-dose combination FTC/TDF-TAF/RPV versus fixed-dose combination 3TC/ABC/DTG in HIV-1-infected, treatment experienced and virologically suppressed patients: a cohort study**
Gaetana Sterrantino, Italy
- PE2/60 **COPEDOL: a 2-year French multicentric, observational, longitudinal retro-prospective study, in pretreated HIV-1-infected patients starting dolutegravir based regimen due to treatment failure**
Roland Landman, France
- PE2/61 **Drug-drug interactions with recommended first-line antiretroviral therapy in real-world settings**
Wang-Huei Sheng, Taiwan, Republic of China
- PE2/62 **Determinants of switching to TAF-based cART or dual combinations (DC) from TDF-based regimens in a cohort of HIV-infected individuals with controlled viral load ≤ 50 copies/mL**
Alessandra Vergori, Italy
- PE2/63 **An early proactive switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) is effective in maintaining virologic control and improving quality of life (QoL) in patients with a primary HIV-1 infection (PHI). An interim analysis of a phase IV clinical trial (ESTER study)**
Marta Camici, Italy
- PE2/64 **Prevalence of neuropsychiatric conditions in patients living with HIV-1 treated with antiretroviral therapies - a perspective from US Medicaid**
Wing Chow, United States
- PE2/65 **Switch to dolutegravir dual regimens and inflammation mediated by annexin**
Claudio Ucciferri, Italy

Scientific Programme

- PE2/66 **Efficacy of dual antiretroviral therapy (ART) as intermittent short cycle regimen in virologically suppressed HIV-infected patients: an observational cohort**
Romain Palich, France
- PE2/67 **Modelling time varying viral load and CD4 cell counts response to antiretroviral therapy in a cohort of HIV naive patients**
Margarida Tavares, Portugal
- PE2/68 **Impact of switching to E/C/F/TAF on lipid profile and renal function in HIV-infected patients**
Bilgul Mete, Turkey

ePosters
12:45 - 20:00

Exhibition hall

Antiretroviral randomized clinical trials

- PE3/1 **Genital HIV-1 RNA and DNA shedding in virologically suppressed individuals switching from triple- to dual- or monotherapy: pooled results from two randomized controlled trials**
Laurent Hocqueloux, France
- PE3/2 **Comparison of the Ease of Swallowability of B/F/TAF placebo compared to DTG/ABC/3TC placebo**
John Ernest McKinnon, United States
- PE3/3 **Evaluation of total HIV-DNA changes in HIV-1 infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-One Study**
Maria Mercedes Santoro, Italy
- PE3/4 **Phase-3 trials of new antiretrovirals are not representative of the global HIV epidemic**
Toby Pepperrell, United Kingdom
- PE3/5 **Impact of susceptibility scoring on virologic response in heavily treatment-experienced participants with HIV-1 receiving a fostemsavir-based antiretroviral regimen: results through week 96 from the randomized cohort of the Phase 3 BRIGHT study**
Peter Ackerman, United States
- PE3/6 **Reversibility of dolutegravir/lamivudine/abacavir neuropsychiatric toxicity after 24 weeks of switching to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (EVG/c/FTC/TAF). The DREAM Clinical Trial**
Ignacio Pérez-Valero, Spain
- PE3/7 **A switch to dolutegravir in combination with boosted darunavir is safe and effective in suppressed patients with HIV - a predefined psychosocial subanalysis of the DUALIS study**
Christoph Spinner, Germany
- PE3/8 **Tenofovir alafenamide versus tenofovir disoproxil fumarate - is there a true difference in safety?**
Toby Pepperrell, United Kingdom
- PE3/9 **Biologic sex is not the only difference between men and women: data from the Doravirine phase 2/3 clinical trials**
Sharon Walmsley, Canada

Scientific Programme

- PE3/10 **No metabolic or renal benefits when switching to an NRTI-free dolutegravir-containing 2 drug regimen (2DR) - a subanalysis of the DUALIS study**
Christoph Boesecke, Germany
- PE3/11 **Sustained viral suppression with dolutegravir monotherapy during 9,899 patient weeks of follow-up in individuals starting combination antiretroviral therapy during primary HIV infection (EARLY SIMPLIFIED): a randomized, controlled, multi-site, non-inferiority trial**
Dominique Laurent Braun, Switzerland
- PE3/12 **Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in patients with human immunodeficiency virus (HIV)-1 infection: age, race/ethnicity, and gender subgroup analyses from the DIAMOND study**
David Anderson, United States
- PE3/13 **A systematic review and meta-analysis evaluating the risk of central nervous system adverse events in randomised controlled trials of dolutegravir**
Khadija Muniath Chowdhury, United Kingdom
- PE3/14 **Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naïve adults**
Chloe Orkin, United Kingdom
- PE3/15 **Switching from a 3-drug tenofovir alafenamide (TAF)-based regimen (TBR) to a 2-drug dolutegravir/lamivudine (2DR, DTG/3TC FDC) was not associated with a higher frequency of intermittent viremia in suppressed patients in the TANGO study**
Ruolan Wang, United States
- PE3/16 **Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): week 96 results**
Peter J Ruane, United States
- PE3/17 **Single doses of long-acting capsid inhibitor GS-6207 administered by subcutaneous injection are safe and efficacious in people living with HIV**
Eric S Daar, United States
- PE3/18 **Long-term safety and efficacy of rilpivirine plus nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 7-year roll-over study from phase 2 and 3 clinical studies**
Jean-Michel Molina, France
- PE3/20 **Prevalence of archived HIV-1 DNA resistance-associated mutations (RAMs) and their lack of effect on virologic outcome at week 96 in antiretroviral treatment (ART)-experienced, virologically suppressed patients receiving the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in the EMERALD phase III trial**
Erkki Lathouwers, Belgium
- PE3/21 **Islatravir efficacy and safety for selected demographic and baseline subgroups from a Phase 2 trial in treatment naïve adults with HIV-1 infection**
Jean-Michel Molina, France

ePosters
12:45 - 20:00

Exhibition hall

Antiretroviral therapy preclinical

Scientific Programme

- PE4/3 **In vivo dissection of the effects of HIV and antivirals on mitochondrial function in chronic treated HIV**
Theodoros Kelesidis, United States
- PE4/4 **The main barriers to “Test and Start” in Central Asia from the service providers' and patients' point of view**
Yelena Kudussova, Kazakhstan
- PE4/5 **Preclinical aspects of an anti-HIV molecule targeting vimentin**
Celia Berta Fernandez-Ortega, Cuba
- PE4/6 **PK/PD modelling of bnAbs for HIV treatments identifying knowledge gaps**
Mark Baker, Switzerland
- PE4/7 **A new inhibitor of HIV-1 infection exploiting host intracellular signaling to alter viral RNA processing**
Raymond Waiman Wong, Canada

ePosters
12:45 - 20:00

Exhibition hall

Behavioural interventions

- PE5/1 **Close group social media network and social gatherings for comprehensive HIV services among adolescent MSM in Lagos Nigeria**
Orobosa Enadeghe, Nigeria
- PE5/2 **Good hygiene practices post circumcision: a case for low adverse events in VMMC**
Timothy Kipkosgei, Kenya
- PE5/3 **Challenges of implementing HIV counselling and testing (HCT) campaigns for higher education distance learning students at University of South Africa**
Nkay Pascal Kiabilua, South Africa
- PE5/4 **Enhancing effective HIV prevention among girls by fighting child marriage and sexual and gender based violence in Karonga district, Malawi**
Shora Manuel Kauluka, Malawi
- PE5/5 **Effectiveness of rapid HIV and HCV testing programmes based on mobile units**
Ekaterina Zinger, Russian Federation
- PE5/6 **It can't happen to me - tackling cognitive mistakes and HIV using a national campaign**
Arian Diskovic, Croatia
- PE5/7 **Is mobility still a HIV/STI associated vulnerable factor in the changing sex work dynamics among female sex workers in India? - Emerging evidence**
Priyanka Dixit, India
- PE5/8 **“Amare con Sapienza”: an Italian digital ambient media prevention campaign in one of the largest European University to increase U=U, PreP, TasP knowledge**
Serena Vita, Italy
- PE5/9 **Assessing high risky sexual behaviors in vulnerable women in northern Uganda: baseline results of “Pe Atye Kena, no longer alone” study**
Antonella Cingolani, Italy

Scientific Programme

- PE5/10 **HIV/AIDS educational program for secondary school female students in Iran: a school-based randomized controlled trial**
Farid Yousefi, Iran, Islamic Republic of

ePosters
12:45 - 20:00

Exhibition hall

Cascade of care

- PE6/1 **Self-reported non-receipt of HIV test results: a silent barrier to HIV epidemic control in Mozambique**
Didier Mugabe, Mozambique
- PE6/2 **Improvement in ART initiation in different regions of Ukraine from 2010 to 2014**
Tetiana Salyuk, Ukraine
- PE6/3 **The HIV treatment cascade in Azerbaijan, 2018**
Natig Zulfugarov, Azerbaijan
- PE6/4 **Seven years of European Testing Week: impact of a regional awareness campaign on increase in awareness and testing activities in Europe**
Lauren Combs, Denmark
- PE6/5 **Impact of integrated family planning and HIV services on early postpartum contraceptive use among women with HIV in the Eastern Cape, South Africa**
Oladele Vincent Adeniyi, South Africa
- PE6/6 **The first report of Prevention of Mother-to-Child Transmission (PMTCT) of HIV in Islamic Republic of Iran**
Ebrahim Ghaderi, Iran, Islamic Republic of
- PE6/7 **New HIV diagnosis and linkage to care in two outpatient units in South Europe**
Alessio Pampaloni, Italy
- PE6/8 **The HIV- and HCV-cascade in Swiss opioid agonist treatment (OAT) patients - the SAMMSU-cohort**
Andrea Bregenzer, Switzerland
- PE6/9 **Increased Integrated testing for HIV and HCV in health care facilities: examples from the INTEGRATE activities in Lithuania and Romania**
Raimonda Matulionyte, Lithuania
- PE6/10 **AIDS and late presentation follows testing gaps in Poland - data from Test and Keep in care (TAK) Polska project**
Justyna Kowalska, Poland
- PE6/11 **Loss to follow-up and re-linkage to care in a single cohort study: who do we re-link to care?**
Laura Magnasco, Italy
- PE6/12 **Expanding access to HIV tests in 13 cities in Indonesia: an interrupted time series investigating effect of HIV policy intervention using six years population data**
Yane Tarigan, Australia
- PE6/13 **Link HIV-infected injection drug users after the imprisonment to continuum of HIV care program in Taiwan**
Wei-Wei Wu, Taiwan, Republic of China

Scientific Programme

- PE6/14 **HIV continuum of care by sex and mode of transmission in Spain, 2016: use of different sources of information**
Victoria Hernando, Spain
- PE6/15 **Temporal trends in time from HIV diagnosis to viral load suppression in CoRIS**
Belén Alejos, Spain
- PE6/16 **Navigation of HIV positive clients. Reasons of gaps in HIV cascade among PWID**
Oksana Pashchuk, Ukraine
- PE6/17 **Tracing the patterns of HIV-1 transmission among individuals with different time to diagnosis in Greece**
Evangelia-Georgia Kostaki, Greece
- PE6/18 **Late diagnosis and delayed presentation in Korean HIV/AIDS cohort**
Shin Woo Kim, Korea, Republic of
- PE6/19 **Interruption of HIV care: understanding the predictors and outcomes in the Belgian national HIV cohort**
Dominique Van Beckhoven, Belgium
- PE6/20 **The HIV continuum of care: current situation and advances. A systematic review**
Georgia Vourli, Greece
- PE6/21 **The contribution of a partnership with a civil society organization (SCO) to early HIV diagnosis and UNAIDS goals**
Antonio Diniz, Portugal
- PE6/22 **HIV cascade of care in Turkey: data from the HIV-TR cohort**
Deniz Gökengin, Turkey
- PE6/23 **Cascade analysis of anonymous voluntary HIV counseling and testing among HIV-infected patients in Taiwan**
Chun-Yuan Lee, Taiwan, Republic of China
- PE6/24 **Late presentation of HIV in Armenia**
Trdat Grigoryan, Armenia
- PE6/25 **Oral self-testing for individuals absent or refusing testing during home-based HIV testing - a cluster-randomized trial in Lesotho (HOSENG trial)**
Tracy R Glass, Switzerland
- PE6/26 **Acceptability of rapid tests for migrants during the medical consultation at the migration point**
Martin Duracinsky, France
- PE6/27 **Evaluation of the “test and treat” strategy in an high-income setting: data from a multicenter Italian cohort**
Gianmaria Baldin, Italy
- PE6/28 **Pill box return as a predictor of treatment outcome to antiretroviral therapy in PLHIV: a prospective cohort study**
Robert Ndege, Tanzania, United Republic of
- PE6/29 **Potentially missed opportunity to diagnose HIV with standard testing algorithm among adult patients with ongoing mononucleosis-like illness**
Anna Vassilenko, Belarus

Scientific Programme

- PE6/30 **HIV Continuum of Care Cascade in Cluj County, Romania. Comparative situation of the years 2016, 2017, 2018**
Adriana Topan, Romania
- PE6/31 **People living with HIV lost to follow up in the Paris region area and actions carried out by HIV care centers**
Nicolas Vignier, France
- PE6/32 **Far from 90-90-90 goals in Latin America**
Maria Greco, Argentina
- PE6/33 **Barriers to involving patients in ART as a challenge to the national health system in Ukraine**
Serhii Riabokon, Ukraine
- PE6/34 **Index testing and intensified case finding for efficiency in HIV testing in Rwanda**
Eric Remera, Switzerland

ePosters
12:45 - 20:00

Exhibition hall

Clinical case

- PE7/1 **Disseminated histoplasmosis in HIV, a key point of interest in Latin America**
Nelson Delgado, Ecuador
- PE7/2 **H-ART to Heart: a 43 year old body builder with HIV on anti-retroviral therapy with recurrent myocardial infarctions (5 heart attacks)**
Gavin Paul Raphael Manmathan, United Kingdom
- PE7/3 **Immune reconstitution inflammatory syndrome presenting as toxoplasma macular retinochoroiditis of eyes**
Dombu Guiafaing Reine Charlye, Cameroon
- PE7/4 **Invasive pulmonary aspergillosis and pulmonary tuberculosis in newly HIV diagnosed patients without prior ART exposure: differential diagnosis difficulties, treatment strategy**
Katerina Lytvin, Ukraine
- PE7/5 **Pseudotumor mimicking lung malignancy as a clinical presentation of Mycobacterium Avium infection in AIDS patient**
Luka Jovanovic, Serbia
- PE7/6 **Use of ibalizumab in a heavily treatment-experienced HIV-1-infected subject harbouring a multidrug-resistant virus**
Diana Canetti, Italy
- PE7/7 **Successful use of long-acting injectable cabotegravir and rilpivirine combination therapy in a patient with HIV-1 infection unable to absorb oral medication**
Razan Saman, United Kingdom
- PE7/8 **Cutaneous malignancy in a Romanian HIV-infected patient: diagnosis and treatment challenges**
Irina Cristiana Ianache, Romania
- PE7/9 **Autoantibodies, drugs and a failing liver**
Sonia Raffae, United Kingdom

Scientific Programme

ePosters
12:45 - 20:00

Exhibition hall

Clinical trials of vaccines

- PE8/1 **Seroprevalence of vaccine preventable viral diseases and vaccine response among HIV positive patients**
Fatma Sebnem Erdinc, Turkey
- PE8/2 **Could we recommend the current herpes zoster vaccine for patients living with HIV (PLHIV)?**
Thomas Huleux, France

ePosters
12:45 - 20:00

Exhibition hall

Co-morbidities, ageing

- PE9/1 **Detectable subclinical myocardial abnormalities in people living with HIV: insights from cardiac magnetic resonance imaging (MRI)**
Gavin Paul Raphael Manmathan, United Kingdom
- PE9/2 **Hypertension and ECG alterations in HIV positive patients in DREAM centres in Mozambique**
Isotta Triulzi, Italy
- PE9/3 **Cardiovascular events are declining in men with HIV aged 50 years or older in Austria**
Maria Kitchen, Austria
- PE9/4 **Prevalence of HIV-associated neurocognitive disorder (HAND) in Turkey and assessment of Addenbrooke's Cognitive Examination Revised (ACE-R) test as a screening tool**
Volkan Korten, Turkey
- PE9/5 **Pilot study assessing the Rotterdam Healthy Aging Score in a cohort of HIV-positive adults**
Sharon Walmsley, Canada
- PE9/6 **Obesity and HIV - the overlapping epidemics**
Justyna Kowalska, Poland
- PE9/7 **Exhaled nitric oxide levels are higher in people living with HIV compared to uninfected controls suggesting increased eosinophilic pulmonary inflammation**
Rebekka Faber Thudium, Denmark
- PE9/8 **Comparison of changes in bone microarchitecture with abacavir-lamivudine versus tenofovir disoproxil fumarate-emtricitabine in adults living with HIV**
Roger Bedimo, United States
- PE9/9 **Limitations of FRAX equation for predicting low bone mineral density or bone loss progression among people living with HIV: the role of secondary causes of osteoporosis**
Pilar Vizcarra, Spain
- PE9/10 **Elevated body mass index during pregnancy and gestational weight gain in HIV-infected women in Cape Town, South Africa: association with adverse birth outcomes**
Hlengi Madlala, South Africa
- PE9/11 **Facilitating primary care non-antiretroviral drug prescribing in people living with HIV: the Think ARV project**
Jaime Vera, United Kingdom

Scientific Programme

- PE9/12 **Characterization of moderate and severe anemia by peripheral blood smear in HIV infected patients in the Kilombero and Ulanga antiretroviral cohort**
Vanessa Anton-Vazquez, United Kingdom
- PE9/13 **HIV infection and smoking: PET imaging reveals early pulmonary perfusion abnormalities**
Puja Kohli, United States
- PE9/14 **Bariatric surgery in HIV obese patients: first results of the French ObéVIH ongoing study**
Valérie Pourcher, France
- PE9/16 **Plasma cotinine cut-off for distinguishing smokers from non-smokers among people living with HIV (PLWH)**
Omid Reza Hosseini, Denmark
- PE9/17 **An analysis of HIV and co-morbidity profiles for adults accessing health care in Khayelitsha, South Africa**
Richard Osei-Yeboah, South Africa
- PE9/18 **Femoral arteries better indicator than carotid arteries of cardiovascular risk in HIV/AIDS patients**
Gordana Dragovic Lukic, Serbia
- PE9/19 **Cardiovascular risk assessment in PLWH over 50: agreement between cardiovascular risk predictors and Coronary Artery Calcium CT Scoring (CACS)**
Branca Pereira, United Kingdom
- PE9/20 **Safety and tolerance of denosumab in HIV patients**
Sara Vela, Spain
- PE9/21 **Lower incidence of liver steatosis in patients treated with lamivudine plus dolutegravir dual therapy**
Davide Moschese, Italy
- PE9/22 **Correlations between computerised and standard cognitive testing in persons with HIV and controls**
Davide De Francesco, United Kingdom
- PE9/23 **Whole body MRI detects high prevalence of incidental findings in older HIV-1-infected patients participating in a randomised, controlled trial of maraviroc and/or metformin for non-alcoholic fatty liver disease**
Sarah Pett, United Kingdom
- PE9/24 **An analysis of potential drug-drug interactions in an aging HIV cohort**
Pádraig Gardiner, Ireland
- PE9/25 **A standardized comparison of cardiovascular risk factor prevalence between people living with HIV and general population in Spain**
Vicente Estrada, Spain
- PE9/26 **Subclinical atherosclerosis burden by ultrasound in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors**
Vicente Estrada, Spain
- PE9/27 **Subcutaneous adipose tissue modifications induced by a switch to dual raltegravir-maraviroc therapy in controlled HIV-infected patients: a sub-study of the ANRS-ROCnRAL157 clinical trial**
Jacqueline Capeau, France

Scientific Programme

- PE9/28 **Results of 10 year experience of a specialist clinic for people living with HIV over 50 at Chelsea and Westminster Hospital**
Branca Pereira, United Kingdom
- PE9/29 **Discordance in diagnosis of osteoporosis in HIV-infected patients: prevalence, characteristics, and impact on FRAX equation**
Pilar Vizcarra, Spain
- PE9/30 **CD4/CD8 ratio is a better indicator of acute phase inflammation than absolute CD4 count during virally-suppressed HIV infection**
Rodney Rousseau, Canada
- PE9/31 **Immune activation and chronic inflammation: is there an additional effect of HIV in a geriatric population?**
Clotilde Allavena, France
- PE9/32 **Trends in cardiovascular risk factors and estimated 10-year cardiovascular risk score in a spanish cohort of PLWH: 2010-2018**
Francisco Fanjul, Spain
- PE9/33 **Prevalence of depression and associated psychosocial factors among HIV positive patients attending ART clinic at Gulu Regional Referral Hospital**
Ronald Kiyemba, Uganda
- PE9/34 **Potentially inappropriate medications in older adults with HIV in the region of Madrid, Spain**
Beatriz López-Centeno, Spain
- PE9/35 **Impact of the reproductive/hormonal status on weight, fat and insulin resistance in HIV-infected women switching from a PI regimen to dual raltegravir-etravirine therapy: results from the ANRS163-ETRAL trial at 48 and 96 weeks**
Jacqueline Capeau, France
- PE9/37 **Age- and sex-related differences in concomitant diseases and use of co-medication in patients with treated HIV-infection in Germany**
Karen Martin, Germany
- PE9/38 **Kidney transplantation in HIV-positive patients in Israel including the first case of HIV-positive living donor to HIV-positive recipient with a 7-year follow-up**
Eugene Katchman, Israel
- PE9/39 **Vitamin D deficiency and frailty phenotype in HIV-infected men**
Fiona Bhondoekhan, United States
- PE9/40 **The UCSD performance-based skills assessment is associated to cognitive performance in HIV positive population with very good immunological condition**
Valentina Delle Donne, Italy
- PE9/41 **Alcohol, smoking and the association with HIV virological non-suppression among people living with HIV on ART**
Timothy Peter Wynne Jones, United Kingdom
- PE9/42 **Decreasing incidence of diabetes mellitus in HIV-positive Taiwanese patients on combination antiretroviral therapy from 2004 to 2011**
Pei-Ying Wu, Taiwan, Republic of China
- PE9/43 **Incidental findings in PLWH over 50 undergoing coronary artery calcium scoring (CACS) for cardiovascular risk assessment**
Maria Mazzitelli, United Kingdom

Scientific Programme

- PE9/44 **Aging biomarkers, inflammatory cytokines and development of cardiovascular ischemic events or diabetes in HIV-infected persons**
Jose I Bernardino, Spain
- PE9/45 **Falls but not frailty are common in people living with HIV using an mHealth platform: issues of ageing within the EmERGE cohort**
Tom Levett, United Kingdom
- PE9/46 **A standardized comparison of cardiovascular risk factor treatment in people living with HIV and general population**
Vicente Estrada, Spain
- PE9/48 **Perceptions of ageing and desire for ageing information amongst users of the EmERGE mHealth platform**
Tom Levett, United Kingdom
- PE9/49 **Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older: week 48 results from a phase 3b, open-label trial**
Franco Maggiolo, Italy
- PE9/50 **Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older**
Hans-Jürgen Stellbrink, Germany
- PE9/51 **HIV testing in patients diagnosed with community acquired pneumonia or primary lung cancer from 2014 to 2018 in a tertiary reference hospital in Northern Spain**
Teresa Rubio Obanos, Spain
- PE9/52 **Menopause in aging women living with HIV: changes in bone mineral density and trabecular bone score**
Giovanni Guaraldi, Italy
- PE9/53 **Higher anti-CMV IgG concentrations are not associated with longitudinal brain injury in virally suppressed people with HIV**
Jonathan Underwood, United Kingdom
- PE9/55 **Higher Prevalence of CKD in HIV+ individuals compared to the general population**
Stefan Esser, Germany
- PE9/56 **Effect of CMV viraemia on endothelial dysfunction over 42 weeks in Malawian adults initiating ART with advanced immune suppression**
Christine Kelly, Ireland
- PE9/57 **High prevalence of neurocognitive impairment in adults with perinatally acquired HIV infection**
Irene Portilla-Tamarit, Spain
- PE9/58 **Modeling 2018 AHA cholesterol guidelines in HIV**
Giacomo Ciusa, Italy
- PE9/59 **A multi-disciplinary Neuro-HIV Platform in managing patients with neurocognitive impairment**
Phanie Bidlingmeyer, Switzerland
- PE9/60 **Archi-Prevaleat project. A national register of color-Doppler ultrasonography of the epi-aortic vessels in patients living with HIV**
Salvatore Martini, Italy

Scientific Programme

- PE9/61 **Preliminary results of a diagnostic-therapeutic work-up to early detect cardiovascular disease in HIV positive patients**
Giovanni Millotti, Italy
- PE9/62 **Bone mineral density changes in young African women on tenofovir disoproxil fumarate antiretroviral therapy and non-hormonal contraception**
Flavia Kiweewa Matovu, Uganda
- PE9/63 **Examination of HIV-infected patients regarding weight gain while using integrase inhibitors in Japan**
Ryoko Sekiya, Japan
- PE9/65 **Predictors of sarcopenia and its impact on components of the frailty phenotype in an Asian population living with HIV**
Grace Lui, Hong Kong
- PE9/66 **Failure to restore CD4 cell count with combination antiretroviral therapy is associated with increased systemic inflammation**
Rodney Rousseau, Canada
- PE9/67 **High prevalence of left ventricular systolic dysfunction assessed by speckle tracking in asymptomatic HIV patients**
Dimitris Basoulis, Greece
- PE9/68 **Polypharmacy and drug-drug interactions - prevalence in a Portuguese HIV Metabolic Clinic**
Joana Fragoso, Portugal
- PE9/69 **Bone density alterations in the HIV-infected patient - epidemiologic characterization of a Portuguese cohort**
Diogo Guerra, Portugal
- PE9/70 **Cigarette smoking disproportionately impairs nitric oxide signaling in pulmonary artery endothelial cells in HIV: role of viral and host factors**
Saurabh Aggarwal, United States
- PE9/71 **Frailty phenotype in older virologically suppressed PLWHIV is strongly correlated with specific comorbidities and tobacco use**
Christina Katerina Psomas, France
- PE9/72 **HIV-FUNCFRIL study: differences between women and men aging with HIV**
Fátima Brañas, Spain
- PE9/73 **Prevalence, risk factors and outcomes of cardiovascular, metabolic and chronic kidney diseases in HIV-infected vs. uninfected adults in sub-Saharan Africa: a systematic review and meta-analysis**
Ajibola Awotiwon, South Africa
- PE9/74 **People living with HIV are more likely to be screened for cardiovascular disease risk factors than other members of the general population in Botswana - a community based study**
Onkabetse Julia Molefe-Baikai, Botswana
- PE9/75 **APOL1 high risk genotype has an adverse impact on kidney function in African HIV-infected patients with high viral load**
Nongodo Firmin Kabore, France
- PE9/76 **Comparison of 2 frailty scores in PLWHIV aged 50 and over: SOF index and FRIED phenotype**
Christina Katerina Psomas, France

Scientific Programme

- PE9/77 **Annexin V, Annexin A1 and cardiovascular risk in HIV population**
Claudio Ucciferri, Italy
- PE9/78 **Could we consider the intima-media thickness (c-IMT) > 1mm as a risk factor for cardiovascular diseases in HIV+ subjects chronically treated with antiretrovirals?**
Alessio Pampaloni, Italy
- PE9/79 **Immune reconstitution inflammatory syndrome (IRIS) in HIV-infected hospitalized patients with advanced disease**
Alberto Díaz-de Santiago, Spain
- PE9/80 **Low Body Mass Index (BMI) in ART naïve HIV-positive subjects and risk of virological failure and drug discontinuation: data from the ICONA Foundation Cohort**
Roberto Rossotti, Italy
- PE9/81 **Sistatin C, KIM1 and NGAL as biological markers for detecting early kidney injury in HIV positive patients**
Aslıhan Ulu, Turkey
- PE9/82 **Long-term AIDS survivors: comorbidities and polypharmacy a new challenge**
María José Galindo Puerto, Spain
- PE9/83 **Risk Factors associated to immune reconstitution inflammatory syndrome (IRIS) in HIV-infected hospitalized patients with advanced disease**
Alberto Díaz-de Santiago, Spain
- PE9/84 **Sleep disorders and depression through efavirenz to dolutegravir transition in Brazil: what really changed after all**
Melissa Medeiros, Brazil
- PE9/85 **Patterns of inflammation and comorbidity in Human Immunodeficiency Virus (HIV) infection: a clustering analysis from the CARDAMONE study**
Sonia Zebachi, France
- PE9/86 **Cognitive impairment in patients with HIV in a Mexican hospital**
Lucia Carrazco Ibarra, Mexico
- PE9/87 **Clinical management of ageing people living with HIV in Europe: The view of the care providers**
Marta Boffito, United Kingdom
- PE9/88 **Real-word characterization of the Portuguese population living with HIV who initiated Raltegravir based-regimen in the last three years - REALITY Study**
Joana Almeida, Portugal
- PE9/89 **Long-term lipid-lowering-therapy in HIV is clinically effective**
Henning Drechsler, United States

ePosters
12:45 - 20:00

Exhibition hall

Gender issues

- PE10/1 **Patient, clinical and virus genetic characteristics of migrants from Eastern, Central and Western Africa enrolled in the SHCS**
Nadine Bachmann, Switzerland

Scientific Programme

- PE10/2 **Menopause impacts drug use and mental health in women with HIV in Switzerland**
Anna Hachfeld, Switzerland
- PE10/3 **Gender-specific analysis of a German cohort of HIV-infected patients on Raltegravir-based therapy shows distinctive baseline co-morbidity profiles of women versus men but no impact on treatment outcomes**
Karen Martin, Germany
- PE10/4 **Menopausal symptoms, sleep disorders and anxiety/depression among premenopausal and postmenopausal HIV-infected women: a multicenter cohort study in Spain**
Ines Suarez, Spain
- PE10/5 **An evaluation of the care given to older women attending an HIV clinic in London**
Claire Williams, United Kingdom
- PE10/6 **Anti-Mullerian hormone a plausible indicator of cardiometabolic risk in HIV-infected women**
Umbelina Caixas, Portugal
- PE10/7 **Differences in sexual health among HIV infected and uninfected women of child-bearing age**
Raffaella Marocco, Italy

ePosters
12:45 - 20:00

Exhibition hall

HIV and marginalised groups

- PE11/1 **Sexual behaviors and seroprevalence of HIV, HBV, and HCV among hill tribe youths of Northern Thailand**
Tawatchai Apidechkul, Thailand
- PE11/3 **The blind spot: high HIV burden among slum-dwelling school-age girls in Kampala, Uganda**
Jude Thaddeus Ssensamba, Uganda
- PE11/4 **Research of behavioral models of transgender people leading to high rates of HIV prevalence in Ukraine**
Igor Medvid, Ukraine
- PE11/5 **Outreach services for HIV testing and prevention among female transgender commercial sex workers in Milan: different approaches for different populations?**
Giuseppe Lapadula, Italy
- PE11/6 **The impact of unstable housing on HIV treatment outcomes in people living with HIV/AIDS in an urban setting of Southern Europe**
Hernando Knobel, Spain
- PE11/7 **Reflection of sex work criminalization in court judgements targeting to protect health, sanitary and epidemiological well-being**
Marina Avramenko, Russian Federation
- PE11/8 **Caring for the Transgender HIV-positive patient**
Chiara Picarelli, Italy
- PE11/9 **Association of current Estradiol use with carotid intimal media thickness among transgender women: a cross-sectional study**
Rodrigo Moreira, Brazil

Scientific Programme

- PE11/10 **HIV and migrants: a demographic and clinical characterization of migrants under follow up at an Infectious Diseases Department in Lisbon, Portugal**
Marta Leal dos Santos, Portugal

ePosters
12:45 - 20:00

Exhibition hall

HIV cure

- PE12/1 **Comparison of three commercial kits for quantitative analysis of HIV-1 RNA produced in Russia**
Ilya Lapovok, Russian Federation
- PE12/2 **Optimization of genotyping by phenotypic analysis of clinical HIV-1 subtype CRF01_AE isolates from South-East Asia**
Nina Marty, Switzerland

ePosters
12:45 - 20:00

Exhibition hall

HIV drug resistance

- PE13/1 **Darunavir resistance among patients exposed to protease inhibitors failing ARV therapy**
Luis Fernando Brigido, Brazil
- PE13/2 **Prevalence and factors associated to the detection (population and next generation sequencing) of archived 3TC resistance mutations in aviremic HIV-infected adults (GEN-PRO)**
Lourdes Domínguez-Domínguez, Spain
- PE13/4 **Monitoring the prevalence of transmitted HIV drug resistance in Hungary**
Eva Ay, Hungary
- PE13/5 **Predominant reverse transcriptase resistance mutations as barriers to achieving elimination of mother-to-child transmission of HIV in South Africa**
Oladele Vincent Adeniyi, South Africa
- PE13/6 **Virologic failure and human immunodeficiency virus drug resistance in adolescents on antiretroviral therapy in Yaounde and Douala**
Magaly Jeanne Estelle Moukoko Mbonjo, Cameroon
- PE13/7 **Selection of integrase inhibitor (INI) resistance mutations in an INI experienced patient treated by Bictegravir**
Thanes Vanig, United States
- PE13/8 **Impact of HIV-1 subtypes and integrase natural polymorphisms on virological response to first-line integrase inhibitors based regimens**
Daniele Armenia, Italy
- PE13/9 **HIV-1 integrase inhibitor resistance associated mutations defined by majority and minority populations among individuals failing therapy**
Smitha Gudipati, United States

Scientific Programme

- PE13/10 **HIV-1 diversity and antiretroviral resistance among bulgarian citizens infected abroad and foreigners registered with HIV/AIDS in bulgaria from 2012 to 2017 (preliminary analysis)**
Ivailo Alexiev, Bulgaria
- PE13/11 **Analytical treatment interruption and its association with rearrangement of peripheral archived resistance mutations**
Claudia Alteri, Italy
- PE13/12 **A low level of darunavir resistance-associated mutation emergence in patients with virological failure during long term use of darunavir in people living with HIV, the French ANRS CO3 Aquitaine cohort**
Fabrice Bonnet, France
- PE13/13 **Patients infected with multi-class resistant HIV-1 and with viral suppression treated with no more than one active drug: comparison of historical resistance reports and drug resistance in proviral DNA**
Christian Hoffmann, Germany
- PE13/14 **Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance in people living with HIV-1 (PLWH) subtype non-B from the Swiss HIV Cohort Study (SHCS)**
Martina L. Reichmuth, Switzerland
- PE13/15 **HIV-1 from antiretroviral-naïve and experienced patients lack capsid substitutions associated with GS-6207 in vitro resistance**
Anne-Geneviève Marcelin, France
- PE13/16 **Long-term efficacy, safety and durability of ibalizumab in expanded access study**
Graeme Moyle, United Kingdom
- PE13/17 **Clinical impact of minority mutations in patients failing an integrase inhibitor-based regimen: what do clinicians do?**
Smitha Gudipati, United States
- PE13/18 **Identification of HIV-1 transmission clusters in Croatia, 2014 - 2017: evidence for the forward spread of HIV-1 resistant variants**
Josip Begovac, Croatia
- PE13/19 **High levels of resistance among HIV-1 treatment naive patients in Greece, a nationwide study: evidence for country and regional level transmission networks**
Dimitris Chatzidimitriou, Greece
- PE13/20 **A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring NRTI resistance mutations M184V/I +/- TAMs (GS-US-292-1824): week 24 results**
Ignacio Pérez-Valero, Spain
- PE13/21 **Sustained viral suppression among participants with pre-existing M184V/I who switched to bicitgravir/emtricitabine/tenofovir alafenamide**
Kristen Andreatta, United States
- PE13/22 **Absence of naturally existing resistance against the HIV-1 capsid inhibitor GS-6207 in HIV-1 primary isolates**
Christian Callebaut, United States
- PE13/23 **Impacts assessment of home based care program over adherence to ART among adolescence living with HIV and AIDS in Blantyre Malawi**
Lesily Samson Kapile, Malawi

Scientific Programme

- PE13/24 **Correlation of results analysis drug resistance of HIV-1 among patients with virological failure by next-generation sequencing and traditional population sequencing**
Alina Kirichenko, Russian Federation
- PE13/25 **Analysis of the latent reservoir of a patient infected with HIV under PrEP by single full-length HIV-1 amplification**
Maximilian Damagnez, Germany
- PE13/26 **Drug resistance profile according to HIV-1 viral load after long-term exposure to antiretroviral treatment in the absence of routine virological monitoring: results from a programmatic cohort in sub-Saharan Africa**
Giovanni Villa, United Kingdom
- PE13/27 **In vitro analysis of replicative capacity and phenotypic susceptibility of integrase mutant HIV-2 viruses**
Quentin Le Hingrat, France
- PE13/28 **Treatment simplification with two-drug regimens: impact of transmitted drug resistance mutations in residents of South-East Austria**
Evelyn Stelzl, Austria
- PE13/29 **Baseline resistance to Doravirine depends on the algorithm used for interpretation**
Carlos Guerrero Beltrán, Spain
- PE13/30 **Baseline resistance to EACS first line recommended antiretroviral regimens in newly diagnosed patients in Spain**
Federico García, Spain
- PE13/31 **A retrospective evaluation of a national home infusion provider's approach to medication adherence of parenteral ibalizumab-uiyk in the alternate-site and homecare setting**
Kathryn Andrusko-Furphy, United States
- PE13/32 **Prevalence of HIV-1 drug resistance among patients with antiretroviral therapy failure in Moscow region, Russia**
Natalya Lebedeva, Russian Federation
- PE13/33 **HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa: implications for elimination of mother-to-child transmission**
Oladele Vincent Adeniyi, South Africa
- PE13/34 **Antiretroviral Resistance patterns in HIV-1 infected patients failing to second-line in Bamako, Mali**
Almoustapha Issiaka Maiga, Mali

ePosters
12:45 - 20:00

Exhibition hall

HIV-associated and non HIV-associated tumours

- PE14/1 **Prevalence of anal dysplasia among persons living with human immunodeficiency virus (HIV)**
Adelaine Lopez, Philippines
- PE14/2 **HIV infection is associated with reduced survival among hepatocellular carcinoma cases from an urban referral hospital: Kampala, Uganda**
Sara Nsibirwa, Uganda

Scientific Programme

- PE14/3 **High prevalence of anal and cervical dysplasia in a cohort of HIV-infected women, but low prevalence of concomitant lesions**
Ana Gomez, Ecuador
- PE14/4 **Malignant and benign skin lesions in HIV-1 infected people**
Alessandra Latini, Italy
- PE14/5 **Results of HPV-testing for anal screening in HIV-infected women**
Anna Popova, Russian Federation
- PE14/6 **COHORT SDT (Granada): decrease of the incidence of HSIL+ in the anal mucosa of HIV+ patients MSM after the performance of a screening, diagnostic and therapeutic program (2010-2018)**
Carmen Hidalgo-Tenorio, Spain
- PE14/7 **Prospective longitudinal study on immunogenicity and safety of vaccination against human papillomavirus (HPV) with the 9valent vaccine in HIV-positive women, the Papillon study: preliminary results on tolerance and safety**
Déborah Konopnicki, Belgium
- PE14/8 **Cancer trends and outcomes in a cohort of people living with HIV**
Andrea De Vito, Italy
- PE14/9 **Rate of HCC occurrence and associated risk factors in a multicentric cohort of HIV/HCV co-infected patients treated with DAAs**
Alice Toschi, Italy

ePosters
12:45 - 20:00

Exhibition hall

Human genomics

- PE15/1 **Genetic characterization of the near full-length genome of an HIV-1 A1/C/D/K/B unique recombinant form from the Eastern Cape, South Africa: a case report**
Oladele Vincent Adeniyi, South Africa
- PE15/2 **Impact of KIR and their ligands (HLA allele) on susceptibility to selected viral opportunistic conditions and HIV plasma viral load in HIV+ patients**
Magdalena Leszczyszyn-Pynka, Poland
- PE15/3 **The identification and causal analysis of aberrant CD4 counts in an HIV cohort in Southern Alberta, Canada**
Raynell Lang, Canada
- PE15/4 **Placental gene expression profiles and pathways in HIV-1 positive Cameroonian women under ART**
Forgu Esemu Livo, Cameroon
- PE15/5 **Functional clustering and association of HLA class I alleles to viral load in HIV-positive and ART-naïve participants from the INSIGHT START study**
Adrian Gabriel Zucco, Denmark
- PE15/6 **miRNA expression profiling in subcutaneous adipose tissue of monozygotic twins discordant for HIV infection: validation of differentially expressed miRNA and bioinformatic analysis**
Nicola Squillace, Italy

Scientific Programme

PE15/7 **Factors influencing late presentation into care of HIV disease**
Bogusz Aksak-Wąs, Poland

ePosters
12:45 - 20:00

Exhibition hall

Immunology

- PE16/1 **Immunological and metabolic effects of dasatinib treatment in IL7-stimulated CD4+ T-cells subpopulations**
Humberto Erick De La Torre Tarazona, Spain
- PE16/2 **New T- and B-lymphocytes production and T-cell receptor diversity in young adults perinatally infected by HIV**
Martina Properzi, Italy
- PE16/3 **In Vivo modelling of mechanisms of HIV-1-related monocyte dysfunction**
Theodoros Kelesidis, United States
- PE16/4 **Lectin-like oxidized low-density lipoprotein (LOX-1) is elevated in proinflammatory monocytes in chronic treated HIV**
Theodoros Kelesidis, United States
- PE16/5 **In vivo dissection of the impact of HIV-1 versus antivirals on immune activation in chronic treated HIV**
Theodoros Kelesidis, United States
- PE16/6 **Differential impact of HIV-1 versus antivirals on systemic inflammation in chronic treated HIV**
Theodoros Kelesidis, United States
- PE16/7 **Correlation between blood telomere length and CD4+ CD8+ T-cell subsets in HIV-1-positive individuals with long-term virological suppression on antiretroviral therapy**
Javier Rodríguez-Centeno, Spain
- PE16/9 **Phenotypical recovery of the T-cell pool following switch to dual and triple INSTI-based cART**
Camilla Tincati, Italy
- PE16/11 **Expression of PD-1 in a population of double-negative T cells (CD3+CD4-CD8-) in HIV-infected patients - the preliminary study results**
Weronika Rymer, Poland
- PE16/12 **Targeting inflammation in chronic treated HIV with oral ApoA-I mimetics**
Theodoros Kelesidis, United States
- PE16/13 **Poor recovery of T-cell receptor repertoire despite long-term antiretroviral therapy**
James Brown, United Kingdom

ePosters
12:45 - 20:00

Exhibition hall

Morbidity/mortality in the era of cART

Scientific Programme

- PE20/1 **The association of rare HLA alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies**
Christina Ekenberg, Denmark
- PE20/2 **Neutrophil-to-lymphocyte ratio compared to CD4+:CD8+ T-cell ratio as a predictor of non-AIDS events in treated people living with HIV**
Nick Power, Ireland
- PE20/3 **Factors associated with virologic failure in women with HIV: Condesa specialized clinics, Mexico City**
Teresita De Jesús Cabrera Lòpez, Mexico
- PE20/4 **Causes of death among a cohort of HIV-infected adults in rural Tanzania**
Fiona Vanobberghen, Switzerland
- PE20/5 **Predictors of early mortality among adult HIV-infected patients on antiretroviral therapy in a Kenyan pastoralist community: a retrospective cohort study**
Paul Yonga, Kenya
- PE20/6 **Trends in underlying causes of death in HIV - infected patients from 2016 to 2018 in Ukraine: a cohort study**
Tetiana Kyrychenko, Ukraine
- PE20/7 **Dynamic of CD4+/CD8+ ratio in late presenters: impact on clinical outcomes**
Marta Rava, Spain
- PE20/8 **Retrospective investigation into the causes of death in HIV-infected patients from Bonn in the era of combined Anti-Retroviral Therapy**
Lukas Knieps, Germany
- PE20/9 **Reduced utility of early procalcitonin in HIV febrile patients admitted to the emergency department**
Chiara Picarelli, Italy
- PE20/10 **Patients with HIV and HCV in intensive care treatment: admission criteria and trends in the intensive care unit (ICU) at the University Hospital of Bonn 2014-2019**
Stefan Schlabe, Germany
- PE20/11 **Burden of disease in PLWH harboring a 4-class drug resistant virus: data from PRESTIGIO Registry**
Maria Rita Parisi, Italy
- PE20/12 **Changing pattern of hospital admissions due to medical conditions in HIV-infected subjects in a European public health care system with free access to antiretroviral treatment**
Joan Raga Almudéver, Spain
- PE20/13 **Association of non-adherence to antiretroviral therapy with cardiovascular outcomes in virologically suppressed persons living with HIV: the Swiss HIV Cohort Study**
Tracy R Glass, Switzerland
- PE20/14 **Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980 - 201**
Katharina Kusejko, Switzerland
- PE20/15 **Low pre-ART CD4 count is associated with increased risk of clinical progression or death even after reaching 500 CD4 cells/ μ L on ART**
Nikos Pantazis, Greece

Scientific Programme

- PE20/16 **A comparative analysis on blood pressure in HIV-infected individuals versus uninfected controls residing in Sub-Saharan Africa: a narrative review**
Edith Phalane, South Africa
- PE20/17 **Causes of death in AIDS/HIV-infected patients at the hospital of infectious diseases in St. Petersburg, Russia**
Olga Sokolova, Russian Federation
- PE20/18 **Dynamics and structure of mortality of HIV-positive people in Ukraine**
Nataliia Bugaienko, Ukraine

ePosters
12:45 - 20:00

Exhibition hall

NASH

- PE22/1 **Assessment of non alcoholic fatty liver disease in a cohort of HIV mono-infected patients**
Paola Columpsi, United Kingdom
- PE22/2 **Non-alcoholic fatty liver disease (NAFLD) and related metabolic disorders among HIV-infected patients in the country of Georgia**
Lali Sharvadze, Georgia
- PE22/3 **Non-alcoholic fatty liver disease is a significant predictor of cardiovascular risk in HIV-infected patients**
Adriana Cervo, Italy
- PE22/4 **Non alcoholic fatty liver disease diagnosed by non-invasive markers in HIV-infected patients**
Carmen Busca, Spain
- PE22/5 **Global prevalence of liver impairment in HIV population in direct antiviral agents (DAA) era: the role of fatty liver disease**
Matilde Sánchez-Conde, Spain

ePosters
12:45 - 20:00

Exhibition hall

Novel consultations, remote care - telemedicine, mobile applications

- PE23/1 **Harnessing mobile technology for health worker capacity building to improve quality of care in resource-constrained settings**
Walter Joseph Arinaitwe, Uganda
- PE23/2 **Feasibility, uptake and acceptability of the EmERGE mHealth app in individuals living with stable HIV in five European countries**
Jenny Whetham, United Kingdom
- PE23/3 **Attracting people who use drugs to HIV prevention and care programs via darknet and messengers: evidence from St. Petersburg, Russia**
Aleksey Lakhov, Russian Federation
- PE23/4 **People living with HIV (PLHIV) and their doctors: adopters and sceptics, and those opened to e-health**
Christine Jacomet, France

Scientific Programme

- PE23/5 **Fitness tracking wearable devices and a dedicated smart phone app (MySAwH App) to predict quality of life in PLWH: a multi-centre prospective study**
Giovanni Guaraldi, Italy
- PE23/6 **The efficiency of introducing the EmERGE Pathway of care for stable Croatian PLHIV**
Eduard J. Beck, United Kingdom
- PE23/7 **‘The 4th 90’: a preliminary assessment of change in quality of life over 1 year of the EmERGE study: PROQOL-HIV and EQ-5D-5L, a descriptive analysis**
Christopher Jones, United Kingdom
- PE23/8 **Measuring empowerment in EmERGE mHealth platform users: a descriptive analysis of interim data**
Stephen Bremner, United Kingdom

ePosters
12:45 - 20:00

Exhibition hall

Other coinfections/Sexually transmitted infections

- PE24/2 **High rates of ocular and neurosyphilis in a large German, city-based university hospital: lessons learned on ocular syphilis**
Laura Franziska Wagner, Germany
- PE24/3 **Decreasing rate of HIV and HBV co-infection in nationwide Korean HIV/AIDS cohort and its meaning**
Yoonjung Kim, Korea, Republic of
- PE24/5 **Prevalence of syphilitic hepatitis among HIV-infected patients in Istanbul, Turkey, a region with increasing incidence of syphilis and HIV infection**
Ozlem Altuntas Aydin, Turkey
- PE24/6 **Seroconversion rate after yellow fever vaccine in HIV- positive patients**
Charlotte Martin, Belgium
- PE24/7 **Low seroprevalence of syphilis infection among key populations in Togo in 2017: a national cross-sectional survey**
Fifonsi Gbeasor, Togo
- PE24/8 **Socio demographics, sexual behavior and clinical manifestations of HIV+ and HIV- patients diagnosed with syphilis, Brussels 2017-2019**
Agnès Libois, Belgium
- PE24/9 **Risk factors and prevalence of syphilis, gonorrhea and chlamydia infections in the Swiss HIV cohort study**
Catrina Mugglin, Switzerland
- PE24/10 **Predictors of serofast state after treatment for syphilis in HIV-infected patients**
Gregor Paul, Germany
- PE24/11 **A proactive approach to assess rising STIs among different at-risk groups of MSM in the early era of PrEP: a real-world clinical care setting**
Christina Katerina Psomas, France

Scientific Programme

- PE24/12 **Profiles of multidrug resistant gonorrhea in HIV-infected patients attending an urban hospital in Uganda**
Christine Katusiime, Uganda
- PE24/13 **Sexually transmitted diseases clinic in a Portuguese Infectious Diseases unit**
Joana Fragoso, Portugal
- PE24/14 **Quantification of DNA human papillomavirus 16 and 18 in anal cells improves the prediction of high grade anal intraepithelial neoplasia in HIV patients**
Marcos Diez, Spain
- PE24/15 **Primary prophylaxis against *Pneumocystis jirovecii* Pneumonia may be effective in preventing severe bacterial pneumonia in HIV-positive patients: findings from a large Italian center**
Alex Dusina, Italy
- PE24/16 **HHV-8 salivary shedding in individuals with different HIV status and sexual behaviour**
Elvira Domonova, Russian Federation
- PE24/17 **Insights into syphilis reinfection in HIV patients: predictors and role of serofast condition**
Chiara Picarelli, Italy
- PE24/18 **Infective endocarditis, a current health problem in Romanian injecting drug users**
Irina Cristiana Ianache, Romania
- PE24/19 **Preventable risk factors and predictors of hepatic and non-hepatic co-morbidities among PLHIV**
Oluwakemi Odukoya, Nigeria
- PE24/20 **Incidence of asymptomatic HAV infection among MSM living with HIV in South-Western Poland**
Aleksandra Szymczak, Poland
- PE24/21 **Behavioural patterns to identify key populations for syphilis prevention**
Sara Andresen, Switzerland
- PE24/22 **Evaluation of a systematic sexually transmitted infections screening pilot programme in HIV-positive men who have sex with men (MSM)**
Paula Prieto, Spain
- PE24/23 **Chemsex in Barcelona: a descriptive approach about men who have sex with men (MSM) who use recreational drugs in a sexual context**
Lorena De la Mora, Spain
- PE24/24 **Analysis of serum metabolite changes in early syphilis patients with or without serologic response after treatment**
Chia-Jui Yang, Taiwan, Republic of China
- PE24/25 **Stable transmission of amoebiasis among newly diagnosed HIV-positive patients in Taiwan, 2009-2018**
Sung-Hsi Huang, Taiwan, Republic of China
- PE24/26 ***Mycoplasma genitalium* resistance against macrolide antibiotics in the Berlin MSM cohort tested with the Allplex MG & AziR Assay (SeeGene)**
Martin Obermeier, Germany

Scientific Programme

- PE24/27 **Predictors of ureaplasma urealyticum urinary colonization in HIV+ pregnant women: a pilot study**
Iacopo Franconi, Italy
- PE24/28 **No indication of decreased syphilis susceptibility with repeated syphilis episodes in HIV-infected men who have sex with men: a multicentre prospective cohort study on risk factors and the potential role of syphilis immunity**
Jan Roth, Switzerland
- PE24/29 **The prevalence of high-risk anal HPV in HIV-positive MSM in Lebanon**
Nesrine Rizk, Lebanon

ePosters
12:45 - 20:00

Exhibition hall

Paediatric, adolescent

- PE25/1 **Effect of cluster of differentiation (CD4) on viral respiratory infection in children, between 0-5 years of age. A study conducted in Kwazulu-Natal, South Africa**
Temitayo Famoroti, South Africa
- PE25/2 **Adolescent HIV and asymptomatic malaria parasitemia (AMP) co-infection**
David Segun Adeniyi, Nigeria
- PE25/3 **Clinical features of viral diarrhea in the children of HIV**
Marufjon Salokhiddinov, Uzbekistan
- PE25/4 **High rate of rubella seronegativity in perinatally-infected HIV women of childbearing age: a case-control study**
Nicolas Dauby, Belgium
- PE25/5 **Health outcomes in adolescents and young adults living with HIV before and after transition to adult care in Barcelona**
Josep Ferrer Arbaizar, Spain
- PE25/6 **Correction of lipid abnormality by integrase inhibitor among children taking ART**
Anna Samarina, Russian Federation
- PE25/7 **Increasing contribution of sexually-transmitted HIV diagnoses in adolescents in Spain**
Enrique Bernal, Spain
- PE25/8 **Factors associated to late presentation of HIV newly diagnosed adolescents in Spain**
Enrique Bernal, Spain
- PE25/9 **Comparison of antiretroviral treatment initiation in HIV newly diagnosed adolescents in Spain**
Melchor Riera Jaume, Spain
- PE25/10 **Oral self-testing for adolescents and young adults absent or declining to test during home-based HIV testing - a mixed-method study embedded in a cluster-randomized trial in Lesotho (ADORE study)**
Alain Amstutz, Switzerland
- PE25/11 **Preterm births in women living with HIV in Switzerland: a 13-year evaluation**
Christian R Kahlert, Switzerland

Scientific Programme

- PE25/12 **Poor clinical outcomes in HIV-infected children who start antiretroviral therapy at an older age**
Kevin P. McKenzie, United States
- PE25/13 **Prevalence and predictors of unintended pregnancies among HIV positive young adults (14-24 years) attending an urban HIV clinic in Uganda**
Mackline Hope, Uganda
- PE25/14 **Microbiota composition in a cohort of underweight HIV-positive children aged 24-72 months in Cape Town, South Africa**
Margaret Van Niekerk, South Africa
- PE25/15 **Influence of maternal parameters on birth outcome in HIV-exposed newborns - 11 year observation**
Karolina Nowicka, Poland

ePosters
12:45 - 20:00

Exhibition hall

Pathogenesis and immunopathogenesis

- PE26/2 **Colonic microbiota exhibits disparate associations with HIV-infection and sexual practices**
Eveline Verheij, Netherlands
- PE26/3 **Zonulin indicates loss of intestinal integrity and microbial translocation in HIV+ patients**
Max Augustin, Germany
- PE26/4 **Distinct pro-inflammatory and cardio-protective effects of antiretroviral drugs in vascular endothelial cells**
Akif A. Khawaja, United Kingdom
- PE26/5 **Bacterial translocation kinetics in HIV-1 infection: from acute to chronic stages**
Paula Aranguren-Rivas, Spain
- PE26/6 **Mitochondrial antioxidants attenuate In vivo liver fibrosis in chronic treated HIV**
Theodoros Kelesidis, United States
- PE26/7 **Mitochondrial antioxidants attenuate In vivo mitochondrial dysfunction and exhaustion in T cells in chronic treated HIV**
Theodoros Kelesidis, United States
- PE26/8 **Inhibition of caspase 1 reduces viral load, CD4 T cell depletion and immune activation in HIV-1 infected humanized mice**
Philipp Adams, Luxembourg
- PE26/9 **Effect of early initiation of ART on alterations in natural killer cells in HIV infected pediatric patients**
Romsha Kumar, India
- PE26/10 **HIV-DNA levels, HLA-B*27 and HLA-DRB1*13 among LTNPs, ECs and HIV controllers**
Arianna Gabrieli, Italy
- PE26/11 **Macromolecule uptake across intestinal epithelia in HIV infection**
Carolin Grünhagen, Germany

Scientific Programme

- PE26/12 **Immune cell activation as a risk factor for hypertension in people living with HIV in Sub-Saharan Africa using the recent American Heart Association and American College of Cardiology Guidelines**
Sepiso Masenga, Zambia

ePosters
12:45 - 20:00

Exhibition hall

Pharmacology, pharmacogenomics and drug interactions

- PE27/1 **Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz based antiretroviral therapy in Zambia: an open label non-randomized interventional trial**
Mike Chaponda, Zambia
- PE27/2 **Ritonavir-boosted darunavir plus two nucleoside reverse transcriptase inhibitors versus other regimens for initial antiretroviral therapy for people with HIV infection: a systematic review**
Tatevik Balayan, Armenia
- PE27/3 **Towards individualization of antiretroviral therapy - more cost-effective than dose intensification in patients**
Bhavik Dalal, India
- PE27/4 **The valproic acid - dolutegravir drug-drug interaction is based on displacement of protein binding and unlikely to be clinically relevant**
Henriette Prins, Netherlands
- PE27/5 **BESIDE - clinical relevance and implications for management of antiretroviral therapy due to recreational drug use in PLWH in Germany**
Karen Martin, Germany
- PE27/6 **Drug-drug interactions between antiretrovirals and carbamazepine or oxcarbazepine: a real-life investigation**
Cristina Gervasoni, Italy
- PE27/7 **Drug-drug interactions between dolutegravir (DTG) and immunosuppressant drugs (IS) in HIV-infected patients with solid organ transplantation (SOT): a single-arm clinical trial (DTGSOT)**
Christian Manzardo, Spain
- PE27/8 **Abacavir hypersensitivity reaction (HSR), associated to baseline false negative HLAB5701 screening, in antiretroviral treatment naive HIV-1 patient**
Salvatore Martini, Italy
- PE27/9 **Central nervous system penetration of antiretroviral drugs in HIV-positive patients with neurocognitive impairment, assessed from paired plasma-CSF concentrations**
Perrine Courlet, Switzerland

ePosters
12:45 - 20:00

Exhibition hall

PrEP

Scientific Programme

- PE28/1 **Establishment of the service system of HIV pre-exposure prophylaxis/post exposure prophylaxis (PrEP/PEP) in a certain area of Southern Taiwan**
Kuei Ying Wang, Taiwan, Republic of China
- PE28/2 **Systematic review of post-migration HIV acquisition within Europe: the case for PrEP interventions for migrants**
Simran Mann, United Kingdom
- PE28/3 **Self-reported STI history and associated factors among German PrEP users**
Uwe Koppe, Germany
- PE28/4 **PrEP implementation among MSM in Ukraine: results of pilot project in Kyiv**
Roman Marchenko, Ukraine
- PE28/5 **Emergency post-exposure prophylaxis (PEP) seeking behaviors among men who have sex with men (MSM) with recent HIV risk exposure in Thailand**
Tarandeep Anand, Thailand
- PE28/6 **The back side: Lymphogranuloma venereum in PrEP-users and PLWH**
Sven Schellberg, Germany
- PE28/7 **Awareness and interest in pre-exposure prophylaxis (PrEP) among MSM population in Serbia**
Vanja Subotic, Serbia
- PE28/8 **PrEP reimbursement and access in Europe: 2019 update**
Krzysztof Tronczyński, Poland
- PE28/9 **Users' perspective of an ideal service model for delivering pre-exposure prophylaxis (PrEP) to men who have sex with men**
Shui Shan Lee, Hong Kong
- PE28/10 **Assessment of the trough concentrations of tenofovir in HIV-negative subjects on pre-exposure prophylaxis: a single center, real-life experience**
Dario Cattaneo, Italy
- PE28/11 **No new HIV infections, but high incidence of syphilis among Pre-exposure Prophylaxis (PrEP) users in Georgia**
Ekaterine Karkashadze, Georgia
- PE28/12 **Feasibility and acceptability of an oral pre-exposure prophylaxis (PrEP) program against HIV targeting female sex workers in Belgium**
Florence Deneumoustier, Belgium
- PE28/13 **First results after 52 weeks of informal PrEP use in a cohort of MSM in Southern Spain**
Alejandro Berto Moran, Spain
- PE28/14 **Clinical outcomes of pre-exposure prophylaxis from clinical center in Warsaw, Poland**
Iwona Cielniak, Poland
- PE28/15 **Where are we with PrEP use in Central and Eastern Europe? - data from the ECEE Network Group**
Josip Begovac, Croatia
- PE28/16 **Sexual risk and HIV preventative behaviours among men who have sex in men in London in the era of HIV pre-exposure prophylaxis, 2019**
Fiona Burns, United Kingdom

Scientific Programme

- PE28/17 **Chemsex and mood disorders under HIV pre-exposure prophylaxis**
Helene Peyriere, France
- PE28/18 **Pre-exposure prophylaxis one year after implementation in Portugal - the reality of a central hospital**
Diogo Guerra, Portugal
- PE28/19 **DISCOVER in Europe: a sub-analysis of the phase 3 randomized, controlled trial of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP)**
Frank Post, United States
- PE28/20 **The Good and Bad of PrEP: a 14 month follow up on awareness, adherence, efficacy and sexually transmitted diseases at Hospital de Curry Cabral**
Marta Leal dos Santos, Portugal
- PE28/21 **PrEP for life: new challenges and barriers in PrEP uptake among men who have sex with men (MSM) and transgender people (TG) in Kyiv, Ukraine**
Dzmitry Filippau, Ukraine
- PE28/22 **Analysis of the need for pre-exposure prophylaxis of HIV among people that have high risk to be infected**
Vitaliy Andres, Ukraine
- PE28/23 **Lesson learnt from a combined HIV prevention using HIV self-testing and oral pre-exposure prophylaxis (PrEP) demonstration project in the United Republic of Tanzania**
Neema Makyo, Tanzania, United Republic of

ePosters
12:45 - 20:00

Exhibition hall

Prevalence, incidence and dynamics of HIV epidemics

- PE29/1 **Monitoring rates and accessibility of HIV and STI's testing, HAV and HBV vaccination among men who have sex with men in Slovenia**
Miran Solinc, Slovenia
- PE29/2 **Data triangulation to re-shape interventions to improve the HIV response: compering data from estimates, case reporting, and sentinel surveillance in Ukraine**
Tetiana Salyuk, Ukraine
- PE29/3 **The impact of frequent cannabis use on injection drug use patterns among people who use drugs in a Canadian setting**
Hudson Reddon, Canada
- PE29/4 **Predicting early loss to follow-up on ART: a retrospective review of clients' retention on ART in North-western Nigeria**
Johnson Okolie, Nigeria
- PE29/5 **The increasing number of late HIV diagnosis among men having sex with men and transgender women in a key population-led HIV testing and treatment facility and its societal implication in the Philippines**
Patrick Eustaquio, Philippines

Scientific Programme

- PE29/6 **HIV transmission network in a cohort of subjects with primary infection in a single clinical center in Rome**
Lavinia Fabeni, Italy
- PE29/7 **Evaluation of a multiassay approach for determination recent HIV infection in the Russian Federation**
Anastasia Murzakova, Russian Federation
- PE29/8 **Ongoing spread of HIV subtype A in Tel Aviv, Israel**
Dan Turner, Israel
- PE29/9 **Simple clinical and laboratory based score may identify HIV infection recency and subsidize HIV surveillance in low and middle-income countries (LMIC), Santo André/Brazil experience**
Elaine Monteiro Matsuda, Brazil
- PE29/10 **Clinical, epidemiological & virological features of primary HIV-1 infection in an HIV reference center in Brussels: a ten years' review**
Arthur Poncelet, Belgium
- PE29/11 **Current trends in HIV genetic diversity in Russia: increase of the unique recombinants prevalence**
Anastasiia Antonova, Russian Federation
- PE29/12 **Analysis of risk factors in HIV/AIDS patients**
Esra Zerdali, Turkey
- PE29/13 **Tracing the first HIV-1 epidemics in the Milan area**
Alessia Lai, Italy
- PE29/14 **Analysis of the local HIV-1 epidemic in Vologda region, Russia: predominance of CRF03_AB and rapid expansion of URFs**
Ekaterina Ozhmegova, Russian Federation
- PE29/15 **Identification of first near full length recombinant genome of HIV-1 in Korea**
Mee-Kyung Kee, Korea, Republic of
- PE29/16 **Characteristics of HIV infection among children in Georgia, 1989-2018**
Natela Chokoshvili, Georgia
- PE29/17 **HIV infection in older patients**
Barbara Belfiori, Italy
- PE29/18 **Seroincidence of the human herpesvirus 8 (HHV 8) infection among HIV-positive patients in Taiwan, 2016-2019**
Yi-Ching Su, Taiwan, Republic of China
- PE29/19 **Risk factors for late presentation for HIV care in 2019 in Ukraine**
Maryna Sukach, Ukraine
- PE29/20 **Incidence of hepatitis C virus infection among people living with HIV(PLHIV): an Egyptian Cohort Study**
Rahma Mohamed, Egypt
- PE29/21 **High HIV prevalence following screening of subjects with HIV indicator conditions in a hospital setting**
Camilla Tincati, Italy

Scientific Programme

- PE29/22 **First decrease in new HIV diagnoses in 2018 among men who have sex with men (MSM), in the East PACA (Provence Alpes Côte-d'Azur) area in France**
Philippe Bouvet de la Maisonneuve, France
- PE29/23 **The collision of public health interventions on HIV-1 spread in Albania by molecular epidemiology**
Shkurti Enkelejda, Albania
- PE29/24 **Two decades of HIV infection late diagnosis: the experience of a Portuguese Hospital**
Sofia Jordão, Portugal
- PE29/25 **Characterization of HIV patients followed in a specialist consultation at a tertiary and university centre**
Fábio Videira Santos, Portugal
- PE29/26 **Trends in epidemiology and clinical picture of late presentation among patients of the Hospital for Infectious Diseases in Warsaw**
Joanna Pula, Poland
- PE29/27 **An evolutionary insight into a growing HIV subtype A epidemic in Serbia**
Marina Siljic, Serbia
- PE29/28 **Change of prevalence, diseases distribution and factors associated with the risk of AIDS presentation in Italy over last decade (2009-2018)**
Andrea Antinori, Italy
- PE29/29 **The effect of gender on late diagnosis of HIV infection in a high incidence European population**
Rita Filipe, Portugal
- PE29/30 **Two decades surveillance of HIV-1 transmitted drug resistance in Serbia**
Valentina Cirkovic, Serbia
- PE29/31 **3M-BRiHT - Manchester Cohort. Investigation of the feasibility and acceptability of rapid HIV testing in a European Emergency Department setting**
Molly M. O'Kane, Ireland
- PE29/32 **HIV-1 A6 subtype: its challenging identification and Southern Russian molecular epidemiology**
Saleta Sierra, Germany
- PE29/33 **Neurodevelopmental assessments to screen for HIV encephalopathy in newly diagnosed infants not on ART in Mozambique**
Jyodi Mohole, United States

ePosters
12:45 - 20:00

Exhibition hall

Prevention of horizontal transmission, cART as prevention

- PE30/1 **Tolerability and treatment completion of tenofovir alafenamide/emtricitabine/rilpivirine (TAF/FTC/RPV) as HIV postexposure prophylaxis**
Marie Chauveau, France

Scientific Programme

ePosters
12:45 - 20:00

Exhibition hall

Social and behavioural science

- PE30/2 **Priorities for behavioral interventions in a group of long term PLWHA - the experience of the Baylor Clinical Centre of Excellence in Constanta, Romania**
Ana-Maria Schweitzer, Romania
- PE30/3 **Will HIV-infected patients taking oral ARV switch to long-acting injectable ART when it become available?**
Marie-Aude Khuong-Josses, France
- PE30/4 **Time perspectives as predictors of depression and suicidal ideation amongst adolescents and young adults with HIV: the moderating role of resilience**
Oluwapelumi Ashamu, Nigeria
- PE30/5 **Social support and quality of life of people living with AIDS receiving ART at BPKIHS**
Ram Sharan Mehta, Nepal
- PE30/7 **Knowledge, attitudes, beliefs and HIV-related behaviour in metropolitan France: investigation in a festive place**
Fernanda Medina, France
- PE30/9 **Injectable long acting antiretrovirals for HIV treatment or prevention: the ANRS CLAPT study**
Laurence Slama, France
- PE30/10 **Quality of life in people living with HIV: a regional survey in Flanders**
Gert Scheerder, Belgium
- PE30/11 **Innovative strategies to sustain community participation in HIV vaccine trials, experience of Makerere University Walter Reed Project (MUWRP) in Kampala, Uganda**
Jauhara Nanyondo, Uganda
- PE30/12 **Stigma among healthcare providers towards people living with HIV/AIDS in India**
Akanksha Rathi, India
- PE30/13 **"I love my life, I don't want to miss a thing": motivators and Barriers to ART adherence among women living with HIV/AIDS in Iran**
Nooshin Amirisani, Iran, Islamic Republic of
- PE30/14 **Medical students as potential sources of information about HIV/AIDS**
Mykola Haras, Ukraine
- PE30/15 **Gender violence, intimate partner violence and domestic violence among HIV-positive patients in Alicante (Spain). Preliminary results of the VIHOLETA study**
Jara Llenas-García, Spain
- PE30/16 **Influence of stigma and discrimination on psychosocial health in children affected by AIDS in Nepal: a cross-sectional study**
Kalpana Gaulee Pokhrel, Nepal
- PE30/17 **The quality of life among people living with HIV in Taiwan in the era of STR**
Chung-Ching Shih, Taiwan, Republic of China
- PE30/18 **Experiences of and factors influencing physical activity in people living with HIV: a qualitative systematic review**
Megan Davies, United Kingdom

Scientific Programme

- PE30/20 **Perception of condom use in the era of pre-exposure prophylaxis (PrEP): a qualitative analysis**
Shui Shan Lee, Hong Kong
- PE30/21 **Recommendations for enabling timely pregnancy disclosure to clinical staff of women living with HIV**
Stefania Mihale, Romania
- PE30/22 **Health-related quality of life in a single center cohort of people living with chronic diseases: comparison between HIV and other clinical conditions**
Antonella Cingolani, Italy
- PE30/23 **Experiences of Dutch obstetric healthcare providers with HIV-positive pregnant women: a qualitative study**
Carlijn Damsté, Netherlands
- PE30/24 **Evaluation of knowledge, attitudes and practices among HIV positive pregnant women and their partners in four healthcare facilities in Malawi**
Isotta Triulzi, Italy
- PE30/25 **Towards the 4th 90, measuring multi-dimensional quality of life in people living with HIV in Aquitaine, France: psychometric properties of the French version of the WHOQOL-HIV BREF**
Diana Barger, France
- PE30/26 **Body size modifies the relationship between internalized HIV stigma and pain in people with HIV in the Southeastern USA**
Kaylee Crockett, United States

ePosters
12:45 - 20:00

Exhibition hall

Standard of care

- PE31/1 **Exploring the attitudes of HIV-positive patients on single-tablet antiretroviral regimens towards generic de-simplification**
Ciara Levey, Ireland
- PE31/2 **Comparison of Immunological and virological response to cART between HIV-1/O and HIV-1/M patients followed-up in France: the ANRS ORIVAO and COPANA studies**
Guillemette Unal, France
- PE31/3 **From HIV diagnosis to antiretroviral therapy initiation in Croatia from 2013 to 2018**
Nikolina Bogdanić, Croatia
- PE31/5 **Tetanus seroprotection in HIV-positive subjects living in Belgium: risk factors for seronegativity, evaluation of medical history and a rapid dipstick test**
Nicolas Dauby, Belgium
- PE31/6 **The prevalence of virologic failure and resistance associated mutations in single and multi-tablet HIV treatment regimens**
Chien-Yu Cheng, Taiwan, Republic of China
- PE31/7 **Development and validation of a risk score for predicting non-adherence to antiretroviral therapy**
Hernando Knobel, Spain

Scientific Programme

- | | |
|---------|---|
| PE31/8 | Measles seroprevalence among HIV infected patients in central part of Poland - vaccination proposal
Ewa Siwak, Poland |
| PE31/9 | Nurse-led annual health review - one year follow up
Marie-Pierre Klein, United Kingdom |
| PE31/11 | Viral hepatitis in HIV-positive patients - testing, prophylaxis and treatment in Central and Eastern Europe
Kerstin Kase, Estonia |
| PE31/12 | Evaluating a national pilot process for reviewing late HIV diagnoses in England and Wales
Ming Jie Lee, United Kingdom |
| PE31/13 | GESIDA quality of care indicators for PLWH: report from two Spanish hospitals 2009-2017
Francisco Fanjul, Spain |
| PE31/14 | Late presentation and barriers to the early HIV diagnosis in Central part of Ukraine
Tetiana Koval, Ukraine |
| PE31/15 | Operational research of barriers and facilitators to harm reduction services for intravenous drug users (including female IDUs)
Tamar Zurashvili, Georgia |
| PE31/16 | A seven-month prospective review of HIV admissions to a regional infectious disease unit in Manchester, UK
Hamzah Zahid Farooq, United Kingdom |
| PE31/17 | Annual health review for people living with HIV - an evaluation
Sarah Edwards, United Kingdom |
| PE31/18 | Analysis of adherence to HIV-positive quality of care indicators and their impact of service quality perceptions in patient: a Spanish cross-sectional study
Alejandra Gimeno García, Spain |

ePosters
12:45 - 20:00

Exhibition hall

Tuberculosis and opportunistic infections

- | | |
|--------|--|
| PE35/1 | Nontuberculous mycobacteria infections in Russian HIV patients: clinical features and outcomes
Mikhail Savchenko, Russian Federation |
| PE35/2 | Human immunodeficiency virus and the outcome of treatment for pulmonary tuberculosis: a retrospective study in Tehran, Iran
Mohammad Bagheri, Iran, Islamic Republic of |
| PE35/3 | Rifampicin pharmacokinetics and pharmacogenetics in Ugandan patients with multi-drug resistant tuberculosis
Jackson K. Mukonzo, Uganda |
| PE35/4 | Mycobacteria-induced immune responses by mucosal-associated invariant T (MAIT) cells are impaired in patients with tuberculosis (TB) and HIV-associated TB
Muki Shey, South Africa |

Scientific Programme

- PE35/5 **Acute onset of cerebral toxoplasmosis in patients with HIV infection**
Tatiana Ermak, Russian Federation
- PE35/6 **Association between immunological status and TB disease development in HIV-infected individuals with LTBI**
Ngai Sze Wong, Hong Kong
- PE35/7 **Amoeba- a swiss army knife for diagnosis and mechanistic understanding of Legionella infection**
Breanne M Head, Canada
- PE35/8 **Causes and outcomes of hospitalizations among HIV positive persons in Georgia's referral institution, 2012-2017**
Nino Rukhadze, Georgia
- PE35/9 **Population pharmacokinetic analysis of dolutegravir in HIV/TB co-infected people with and without rifampicin**
Rajendra Singh, United States
- PE35/10 **Lung function and health-related quality of life among patients following pulmonary tuberculosis treatment in urban Uganda: a cross-sectional study**
Josephine Zawedde, Uganda
- PE35/11 **Clinical and laboratory characterization of progressive multifocal leukoencephalopathy in HIV-infected patients in the intensive care unit**
Anastasia Pokrovskaya, Russian Federation
- PE35/13 **Cryptococcal and tuberculosis coinfection: case series identified through the implementation of an advanced HIV disease package of care linked to a TB active case finding strategy in rural Mozambique**
Alejandro Blanco-Arévalo, Spain
- PE35/14 **Trends in latent tuberculosis screening in a cohort of HIV-infected patients from a low tuberculosis incidence country**
Pedro Palma, Portugal
- PE35/15 **Drug-induced hepatic injury developed in tuberculosis / HIV co-infection treatment**
Sarah Silva, Brazil

ePosters
12:45 - 20:00

Exhibition hall

Vaccines and immune based therapies

- PE36/2 **Development of engineered nanocarrier for controlled delivery of a protease inhibitor**
Saurabh Bhargava, India

ePosters
12:45 - 20:00

Exhibition hall

Viral hepatitis

Scientific Programme

- PE37/1 **Acute hepatitis C infection in HIV-infected patients who achieved viral suppression: incidence and risk factors**
Hsin-Yen Ku, Taiwan, Republic of China
- PE37/2 **HBV infections among HIV infected HAART receiving mothers and their exposed infants in a tertiary hospital in Kenya**
James Kangethe, Kenya
- PE37/3 **Direct-acting antivirals (DAAs) improve liver stiffness measurements but do not improve the Veterans Aging Cohort Study (VACS) Index in HIV /HCV co-infected Egyptian patients: is improved discrimination needed?**
Ahmed Cordie, Egypt
- PE37/4 **HCV/HIV coinfection in the DAA era: which patients have not been treated for HCV?**
Fabian Dario Rodriguez-Monaco, Germany
- PE37/5 **Hepatitis E seroprevalence in HIV-positive patients**
Mustafa Altindis, Turkey
- PE37/6 **Success of unrestricted DAA therapy is limited by HCV reinfections and loss to follow-up in HIV-positive patients**
David Chromy, Austria
- PE37/7 **Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and Hepatitis B Virus (HBV) coinfection**
Yu-Shan Huang, Taiwan, Republic of China
- PE37/8 **Effectiveness of hepatitis a vaccination among people living with HIV in Taiwan: is one dose enough?**
Chia-Jui Yang, Taiwan, Republic of China
- PE37/9 **HIV patients remain at high risk for advanced liver fibrosis after curing HCV infection**
Natalia Bolokadze, Georgia
- PE37/10 **HIV/HCV coinfection in Spain: trouble will soon be over**
Juan Berenguer, Spain
- PE37/11 **Care cascade of incident HCV infection among HIV-positive patients in Taiwan**
Miao-Hui Huang, Taiwan, Republic of China
- PE37/12 **Current characteristics of HIV/HBV coinfecting patients in a single HIV reference centre of Madrid**
Luz Martín-Carbonero, Spain
- PE37/13 **High HCV reinfection rate in MSM living with HIV in Barcelona: the need to focus on high risk population to achieve HCV elimination**
Maria Martínez-Rebollar, Spain
- PE37/14 **Liver disease in HIV-infected subjects in the post-HCV DAA treatment era**
Carmen Busca, Spain
- PE37/15 **Seroprevalence of hepatitis E in a Portuguese cohort of human immunodeficiency virus infected patients**
André Silva-Pinto, Portugal

Scientific Programme

- PE37/16 **Loss of seroprotection against hepatitis B virus (HBV) was associated with lower CD4 counts among HIV-positive patients who were born in the era of nationwide neonatal HBV vaccination**
Yi-Chia Huang, Taiwan, Republic of China
- PE37/17 **Improvement of immunity and hepatic fibrosis after HCV treatment with DAA in people living with HIV and HCV**
Montserrat Laguno, Spain
- PE37/18 **DAA treating Hepatitis C in HIV/HCV coinfectd patients in two prisons of Rome: results and problems**
Sara Lardo, Italy
- PE37/19 **Progress towards eliminating mother-to-child transmission of HIV in the Macha area in Zambia from 2010-2018**
Mutinta Hamahuwa, Zambia
- PE37/20 **Evaluation of the hepatitis C care cascade in the country of Georgia: monitoring 4 years of progress towards elimination**
Tengiz Tsertsvadze, Georgia
- PE37/21 **Epidemiology of HIV, HBV and HCV co-infection in Israel**
Karen Olshtain-Pops, Israel
- PE37/22 **Hepatitis C treatment outcomes of HIV infected people who inject drugs in a real-world cohort**
Dimitris Basoulis, Greece
- PE37/23 **Treatment of acute HCV infection with direct acting antivirals (DAA) in HIV patients**
Cristina Gómez-Ayerbe, Spain
- PE37/24 **Hepatic fibrosis progression among HIV patients in Israel**
Karen Olshtain-Pops, Israel
- PE37/25 **Acute hepatitis B in persons living with HIV in a low hepatitis B prevalence area during the last two decades**
Luz Martín-Carbonero, Spain
- PE37/26 **Virological response to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients with lamivudine-resistant hepatitis B virus coinfection**
Yu-Shan Huang, Taiwan, Republic of China
- PE37/27 **Impact of direct-acting antiviral (DAA) agents on T cell counts and liver stiffness in HIV/HCV-coinfectd patients: a multicenter prospective observational cohort study**
David Dalmau, Spain
- PE37/28 **Trends of HCV infection among HCV-seronegative, HIV-positive patients in Taiwan between 2011-2018**
Li-Hsin Su, Taiwan, Republic of China
- PE37/29 **The micro-elimination approach to eliminating Hepatitis C: a Fast Track City project**
Franco Maggiolo, Italy
- PE37/30 **Road to HCV elimination in HV/HCV coinfectd patients by screening and universal access to DAA: baseline data from the first screening of NoCo (No-Coinfection) study**
Antonella d'Arminio Monforte, Italy

Scientific Programme

- PE37/31 **HCV cascade of care for HIV/HCV coinfecting individuals in Greece and HCV treatment considerations in clinical practice**
Mina Psychogiou, Greece
- PE37/32 **Hepatitis B core-related antigen and anti-hepatitis B core antibody are not associated with liver fibrosis evolution in HIV-HBV co-infected patients during treatment with tenofovir**
Romuald Cruchet, France
- PE37/33 **Antiretroviral therapy: a possible role in lipid changes after HCV eradication by DAAs**
Alessandra Vergori, Italy
- PE37/34 **Treatment of cirrhotic monoinfected and HCV/HIV coinfecting patients with direct acting antivirals (DAAs)**
Fábio Videira Santos, Portugal
- PE37/35 **Predictors of vaccine efficacy after hepatitis B vaccination in people with HIV infection**
Gerardo Ibarra, Germany
- PE37/36 **Long term response to mandatory anti-HBV vaccination: risks for disease acquisition and opportunities for re-vaccination within the ICONA cohort**
Roberto Rossotti, Italy
- PE37/37 **The assessment of HBsAg serum concentration during chronic hepatitis B phases' identification among HIV/HBV coinfecting patients before antiviral therapy prescription**
Tetiana Melnyk, Ukraine
- PE37/38 **Predictors of liver fibrosis improvement after HCV eradication in HIV+ patients: data from an Italian cohort**
Alessandra Vergori, Italy
- PE37/39 **Long-term follow-up of people who use drugs (PWUD) following HCV infection therapy: drug use patterns among HIV co-infected versus mono-infected patients**
Astou Thiam, Canada
- PE37/40 **Treatment outcome of HCV single vs multi tablet regimen in mono and HIV co-infected people who use drugs (PWUD): a long-term follow-up analysis**
Astou Thiam, Canada

ePosters
12:45 - 20:00

Exhibition hall

Virology

- PE38/1 **Identification of an HIV-1 BC intersubtype recombinant form, which is circulating in Spain**
Javier Enrique Cañada García, Spain
- PE38/2 **Viral reservoir dynamics in very early primary HIV infection (PHI) patients receiving an intensified antiretroviral regimen (ART): a pilot clinical trial**
Juan Ambrosioni, Spain
- PE38/3 **Lamivudine-based two-drug regimens are not associated with an increased risk of detectable rectal HIV-RNA**
Alberto Borghetti, Italy

Scientific Programme

- PE38/4 **Comparison of HIV-1 viral load and drug resistance mutations between cerebrospinal fluid and plasma in patients with HIV and Cryptococcal meningitis co-infection in Botswana**
Nametso Kelentse, Botswana
- PE38/5 **HTLV-II antisense protein Aph-2 negatively regulates HIV-1 transcription**
Rajkumar Londhe, India
- PE38/6 **HIV compartmentalization between plasma and CSF and association with neurocognitive disorders**
Alessandro Lazzaro, Italy
- PE38/7 **Determinants of neurocognitive impairments in a Romanian cohort of young adults with chronic HIV infection**
Simona Ruta, Romania
- PE38/8 **Reconstruction of phylogeography for Indian HIV-1 sub-subtype A1**
Ajit Patil, India
- PE38/9 **Broad and potent neutralizing antibody responses in HIV-1 infected Angolan patients: implications for vaccine design and efficacy**
Francisco Martin, Portugal
- PE38/10 **The XbnAb cohort: a HIV-1 cohort of 304 bnAb inducers and matched controls tailored to study determinants of bnAb induction**
Irene Abela, Switzerland
- PE38/11 **Performance of 'Xpert® HIV-1 Qual assay' for diagnosis of HIV-1 infection using Dried Blood Spot specimens**
Swarali Kurle, India
- PE38/12 **HIV-1 infections belonging to transmission clusters originating in different countries are frequently detected in Spain among newly diagnosed individuals**
Javier Cañada, Spain

ePosters
12:45 - 20:00

Exhibition hall

Vulnerable groups

- PE39/1 **Boys having sex with boys: CD4 count as parameter to estimate the time of infection among HIV seropositive men having sex with men and its societal implications in the Philippines**
Patrick Eustaquio, Philippines
- PE39/2 **Evaluating factors increasing the vulnerability of adolescent girls and young women to HIV/AIDS infection in selected communities, Akwa Ibom State**
Jessie Inyang, Nigeria
- PE39/3 **Men's perspectives on HIV self-testing in sub-Saharan Africa: a systematic review and meta-synthesis**
Mbuzeleni Hlongwa, South Africa
- PE39/4 **Molecular-biological methods of diagnostics in the investigation of the case of transmission of HIV-infection**
Diana Valutite, Russian Federation

Scientific Programme

- PE39/5 **Implementation of demedicalized and decentralized HIV testing project in Brussels: action test, project for vulnerable populations at high HIV risk in Brussels, including Sub-Saharan African Migrants (SAM)**
Tresors Kouadio, Belgium
- PE39/6 **HIV prevalence, risk-taking behavior and self-testing potential among men who have sex with men and transgender people**
Evgeniy Pisemskiy, Russian Federation
- PE39/7 **Political commitment matters in the elimination of the threat of HIV and HCV and TB among people who use drugs**
Gefra Fulane, Portugal
- PE39/8 **Challenges in health and social care for migrant HIV patients in the Czech Republic**
Elena Tulupova, Czech Republic
- PE39/9 **Integration of hepatitis C cure in housing facility Soleil Evant: health cost implications**
Erika Castro, Switzerland
- PE39/10 **The role of sexual partners of people who inject drugs in better uptake of retention in HIV services**
Marine Gogia, Georgia
- PE39/11 **Male sex workers and ICT: anthropological approach of male sex workers and the different practices online: bareback, PrEP and chemsex**
Maxime Maes, Belgium
- PE39/12 **Portuguese League Against AIDS - mobile screening unit**
Maria Eugénia Saraiva, Portugal
- PE39/13 **Detectable viraemia in the era of successful antiretroviral therapy; engagement with multi-disciplinary services**
Shimu Khamlichi, United Kingdom
- PE39/14 **Optimal HIV self-testing, potential strategies to increase HIV diagnosis in Tanzania**
Neema Makyao, Tanzania, United Republic of

ePosters
12:45 - 20:00

Exhibition hall

Treatment in resource-constrained settings

- PE34/2 **Optimizing clients linkage into ART using family-centered differentiated approach (FCDA) in Kebbi state, northwestern Nigeria: successes and challenges**
Johnson Okolie, Nigeria
- PE34/3 **A multi-stakeholder evaluation of the early implementation experiences of differentiated anti-retroviral therapy (ART) delivery roll-out across Uganda: a qualitative analysis**
Henry Zakumumpa, Uganda
- PE34/5 **Evaluation of the financial cost of treating people living with human immunodeficiency virus in the United Kingdom versus matched HIV-negative controls in 2004, 2010 and 2017**
Scott Francis, United Kingdom

Scientific Programme

- PE34/6 **Continuous quality improvement across the viral load testing spectrum at the Infectious Diseases Institute, Uganda**
Harriet Tibakabikoba, Uganda
- PE34/7 **Pediatric HIV viral load suppression: qualitative insights of barriers and facilitators among caregivers of children on ART in high volume sites in Kisumu County, Kenya**
Nicollate Okoko, Kenya
- PE34/8 **Boosting economic affordability of HIV medicines while considering safety and effectiveness within transition from donor funding. Enabling access to TAF regime with better safety profile in Ukraine through advocacy campaign of community organization**
Zoia Zamikhovska, Ukraine

ePosters
12:45 - 20:00

Exhibition hall

Mother-to-child transmission

- PE21/1 **HIV infection in pregnant women and children in Switzerland: how effective are measures for preventing mother-to-child transmission?**
Martin Gebhardt, Switzerland
- PE21/2 **No evidence for induced glucuronidation of dolutegravir in HIV-infected pregnant women**
Vera Bukkems, Netherlands
- PE21/3 **Comparative analysis of clinic and laboratory parameters and frequency of mother-to-child transmission of HIV among HIV-positive pregnant women with marked immunodeficiency and normal immunological status**
Olga Mozaleva, Russian Federation
- PE21/4 **Analysis of perinatal HIV transmission cases in St. Petersburg**
Anna Samarina, Russian Federation
- PE21/5 **Geopolitical assessment and relevance for acceptance of vaginal delivery in good controlled HIV-infected pregnant women in Japan**
Kimikazu Hayashi, Japan
- PE21/6 **Pregnancy outcomes in HIV-positive women: a retrospective national cohort study from the "Grigorios AIDS Clinic" in Cyprus**
Georgios Siakallis, Cyprus
- PE21/7 **New-born infants from HIV positive women: five years experience of Infectious Diseases Hospital Iasi**
Alexandra Largu, Romania
- PE21/8 **Risk factors for peripartum virological failure in South African pregnant women on anti-retroviral therapy: East London Prospective Cohort Study**
Oladele Vincent Adeniyi, South Africa

Scientific Programme

Industry sponsored session
13:15 - 14:45

Sydney

Industry sponsored session

(For more details, please visit the [conference website](https://eacs-conference2019.com/index.php?article_id=166))

Pre-conference workshop/course
14:00 - 17:00

Samarkand

EATG workshop: STEPS - A community initiative to design the pathway to a long-term remission of HIV infection

Convener: EATG

Welcome and introductions Giulio Maria Corbelli, Italy	14:00 - 14:15
The role of bNAbs in research for long-term drug-free remission of HIV infection Annemarie Wensing, Netherlands	14:15 - 15:00
RIO: UK study using dual long-acting bNAbs Simon Collins, United Kingdom	15:00 - 15:45
The London patient and the Dusseldorf patient: procedures, hopes and challenges Giulia Marchetti, Italy	15:45 - 16:15
Open discussion about the ethical challenges in HIV "cure" research and treatment interruptions	16:15 - 16:45
Wrap up and conclusions Giulio Maria Corbelli, Italy	16:45 - 17:00

Industry sponsored session
15:00 - 16:30

San Francisco

Industry sponsored session

(For more details, please visit the [conference website](https://eacs-conference2019.com/index.php?article_id=166))

Scientific Programme

Ceremony
17:15 - 18:45

Event Hall

Conference opening

Session interpreted in Russian

Access to the webcasted session:

[Opening Welcome](http://resourcelibrary.eacs.cyim.com?mediald=78006)

[Address](http://resourcelibrary.eacs.cyim.com?mediald=78004)

[90-90-90 goals in Europe: In action](http://resourcelibrary.eacs.cyim.com?mediald=78007)

[HIV care beyond 2019: How to address old and new challenges?](http://resourcelibrary.eacs.cyim.com?mediald=78008)

[Community perspective: Inequalities in care](http://resourcelibrary.eacs.cyim.com?mediald=78009)

[European AIDS Clinical Society Award for Excellence in HIV Medicine](http://resourcelibrary.eacs.cyim.com?mediald=78010)

Chairs:

Manuel Battegay, Switzerland
Jürgen Rockstroh, Germany

Opening welcome	17:15 - 17:30
Manuel Battegay, Switzerland Jürgen Rockstroh, Germany	
Address	17:30 - 17:35
Lukas Engelberger, Switzerland	
90-90-90 goals in Europe: In action	17:35 - 17:55
Anastasia Pharris, Sweden	
HIV care beyond 2019: How to address old and new challenges?	17:55 - 18:15
Jens D. Lundgren, Denmark	
Community perspective: Inequalities in care	18:15 - 18:30
Alex Schneider, Switzerland	
European AIDS Clinical Society Award for Excellence in HIV Medicine	18:30 - 18:40
Nathan Clumeck, Belgium	

Ceremony
18:45 - 20:00

Exhibition hall

Welcome reception

Scientific Programme

Thursday, 07 November 2019

Industry sponsored session
07:30 - 08:30

San Francisco

Industry sponsored session

(For more details, please visit the [conference website](https://eacs-conference2019.com/index.php?article_id=166))

Workshop/Symposium
07:30 - 08:30

Sydney

BRAHMS and the STIPnet (European HIV&STI Prevention Network) study meeting

Chairs:

Hendrik Streeck, Germany

BRAHMS and STIPnet - an update

07:30 - 07:45

Hendrik Streeck, Germany

Data analysis within the STIPnet study: possible projects

07:45 - 08:00

Klaus Jansen, Germany

PrEP and STIs among MSM in France

08:00 - 08:15

Jean-Michel Molina, France

Are we expecting an increase of STI because of PrEP uptake?

08:15 - 08:30

Pep Coll, Spain

Meet-the-expert/Clinical cases
07:30 - 08:30

Samarkand + Osaka

Public Health Topics: Supporting PrEP implementation in European settings

Chairs:

Teymur Noori, Sweden

Milosz Parczewski, Poland

Meet-the-expert/Clinical cases
07:30 - 08:30

Shanghai 3

TB co-organised with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

Chairs:

Emmanuelle Cambau, France

José M. Miro, Spain

Scientific Programme

Meet-the-expert/Clinical cases
07:30 - 08:30

Boston 1-3

How to get your biomedical paper published

Organised by Karger

Chairs:

Paul Lavender, Switzerland

Meet-the-expert/Clinical cases
07:30 - 08:30

Darwin

Prevention, screening, and treatment: Are we ignoring anal cancer in PLWH?

Chairs:

Stefan Esser, Germany

Boris Revollo, Spain

Meet-the-expert/Clinical cases
07:30 - 08:30

Kairo 2

Drug resistance in HIV and how to treat?

Chairs:

Linos Vandekerckhove, Belgium

Annemarie Wensing, Netherlands

CC3/1

Bictegravir virology failure with emergence of a previously unreported mutation in the integrase gene

07:30 - 07:50

Francois Raffi, France

Plenary lecture
08:30 - 09:00

Event Hall

PL1, The latent HIV-1 reservoir

Session interpreted in Russian

Access to the webcasted session:

Chairs:

Marylyn Addo, Germany

The latent HIV-1 reservoir

08:30 - 08:55

Matthieu Perreau, Switzerland

European Hector Research Award in HIV 2019 ceremony - Best basic science, translational paper

08:55 - 09:00

Georg Behrens, Germany

Scientific Programme

Plenary lecture
09:00 - 09:30

Event Hall

PL2, New drugs - Who would need them?

Session interpreted in Russian

Access to the webcasted session:

[New drugs - Who would need them?](http://resourcelibrary.eacs.cyim.com?mediald=78015)

Chairs:

Esteban Martínez, Spain

New drugs - Who would need them?

Chloe Orkin, United Kingdom

ePosters
09:00 - 18:00

Exhibition hall

Antiretroviral therapy preclinical

- PE4/3 **In vivo dissection of the effects of HIV and antivirals on mitochondrial function in chronic treated HIV**
Theodoros Kelesidis, United States
- PE4/4 **The main barriers to “Test and Start” in Central Asia from the service providers' and patients' point of view**
Yelena Kudusova, Kazakhstan
- PE4/5 **Preclinical aspects of an anti-HIV molecule targeting vimentin**
Celia Berta Fernandez-Ortega, Cuba
- PE4/6 **PK/PD modelling of bnAbs for HIV treatments identifying knowledge gaps**
Mark Baker, Switzerland
- PE4/7 **A new inhibitor of HIV-1 infection exploiting host intracellular signaling to alter viral RNA processing**
Raymond Waiman Wong, Canada

ePosters
09:00 - 18:00

Exhibition hall

HIV drug resistance

- PE13/1 **Darunavir resistance among patients exposed to protease inhibitors failing ARV therapy**
Luis Fernando Brigido, Brazil
- PE13/2 **Prevalence and factors associated to the detection (population and next generation sequencing) of archived 3TC resistance mutations in aviremic HIV-infected adults (GEN-PRO)**
Lourdes Domínguez-Domínguez, Spain
- PE13/4 **Monitoring the prevalence of transmitted HIV drug resistance in Hungary**
Eva Ay, Hungary

Scientific Programme

- PE13/5 **Predominant reverse transcriptase resistance mutations as barriers to achieving elimination of mother-to-child transmission of HIV in South Africa**
Oladele Vincent Adeniyi, South Africa
- PE13/6 **Virologic failure and human immunodeficiency virus drug resistance in adolescents on antiretroviral therapy in Yaounde and Douala**
Magaly Jeanne Estelle Moukoko Mbonjo, Cameroon
- PE13/7 **Selection of integrase inhibitor (INI) resistance mutations in an INI experienced patient treated by Bictegravir**
Thanes Vanig, United States
- PE13/8 **Impact of HIV-1 subtypes and integrase natural polymorphisms on virological response to first-line integrase inhibitors based regimens**
Daniele Armenia, Italy
- PE13/9 **HIV-1 integrase inhibitor resistance associated mutations defined by majority and minority populations among individuals failing therapy**
Smitha Gudipati, United States
- PE13/10 **HIV-1 diversity and antiretroviral resistance among bulgarian citizens infected abroad and foreigners registered with HIV/AIDS in bulgaria from 2012 to 2017 (preliminary analysis)**
Ivailo Alexiev, Bulgaria
- PE13/11 **Analytical treatment interruption and its association with rearrangement of peripheral archived resistance mutations**
Claudia Alteri, Italy
- PE13/12 **A low level of darunavir resistance-associated mutation emergence in patients with virological failure during long term use of darunavir in people living with HIV, the French ANRS CO3 Aquitaine cohort**
Fabrice Bonnet, France
- PE13/13 **Patients infected with multi-class resistant HIV-1 and with viral suppression treated with no more than one active drug: comparison of historical resistance reports and drug resistance in proviral DNA**
Christian Hoffmann, Germany
- PE13/14 **Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance in people living with HIV-1 (PLWH) subtype non-B from the Swiss HIV Cohort Study (SHCS)**
Martina L. Reichmuth, Switzerland
- PE13/15 **HIV-1 from antiretroviral-naïve and experienced patients lack capsid substitutions associated with GS-6207 in vitro resistance**
Anne-Geneviève Marcelin, France
- PE13/16 **Long-term efficacy, safety and durability of ibalizumab in expanded access study**
Graeme Moyle, United Kingdom
- PE13/17 **Clinical impact of minority mutations in patients failing an integrase inhibitor-based regimen: what do clinicians do?**
Smitha Gudipati, United States
- PE13/18 **Identification of HIV-1 transmission clusters in Croatia, 2014 - 2017: evidence for the forward spread of HIV-1 resistant variants**
Josip Begovac, Croatia

Scientific Programme

- PE13/19 **High levels of resistance among HIV-1 treatment naive patients in Greece, a nationwide study: evidence for country and regional level transmission networks**
Dimitris Chatzidimitriou, Greece
- PE13/20 **A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring NRTI resistance mutations M184V/I +/- TAMs (GS-US-292-1824): week 24 results**
Ignacio Pérez-Valero, Spain
- PE13/21 **Sustained viral suppression among participants with pre-existing M184V/I who switched to bictegravir/emtricitabine/tenofovir alafenamide**
Kristen Andreatta, United States
- PE13/22 **Absence of naturally existing resistance against the HIV-1 capsid inhibitor GS-6207 in HIV-1 primary isolates**
Christian Callebaut, United States
- PE13/23 **Impacts assessment of home based care program over adherence to ART among adolescence living with HIV and AIDS in Blantyre Malawi**
Lesily Samson Kapile, Malawi
- PE13/24 **Correlation of results analysis drug resistance of HIV-1 among patients with virological failure by next-generation sequencing and traditional population sequencing**
Alina Kirichenko, Russian Federation
- PE13/25 **Analysis of the latent reservoir of a patient infected with HIV under PrEP by single full-length HIV-1 amplification**
Maximilian Damagnez, Germany
- PE13/26 **Drug resistance profile according to HIV-1 viral load after long-term exposure to antiretroviral treatment in the absence of routine virological monitoring: results from a programmatic cohort in sub-Saharan Africa**
Giovanni Villa, United Kingdom
- PE13/27 **In vitro analysis of replicative capacity and phenotypic susceptibility of integrase mutant HIV-2 viruses**
Quentin Le Hingrat, France
- PE13/28 **Treatment simplification with two-drug regimens: impact of transmitted drug resistance mutations in residents of South-East Austria**
Evelyn Stelzl, Austria
- PE13/29 **Baseline resistance to Doravirine depends on the algorithm used for interpretation**
Carlos Guerrero Beltrán, Spain
- PE13/30 **Baseline resistance to EACS first line recommended antiretroviral regimens in newly diagnosed patients in Spain**
Federico García, Spain
- PE13/31 **A retrospective evaluation of a national home infusion provider's approach to medication adherence of parenteral ibalizumab-uiyk in the alternate-site and homecare setting**
Kathryn Andrusko-Furphy, United States
- PE13/32 **Prevalence of HIV-1 drug resistance among patients with antiretroviral therapy failure in Moscow region, Russia**
Natalya Lebedeva, Russian Federation

Scientific Programme

- PE13/33 **HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa: implications for elimination of mother-to-child transmission**
Oladele Vincent Adeniyi, South Africa
- PE13/34 **Antiretroviral Resistance patterns in HIV-1 infected patients failing to second-line in Bamako, Mali**
Almoustapha Issiaka Maiga, Mali

ePosters
09:00 - 18:00

Exhibition hall

Human genomics

- PE15/1 **Genetic characterization of the near full-length genome of an HIV-1 A1/C/D/K/B unique recombinant form from the Eastern Cape, South Africa: a case report**
Oladele Vincent Adeniyi, South Africa
- PE15/2 **Impact of KIR and their ligands (HLA allele) on susceptibility to selected viral opportunistic conditions and HIV plasma viral load in HIV+ patients**
Magdalena Leszczyszyn-Pynka, Poland
- PE15/3 **The identification and causal analysis of aberrant CD4 counts in an HIV cohort in Southern Alberta, Canada**
Raynell Lang, Canada
- PE15/4 **Placental gene expression profiles and pathways in HIV-1 positive Cameroonian women under ART**
Forgu Esemu Livo, Cameroon
- PE15/5 **Functional clustering and association of HLA class I alleles to viral load in HIV-positive and ART-naïve participants from the INSIGHT START study**
Adrian Gabriel Zucco, Denmark
- PE15/6 **miRNA expression profiling in subcutaneous adipose tissue of monozygotic twins discordant for HIV infection: validation of differentially expressed miRNA and bioinformatic analysis**
Nicola Squillace, Italy
- PE15/7 **Factors influencing late presentation into care of HIV disease**
Bogusz Aksak-Wąs, Poland

ePosters
09:00 - 18:00

Exhibition hall

Immunology

- PE16/1 **Immunological and metabolic effects of dasatinib treatment in IL7-stimulated CD4+ T-cells subpopulations**
Humberto Erick De La Torre Tarazona, Spain
- PE16/2 **New T- and B-lymphocytes production and T-cell receptor diversity in young adults perinatally infected by HIV**
Martina Properzi, Italy

Scientific Programme

- PE16/3 **In Vivo modelling of mechanisms of HIV-1-related monocyte dysfunction**
Theodoros Kelesidis, United States
- PE16/4 **Lectin-like oxidized low-density lipoprotein (LOX-1) is elevated in proinflammatory monocytes in chronic treated HIV**
Theodoros Kelesidis, United States
- PE16/5 **In vivo dissection of the impact of HIV-1 versus antivirals on immune activation in chronic treated HIV**
Theodoros Kelesidis, United States
- PE16/6 **Differential impact of HIV-1 versus antivirals on systemic inflammation in chronic treated HIV**
Theodoros Kelesidis, United States
- PE16/7 **Correlation between blood telomere length and CD4+ CD8+ T-cell subsets in HIV-1-positive individuals with long-term virological suppression on antiretroviral therapy**
Javier Rodríguez-Centeno, Spain
- PE16/9 **Phenotypical recovery of the T-cell pool following switch to dual and triple INSTI-based cART**
Camilla Tincati, Italy
- PE16/11 **Expression of PD-1 in a population of double-negative T cells (CD3+CD4-CD8-) in HIV-infected patients - the preliminary study results**
Weronika Rymer, Poland
- PE16/12 **Targeting inflammation in chronic treated HIV with oral ApoA-I mimetics**
Theodoros Kelesidis, United States
- PE16/13 **Poor recovery of T-cell receptor repertoire despite long-term antiretroviral therapy**
James Brown, United Kingdom

ePosters
09:00 - 18:00

Exhibition hall

Pathogenesis and immunopathogenesis

- PE26/2 **Colonic microbiota exhibits disparate associations with HIV-infection and sexual practices**
Eveline Verheij, Netherlands
- PE26/3 **Zonulin indicates loss of intestinal integrity and microbial translocation in HIV+ patients**
Max Augustin, Germany
- PE26/4 **Distinct pro-inflammatory and cardio-protective effects of antiretroviral drugs in vascular endothelial cells**
Akif A. Khawaja, United Kingdom
- PE26/5 **Bacterial translocation kinetics in HIV-1 infection: from acute to chronic stages**
Paula Aranguren-Rivas, Spain
- PE26/6 **Mitochondrial antioxidants attenuate In vivo liver fibrosis in chronic treated HIV**
Theodoros Kelesidis, United States

Scientific Programme

- PE26/7 **Mitochondrial antioxidants attenuate In vivo mitochondrial dysfunction and exhaustion in T cells in chronic treated HIV**
Theodoros Kelesidis, United States
- PE26/8 **Inhibition of caspase 1 reduces viral load, CD4 T cell depletion and immune activation in HIV-1 infected humanized mice**
Philipp Adams, Luxembourg
- PE26/9 **Effect of early initiation of ART on alterations in natural killer cells in HIV infected pediatric patients**
Romsha Kumar, India
- PE26/10 **HIV-DNA levels, HLA-B*27 and HLA-DRB1*13 among LTNPs, ECs and HIV controllers**
Arianna Gabrieli, Italy
- PE26/11 **Macromolecule uptake across intestinal epithelia in HIV infection**
Carolin Grünhagen, Germany
- PE26/12 **Immune cell activation as a risk factor for hypertension in people living with HIV in Sub-Saharan Africa using the recent American Heart Association and American College of Cardiology Guidelines**
Sepiso Masenga, Zambia

ePosters
09:00 - 18:00

Exhibition hall

Vaccines and immune based therapies

- PE36/2 **Development of engineered nanocarrier for controlled delivery of a protease inhibitor**
Saurabh Bhargava, India

ePosters
09:00 - 18:00

Exhibition hall

Virology

- PE38/1 **Identification of an HIV-1 BC intersubtype recombinant form, which is circulating in Spain**
Javier Enrique Cañada García, Spain
- PE38/2 **Viral reservoir dynamics in very early primary HIV infection (PHI) patients receiving an intensified antiretroviral regimen (ART): a pilot clinical trial**
Juan Ambrosioni, Spain
- PE38/3 **Lamivudine-based two-drug regimens are not associated with an increased risk of detectable rectal HIV-RNA**
Alberto Borghetti, Italy
- PE38/4 **Comparison of HIV-1 viral load and drug resistance mutations between cerebrospinal fluid and plasma in patients with HIV and Cryptococcal meningitis co-infection in Botswana**
Nametso Kelentse, Botswana
- PE38/5 **HTLV-II antisense protein Aph-2 negatively regulates HIV-1 transcription**
Rajkumar Londhe, India

Scientific Programme

- PE38/6 **HIV compartmentalization between plasma and CSF and association with neurocognitive disorders**
Alessandro Lazzaro, Italy
- PE38/7 **Determinants of neurocognitive impairments in a Romanian cohort of young adults with chronic HIV infection**
Simona Ruta, Romania
- PE38/8 **Reconstruction of phylogeography for Indian HIV-1 sub-subtype A1**
Ajit Patil, India
- PE38/9 **Broad and potent neutralizing antibody responses in HIV-1 infected Angolan patients: implications for vaccine design and efficacy**
Francisco Martin, Portugal
- PE38/10 **The XbnAb cohort: a HIV-1 cohort of 304 bnAb inducers and matched controls tailored to study determinants of bnAb induction**
Irene Abela, Switzerland
- PE38/11 **Performance of 'Xpert® HIV-1 Qual assay' for diagnosis of HIV-1 infection using Dried Blood Spot specimens**
Swarali Kurle, India
- PE38/12 **HIV-1 infections belonging to transmission clusters originating in different countries are frequently detected in Spain among newly diagnosed individuals**
Javier Cañada, Spain

ePosters
09:00 - 18:00

Exhibition hall

Antiretroviral observational studies

- PE2/1 **A study of the effect of antiretroviral therapy on sexual risk behavior in a high-risk cohort of Congolese women**
Samuel Bitu, Congo, the Democratic Republic of the
- PE2/2 **Coagulation system and HIV infection: a review**
Nnamdi Nwachukwu, Nigeria
- PE2/3 **Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-naïve HIV-1 infected patients - 24-month results from the German TAFNES cohort study**
Hans-Jürgen Stellbrink, Germany
- PE2/4 **"Attracting men" - extended clinic hours as differentiated model of care in an urban Malawian cohort**
Sam Phiri, Malawi
- PE2/5 **HIV care in India: a systematic review of barriers to anti-retroviral therapy adherence**
Charu Kohli, India
- PE2/6 **Comparing NRTI-sparing dual regimens using data from the Swiss HIV cohort study**
Jim Young, Switzerland

Scientific Programme

- PE2/7 **Physicians' opinions on generic antiretroviral drugs and single tablet regimen (STR) de-simplification for the treatment of HIV infection: a multicentre survey in Spain**
Inés Suárez-García, Spain
- PE2/8 **Simplifying salvage regimens with darunavir-based dual therapy in HIV-infected individuals harboring multidrug-resistance**
Pilar Vizcarra, Spain
- PE2/9 **Clinical outcomes among HIV-infected Africans with advanced disease in Spain**
Adrià Ramírez-Mena, Switzerland
- PE2/10 **The Treatment of Primary HIV (TopHIV) cohort: a prospective multicenter cohort in Germany**
Melanie Stecher, Germany
- PE2/11 **No decrease in CD4/CD8 ratio after 36 months therapy in patients who were switched to two dual regimens containing rilpivirine**
Cecilia Tortajada, Spain
- PE2/12 **Clinical experience of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in real life practice: data from the Turkish HIV-TR cohort**
Volkan Korten, Turkey
- PE2/13 **Real world utilisation of raltegravir 1200mg once daily (The RETRO Study)**
Christine Mackay, United Kingdom
- PE2/14 **Effectiveness, persistence and safety in treatment-naïve and treatment-experienced HIV-1 infected patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) - 12-month evaluation of the French TARANIS cohort**
Jean-Luc Meynard, France
- PE2/15 **24-month evaluation of the German TAFNES cohort - Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF + 3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-experienced HIV-1 infected patients**
Heribert Knechten, Germany
- PE2/16 **Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected adult patients in routine clinical practice - 6 months results of the BICSTaR cohort**
Stefan Esser, Germany
- PE2/17 **Short-term increase in Body Mass Index and systolic blood pressure elevation in treatment naïve persons starting INSTI-based antiretroviral therapy**
Ronald Galdamez, Spain
- PE2/18 **Baseline characteristics in JUNGLE, a German observational cohort study of Juluca as 2-drug Regimen in virologically suppressed patients, compared to the phase-3 SWORD 1 & 2 study populations**
F. Schabaz, Germany
- PE2/19 **Examining the efficacy in clinical practice of the dual antiretroviral therapy regimen of boosted protease inhibitors with maraviroc**
Abhishek Katiyar, United Kingdom
- PE2/20 **Good efficacy but side effects including hypercholesterolemia and body weight gain after switching to dolutegravir plus booster protease inhibitor regimen among treatment experienced HIV-positive patients**
Yu-Lin Lee, Taiwan, Republic of China

Scientific Programme

- PE2/21 **Rates of DTG/ABC/3TC discontinuation in a real-life setting: no surprises found in reported adverse events**
Ana Gorgulho, Portugal
- PE2/22 **Low baseline HIV viral loads with a history of PrEP use - how should these patients be managed?**
Victoria Tittle, United Kingdom
- PE2/23 **Lamivudine-based maintenance 2-drugs regimens: an algorithm for the estimation of 2-years risk of virological failure in clinical practice**
Alberto Borghetti, Italy
- PE2/24 **Adding raltegravir to a bPI failing regimen was not associated with higher virologic suppression**
Monica Maria Gomes-da-Silva, Brazil
- PE2/25 **Neuropsychiatric tolerability of bictegrovir combined with FTC/TAF in clinical practice**
Christian Hoffmann, Germany
- PE2/26 **Real-world clinical outcomes of patients switched from complex multi-tablet regimens to TAF-based single-tablet regimens plus a boosted protease inhibitor**
Charlotte-Paige Rolle, United States
- PE2/27 **Dual therapy with fixed dose combination of darunavir/ritonavir plus raltegravir in HIV-infected patients in Argentina**
Diego Martin Cecchini, Argentina
- PE2/28 **Detectability of HIV residual viremia despite therapy is highly associated with treatment with protease inhibitor**
Gilles Darcis, Belgium
- PE2/29 **Prediction of virological failure in patients with low level HIV-1 viremia using a joint latent class model**
Enrique Bernal, Spain
- PE2/30 **Comparing effectiveness and tolerability of emtricitabine/tenofovir alafenamide (F/TAF) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV-1 infected adult patients in routine clinical practice: a cross cohort analysis**
Stefan Esser, Germany
- PE2/31 **Effectiveness of Dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients**
Rakan Nasreddine, Belgium
- PE2/32 **Characterizations of weight gain following antiretroviral regimen initiation in treatment-naïve individuals living with HIV**
Ricky Hsu, United States
- PE2/33 **How to RESPOND to modern challenges for people living with HIV: a new cohort collaboration**
Bastian Neesgaard, Denmark
- PE2/34 **ART simplification: use of dual therapy for HIV in a public health reference center (CRT-DST/Aids) in São Paulo, Brazil**
Roberta Schiavon Nogueira, Brazil

Scientific Programme

- PE2/35 **Simplification to dual (2D) antiretroviral therapy (ART) with lamivudine and dolutegravir in HIV-infected patients with solid organ transplantation (SOT): a preliminary single-center experience**
Juan Ambrosioni, Spain
- PE2/36 **Comparable effectiveness of Raltegravir-based dual therapy versus other regimens in patients switched for maintenance**
Karen Martin, Germany
- PE2/37 **Comparison of a two-drug regimen (dolutegravir/rilpivirine) to standard three-drug regimens in virologically suppressed, treatment experienced individuals in the real world**
Gerald Pierone, United States
- PE2/38 **Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir in treatment-experienced patients: a multicentre cohort study**
Inés Suárez-García, Spain
- PE2/39 **High persistence of dolutegravir-containing 2-drug regimens in routine clinical care**
Sebastian Noe, Germany
- PE2/40 **Virologic, immunologic and clinical outcomes in antiretroviral treatment (ART) naïve individuals in the RESPOND cohort collaboration**
Amanda Mocroft, United Kingdom
- PE2/41 **A retrospective analysis of the EuResist data set assessing HIV dual therapy success in a real-life context**
Michael Böhm, Germany
- PE2/42 **The real-world impact of switching to tenofovir-alafenamide (TAF) on metabolic co-morbidities in PLWH aged over 60s**
Ming Jie Lee, United Kingdom
- PE2/43 **Effect of simplification to INSTI-based dual therapy on residual inflammation and viral reservoir**
Giulia Marchetti, Italy
- PE2/44 **Changes in LDL after switch from TDF to TAF in the U.S.**
Paddy Mallon, Ireland
- PE2/45 **A retrospective analysis of the EuResist data set assessing if NRTI resistance impairs INSTI based treatment with NRTI backbone**
Michael Böhm, Germany
- PE2/46 **Impact of archived M184V/I mutations on the effectiveness of switching to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide among virologically suppressed HIV-positive patients**
Chien-Ching Hung, Taiwan, Republic of China
- PE2/47 **Central nervous system (CNS) side effects and viral blips post cART switch from atazanavir boosted with ritonavir (ATZ/r) to atazanavir boosted with cobicistat (ATZ/c)**
Stephanie Tyler, United Kingdom
- PE2/48 **Quantitation of cellular HIV-1 DNA levels by droplet digital PCR in virologically-suppressed patients switching to dolutegravir plus lamivudine: a prospective study**
Francesca Lombardi, Italy

Scientific Programme

- PE2/49 **Evaluation of weight gain in incarcerated individuals living with HIV/AIDS after switching to a raltegravir-based regimen**
Melissa Badowski, United States
- PE2/50 **Determinants of viral non-suppression among people living with HIV (PLHIV) in rural setting, Neno: a retrospective cohort study**
Potiphar Damiano, Malawi
- PE2/51 **Risk of developing HIV resistance in patients with low level viraemia in a large London cohort**
Naomi Fitzgerald, United Kingdom
- PE2/52 **Virological outcomes of first line regimens in women living with HIV from Icona cohort: comparison with clinical trial data**
Cristina Mussini, Italy
- PE2/53 **Well-being in people living with HIV/AIDS (PLWHA) according to cART exposure: data from IOCONA cohort**
Antonella Cingolani, Italy
- PE2/54 **Body composition changes in HIV: do INSTI matter?**
Giovanni Guaraldi, Italy
- PE2/55 **Dolutegravir-based regimens are associated with weight gain over two years following ART-initiation in ART-naïve people living with HIV (PLWH)**
Heidi Crane, United States
- PE2/56 **Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in combination with boosted darunavir (DRV) in treatment experienced patients with HIV**
Lucas Hill, United States
- PE2/57 **Real world data of using Triumeq (dolutegravir/abacavir/lamivudine; DTG/ABC/3TC): final outcomes of the 3-year German TRIUMPH cohort show good virologic effectiveness and safety in clinical routine**
Nils Postel, Germany
- PE2/58 **The effectiveness of E/C/F/TAF in treatment-naïve (TN) or treatment-experienced (TE) adult HIV-infected patients in a real-world setting, results from southern Turkey**
Dilara Inan, Turkey
- PE2/59 **Comparison of efficacy and safety of a switch to fixed-dose combination FTC/TDF-TAF/RPV versus fixed-dose combination 3TC/ABC/DTG in HIV-1-infected, treatment experienced and virologically suppressed patients: a cohort study**
Gaetana Sterrantino, Italy
- PE2/60 **COPEDOL: a 2-year French multicentric, observational, longitudinal retro-prospective study, in pretreated HIV-1-infected patients starting dolutegravir based regimen due to treatment failure**
Roland Landman, France
- PE2/61 **Drug-drug interactions with recommended first-line antiretroviral therapy in real-world settings**
Wang-Huei Sheng, Taiwan, Republic of China
- PE2/62 **Determinants of switching to TAF-based cART or dual combinations (DC) from TDF-based regimens in a cohort of HIV-infected individuals with controlled viral load ≤ 50 copies/mL**
Alessandra Vergori, Italy

Scientific Programme

- PE2/63 **An early proactive switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) is effective in maintaining virologic control and improving quality of life (QoL) in patients with a primary HIV-1 infection (PHI). An interim analysis of a phase IV clinical trial (ESTER study)**
Marta Camici, Italy
- PE2/64 **Prevalence of neuropsychiatric conditions in patients living with HIV-1 treated with antiretroviral therapies - a perspective from US Medicaid**
Wing Chow, United States
- PE2/65 **Switch to dolutegravir dual regimens and inflammation mediated by annexin**
Claudio Ucciferri, Italy
- PE2/66 **Efficacy of dual antiretroviral therapy (ART) as intermittent short cycle regimen in virologically suppressed HIV-infected patients: an observational cohort**
Romain Palich, France
- PE2/67 **Modelling time varying viral load and CD4 cell counts response to antiretroviral therapy in a cohort of HIV naive patients**
Margarida Tavares, Portugal
- PE2/68 **Impact of switching to E/C/F/TAF on lipid profile and renal function in HIV-infected patients**
Bilgul Mete, Turkey

ePosters
09:00 - 18:00

Exhibition hall

Antiretroviral randomized clinical trials

- PE3/1 **Genital HIV-1 RNA and DNA shedding in virologically suppressed individuals switching from triple- to dual- or monotherapy: pooled results from two randomized controlled trials**
Laurent Hocqueloux, France
- PE3/2 **Comparison of the Ease of Swallowability of B/F/TAF placebo compared to DTG/ABC/3TC placebo**
John Ernest McKinnon, United States
- PE3/3 **Evaluation of total HIV-DNA changes in HIV-1 infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-One Study**
Maria Mercedes Santoro, Italy
- PE3/4 **Phase-3 trials of new antiretrovirals are not representative of the global HIV epidemic**
Toby Pepperrell, United Kingdom
- PE3/5 **Impact of susceptibility scoring on virologic response in heavily treatment-experienced participants with HIV-1 receiving a fostemsavir-based antiretroviral regimen: results through week 96 from the randomized cohort of the Phase 3 BRIGHT study**
Peter Ackerman, United States
- PE3/6 **Reversibility of dolutegravir/lamivudine/abacavir neuropsychiatric toxicity after 24 weeks of switching to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (EVG/c/FTC/TAF). The DREAM Clinical Trial**
Ignacio Pérez-Valero, Spain

Scientific Programme

- PE3/7 **A switch to dolutegravir in combination with boosted darunavir is safe and effective in suppressed patients with HIV - a predefined psychosocial subanalysis of the DUALIS study**
Christoph Spinner, Germany
- PE3/8 **Tenofovir alafenamide versus tenofovir disoproxil fumarate - is there a true difference in safety?**
Toby Pepperrell, United Kingdom
- PE3/9 **Biologic sex is not the only difference between men and women: data from the Doravirine phase 2/3 clinical trials**
Sharon Walmsley, Canada
- PE3/10 **No metabolic or renal benefits when switching to an NRTI-free dolutegravir-containing 2 drug regimen (2DR) - a subanalysis of the DUALIS study**
Christoph Boesecke, Germany
- PE3/11 **Sustained viral suppression with dolutegravir monotherapy during 9,899 patient weeks of follow-up in individuals starting combination antiretroviral therapy during primary HIV infection (EARLY SIMPLIFIED): a randomized, controlled, multi-site, non-inferiority trial**
Dominique Laurent Braun, Switzerland
- PE3/12 **Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in patients with human immunodeficiency virus (HIV)-1 infection: age, race/ethnicity, and gender subgroup analyses from the DIAMOND study**
David Anderson, United States
- PE3/13 **A systematic review and meta-analysis evaluating the risk of central nervous system adverse events in randomised controlled trials of dolutegravir**
Khadija Muniath Chowdhury, United Kingdom
- PE3/14 **Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naïve adults**
Chloe Orkin, United Kingdom
- PE3/15 **Switching from a 3-drug tenofovir alafenamide (TAF)-based regimen (TBR) to a 2-drug dolutegravir/lamivudine (2DR, DTG/3TC FDC) was not associated with a higher frequency of intermittent viremia in suppressed patients in the TANGO study**
Ruolan Wang, United States
- PE3/16 **Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): week 96 results**
Peter J Ruane, United States
- PE3/17 **Single doses of long-acting capsid inhibitor GS-6207 administered by subcutaneous injection are safe and efficacious in people living with HIV**
Eric S Daar, United States
- PE3/18 **Long-term safety and efficacy of rilpivirine plus nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 7-year roll-over study from phase 2 and 3 clinical studies**
Jean-Michel Molina, France
- PE3/20 **Prevalence of archived HIV-1 DNA resistance-associated mutations (RAMs) and their lack of effect on virologic outcome at week 96 in antiretroviral treatment (ART)-experienced, virologically suppressed patients receiving the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in the EMERALD phase III trial**
Erkki Lathouwers, Belgium

Scientific Programme

- PE3/21 **Islatravir efficacy and safety for selected demographic and baseline subgroups from a Phase 2 trial in treatment naive adults with HIV-1 infection**
Jean-Michel Molina, France

ePosters
09:00 - 18:00

Exhibition hall

Pharmacology, pharmacogenomics and drug interactions

- PE27/1 **Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz based antiretroviral therapy in Zambia: an open label non-randomized interventional trial**
Mike Chaponda, Zambia
- PE27/2 **Ritonavir-boosted darunavir plus two nucleoside reverse transcriptase inhibitors versus other regimens for initial antiretroviral therapy for people with HIV infection: a systematic review**
Tatevik Balayan, Armenia
- PE27/3 **Towards individualization of antiretroviral therapy - more cost-effective than dose intensification in patients**
Bhavik Dalal, India
- PE27/4 **The valproic acid - dolutegravir drug-drug interaction is based on displacement of protein binding and unlikely to be clinically relevant**
Henriette Prins, Netherlands
- PE27/5 **BESIDE - clinical relevance and implications for management of antiretroviral therapy due to recreational drug use in PLWH in Germany**
Karen Martin, Germany
- PE27/6 **Drug-drug interactions between antiretrovirals and carbamazepine or oxcarbazepine: a real-life investigation**
Cristina Gervasoni, Italy
- PE27/7 **Drug-drug interactions between dolutegravir (DTG) and immunosuppressant drugs (IS) in HIV-infected patients with solid organ transplantation (SOT): a single-arm clinical trial (DTGSOT)**
Christian Manzardo, Spain
- PE27/8 **Abacavir hypersensitivity reaction (HSR), associated to baseline false negative HLAB5701 screening, in antiretroviral treatment naive HIV-1 patient**
Salvatore Martini, Italy
- PE27/9 **Central nervous system penetration of antiretroviral drugs in HIV-positive patients with neurocognitive impairment, assessed from paired plasma-CSF concentrations**
Perrine Courlet, Switzerland

ePosters
09:00 - 18:00

Exhibition hall

Co-morbidities, ageing

Scientific Programme

- PE9/1 **Detectable subclinical myocardial abnormalities in people living with HIV: insights from cardiac magnetic resonance imaging (MRI)**
Gavin Paul Raphael Manmathan, United Kingdom
- PE9/2 **Hypertension and ECG alterations in HIV positive patients in DREAM centres in Mozambique**
Isotta Triulzi, Italy
- PE9/3 **Cardiovascular events are declining in men with HIV aged 50 years or older in Austria**
Maria Kitchen, Austria
- PE9/4 **Prevalence of HIV-associated neurocognitive disorder (HAND) in Turkey and assessment of Addenbrooke's Cognitive Examination Revised (ACE-R) test as a screening tool**
Volkan Korten, Turkey
- PE9/5 **Pilot study assessing the Rotterdam Healthy Aging Score in a cohort of HIV-positive adults**
Sharon Walmsley, Canada
- PE9/6 **Obesity and HIV - the overlapping epidemics**
Justyna Kowalska, Poland
- PE9/7 **Exhaled nitric oxide levels are higher in people living with HIV compared to uninfected controls suggesting increased eosinophilic pulmonary inflammation**
Rebekka Faber Thudium, Denmark
- PE9/8 **Comparison of changes in bone microarchitecture with abacavir-lamivudine versus tenofovir disoproxil fumarate-emtricitabine in adults living with HIV**
Roger Bedimo, United States
- PE9/9 **Limitations of FRAX equation for predicting low bone mineral density or bone loss progression among people living with HIV: the role of secondary causes of osteoporosis**
Pilar Vizcarra, Spain
- PE9/10 **Elevated body mass index during pregnancy and gestational weight gain in HIV-infected women in Cape Town, South Africa: association with adverse birth outcomes**
Hlengi Madlala, South Africa
- PE9/11 **Facilitating primary care non-antiretroviral drug prescribing in people living with HIV: the Think ARV project**
Jaime Vera, United Kingdom
- PE9/12 **Characterization of moderate and severe anemia by peripheral blood smear in HIV infected patients in the Kilombero and Ulanga antiretroviral cohort**
Vanesa Anton-Vazquez, United Kingdom
- PE9/13 **HIV infection and smoking: PET imaging reveals early pulmonary perfusion abnormalities**
Puja Kohli, United States
- PE9/14 **Bariatric surgery in HIV obese patients: first results of the French ObéVIH ongoing study**
Valérie Pourcher, France
- PE9/16 **Plasma cotinine cut-off for distinguishing smokers from non-smokers among people living with HIV (PLWH)**
Omid Rezahosseini, Denmark
- PE9/17 **An analysis of HIV and co-morbidity profiles for adults accessing health care in Khayelitsha, South Africa**
Richard Osei-Yeboah, South Africa

Scientific Programme

- PE9/18 **Femoral arteries better indicator than carotid arteries of cardiovascular risk in HIV/AIDS patients**
Gordana Dragovic Lukic, Serbia
- PE9/19 **Cardiovascular risk assessment in PLWH over 50: agreement between cardiovascular risk predictors and Coronary Artery Calcium CT Scoring (CACS)**
Branca Pereira, United Kingdom
- PE9/20 **Safety and tolerance of denosumab in HIV patients**
Sara Vela, Spain
- PE9/21 **Lower incidence of liver steatosis in patients treated with lamivudine plus dolutegravir dual therapy**
Davide Moschese, Italy
- PE9/22 **Correlations between computerised and standard cognitive testing in persons with HIV and controls**
Davide De Francesco, United Kingdom
- PE9/23 **Whole body MRI detects high prevalence of incidental findings in older HIV-1-infected patients participating in a randomised, controlled trial of maraviroc and/or metformin for non-alcoholic fatty liver disease**
Sarah Pett, United Kingdom
- PE9/24 **An analysis of potential drug-drug interactions in an aging HIV cohort**
Pádraig Gardiner, Ireland
- PE9/25 **A standardized comparison of cardiovascular risk factor prevalence between people living with HIV and general population in Spain**
Vicente Estrada, Spain
- PE9/26 **Subclinical atherosclerosis burden by ultrasound in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors**
Vicente Estrada, Spain
- PE9/27 **Subcutaneous adipose tissue modifications induced by a switch to dual raltegravir-maraviroc therapy in controlled HIV-infected patients: a sub-study of the ANRS-ROCNRAL157 clinical trial**
Jacqueline Capeau, France
- PE9/28 **Results of 10 year experience of a specialist clinic for people living with HIV over 50 at Chelsea and Westminster Hospital**
Branca Pereira, United Kingdom
- PE9/29 **Discordance in diagnosis of osteoporosis in HIV-infected patients: prevalence, characteristics, and impact on FRAX equation**
Pilar Vizcarra, Spain
- PE9/30 **CD4/CD8 ratio is a better indicator of acute phase inflammation than absolute CD4 count during virally-suppressed HIV infection**
Rodney Rousseau, Canada
- PE9/31 **Immune activation and chronic inflammation: is there an additional effect of HIV in a geriatric population?**
Clotilde Allavena, France

Scientific Programme

- PE9/32 **Trends in cardiovascular risk factors and estimated 10-year cardiovascular risk score in a spanish cohort of PLWH: 2010-2018**
Francisco Fanjul, Spain
- PE9/33 **Prevalence of depression and associated psychosocial factors among HIV positive patients attending ART clinic at Gulu Regional Referral Hospital**
Ronald Kiyemba, Uganda
- PE9/34 **Potentially inappropriate medications in older adults with HIV in the region of Madrid, Spain**
Beatriz López-Centeno, Spain
- PE9/35 **Impact of the reproductive/hormonal status on weight, fat and insulin resistance in HIV-infected women switching from a PI regimen to dual raltegravir-etravirine therapy: results from the ANRS163-ETRAL trial at 48 and 96 weeks**
Jacqueline Capeau, France
- PE9/37 **Age- and sex-related differences in concomitant diseases and use of co-medication in patients with treated HIV-infection in Germany**
Karen Martin, Germany
- PE9/38 **Kidney transplantation in HIV-positive patients in Israel including the first case of HIV-positive living donor to HIV-positive recipient with a 7-year follow-up**
Eugene Katchman, Israel
- PE9/39 **Vitamin D deficiency and frailty phenotype in HIV-infected men**
Fiona Bhondoekhan, United States
- PE9/40 **The UCSD performance-based skills assessment is associated to cognitive performance in HIV positive population with very good immunological condition**
Valentina Delle Donne, Italy
- PE9/41 **Alcohol, smoking and the association with HIV virological non-suppression among people living with HIV on ART**
Timothy Peter Wynne Jones, United Kingdom
- PE9/42 **Decreasing incidence of diabetes mellitus in HIV-positive Taiwanese patients on combination antiretroviral therapy from 2004 to 2011**
Pei-Ying Wu, Taiwan, Republic of China
- PE9/43 **Incidental findings in PLWH over 50 undergoing coronary artery calcium scoring (CACS) for cardiovascular risk assessment**
Maria Mazzitelli, United Kingdom
- PE9/44 **Aging biomarkers, inflammatory cytokines and development of cardiovascular ischemic events or diabetes in HIV-infected persons**
Jose I Bernardino, Spain
- PE9/45 **Falls but not frailty are common in people living with HIV using an mHealth platform: issues of ageing within the EmERGE cohort**
Tom Levett, United Kingdom
- PE9/46 **A standardized comparison of cardiovascular risk factor treatment in people living with HIV and general population**
Vicente Estrada, Spain
- PE9/48 **Perceptions of ageing and desire for ageing information amongst users of the EmERGE mHealth platform**
Tom Levett, United Kingdom

Scientific Programme

- PE9/49 **Switching to bicittegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older: week 48 results from a phase 3b, open-label trial**
Franco Maggiolo, Italy
- PE9/50 **Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older**
Hans-Jürgen Stellbrink, Germany
- PE9/51 **HIV testing in patients diagnosed with community acquired pneumonia or primary lung cancer from 2014 to 2018 in a tertiary reference hospital in Northern Spain**
Teresa Rubio Obanos, Spain
- PE9/52 **Menopause in aging women living with HIV: changes in bone mineral density and trabecular bone score**
Giovanni Guaraldi, Italy
- PE9/53 **Higher anti-CMV IgG concentrations are not associated with longitudinal brain injury in virally suppressed people with HIV**
Jonathan Underwood, United Kingdom
- PE9/55 **Higher Prevalence of CKD in HIV+ individuals compared to the general population**
Stefan Esser, Germany
- PE9/56 **Effect of CMV viraemia on endothelial dysfunction over 42 weeks in Malawian adults initiating ART with advanced immune suppression**
Christine Kelly, Ireland
- PE9/57 **High prevalence of neurocognitive impairment in adults with perinatally acquired HIV infection**
Irene Portilla-Tamarit, Spain
- PE9/58 **Modeling 2018 AHA cholesterol guidelines in HIV**
Giacomo Ciusa, Italy
- PE9/59 **A multi-disciplinary Neuro-HIV Platform in managing patients with neurocognitive impairment**
Phanie Bidlingmeyer, Switzerland
- PE9/60 **Archi-Prevalent project. A national register of color-Doppler ultrasonography of the epi-aortic vessels in patients living with HIV**
Salvatore Martini, Italy
- PE9/61 **Preliminary results of a diagnostic-therapeutic work-up to early detect cardiovascular disease in HIV positive patients**
Giovanni Millotti, Italy
- PE9/62 **Bone mineral density changes in young African women on tenofovir disoproxil fumarate antiretroviral therapy and non-hormonal contraception**
Flavia Kiweewa Matovu, Uganda
- PE9/63 **Examination of HIV-infected patients regarding weight gain while using integrase inhibitors in Japan**
Ryoko Sekiya, Japan
- PE9/65 **Predictors of sarcopenia and its impact on components of the frailty phenotype in an Asian population living with HIV**
Grace Lui, Hong Kong

Scientific Programme

- PE9/66 **Failure to restore CD4 cell count with combination antiretroviral therapy is associated with increased systemic inflammation**
Rodney Rousseau, Canada
- PE9/67 **High prevalence of left ventricular systolic dysfunction assessed by speckle tracking in asymptomatic HIV patients**
Dimitris Basoulis, Greece
- PE9/68 **Polypharmacy and drug-drug interactions - prevalence in a Portuguese HIV Metabolic Clinic**
Joana Fragoso, Portugal
- PE9/69 **Bone density alterations in the HIV-infected patient - epidemiologic characterization of a Portuguese cohort**
Diogo Guerra, Portugal
- PE9/70 **Cigarette smoking disproportionately impairs nitric oxide signaling in pulmonary artery endothelial cells in HIV: role of viral and host factors**
Saurabh Aggarwal, United States
- PE9/71 **Frailty phenotype in older virologically suppressed PLWHIV is strongly correlated with specific comorbidities and tobacco use**
Christina Katerina Psomas, France
- PE9/72 **HIV-FUNCFRAIL study: differences between women and men aging with HIV**
Fátima Brañas, Spain
- PE9/73 **Prevalence, risk factors and outcomes of cardiovascular, metabolic and chronic kidney diseases in HIV-infected vs. uninfected adults in sub-Saharan Africa: a systematic review and meta-analysis**
Ajibola Awotiwon, South Africa
- PE9/74 **People living with HIV are more likely to be screened for cardiovascular disease risk factors than other members of the general population in Botswana - a community based study**
Onkabetse Julia Molefe-Baikai, Botswana
- PE9/75 **APOL1 high risk genotype has an adverse impact on kidney function in African HIV-infected patients with high viral load**
Nongodo Firmin Kabore, France
- PE9/76 **Comparison of 2 frailty scores in PLWHIV aged 50 and over: SOF index and FRIED phenotype**
Christina Katerina Psomas, France
- PE9/77 **Annexin V, Annexin A1 and cardiovascular risk in HIVpopulation**
Claudio Ucciferri, Italy
- PE9/78 **Could we consider the intima-media thickness (c-IMT) > 1mm as a risk factor for cardiovascular diseases in HIV+ subjects chronically treated with antiretrovirals?**
Alessio Pampaloni, Italy
- PE9/79 **Immune reconstitution inflammatory syndrome (IRIS) in HIV-infected hospitalized patients with advanced disease**
Alberto Díaz-de Santiago, Spain
- PE9/80 **Low Body Mass Index (BMI) in ART naïve HIV-positive subjects and risk of virological failure and drug discontinuation: data from the ICONA Foundation Cohort**
Roberto Rossotti, Italy

Scientific Programme

- PE9/81 **Sistatin C, KIM1 and NGAL as biological markers for detecting early kidney injury in HIV positive patients**
Aslıhan Ulu, Turkey
- PE9/82 **Long-term AIDS survivors: comorbidities and polypharmacy a new challenge**
María José Galindo Puerto, Spain
- PE9/83 **Risk Factors associated to immune reconstitution inflammatory syndrome (IRIS) in HIV-infected hospitalized patients with advanced disease**
Alberto Díaz-de Santiago, Spain
- PE9/84 **Sleep disorders and depression through efavirenz to dolutegravir transition in Brazil: what really changed after all**
Melissa Medeiros, Brazil
- PE9/85 **Patterns of inflammation and comorbidity in Human Immunodeficiency Virus (HIV) infection: a clustering analysis from the CARDAMONE study**
Sonia Zebachi, France
- PE9/86 **Cognitive impairment in patients with HIV in a Mexican hospital**
Lucia Carrazco Ibarra, Mexico
- PE9/87 **Clinical management of ageing people living with HIV in Europe: The view of the care providers**
Marta Boffito, United Kingdom
- PE9/88 **Real-word characterization of the Portuguese population living with HIV who initiated Raltegravir based-regimen in the last three years - REALITY Study**
Joana Almeida, Portugal
- PE9/89 **Long-term lipid-lowering-therapy in HIV is clinically effective**
Henning Drechsler, United States

ePosters
09:00 - 18:00

Exhibition hall

HIV-associated and non HIV-associated tumours

- PE14/1 **Prevalence of anal dysplasia among persons living with human immunodeficiency virus (HIV)**
Adelaine Lopez, Philippines
- PE14/2 **HIV infection is associated with reduced survival among hepatocellular carcinoma cases from an urban referral hospital: Kampala, Uganda**
Sara Nsibirwa, Uganda
- PE14/3 **High prevalence of anal and cervical dysplasia in a cohort of HIV-infected women, but low prevalence of concomitant lesions**
Ana Gomez, Ecuador
- PE14/4 **Malignant and benign skin lesions in HIV-1 infected people**
Alessandra Latini, Italy
- PE14/5 **Results of HPV-testing for anal screening in HIV-infected women**
Anna Popova, Russian Federation

Scientific Programme

- PE14/6 **COHORT SDT (Granada): decrease of the incidence of HSIL+ in the anal mucosa of HIV+ patients MSM after the performance of a screening, diagnostic and therapeutic program (2010-2018)**
Carmen Hidalgo-Tenorio, Spain
- PE14/7 **Prospective longitudinal study on immunogenicity and safety of vaccination against human papillomavirus (HPV) with the 9valent vaccine in HIV-positive women, the Papillon study: preliminary results on tolerance and safety**
Déborah Konopnicki, Belgium
- PE14/8 **Cancer trends and outcomes in a cohort of people living with HIV**
Andrea De Vito, Italy
- PE14/9 **Rate of HCC occurrence and associated risk factors in a multicentric cohort of HIV/HCV co-infected patients treated with DAAs**
Alice Toschi, Italy

ePosters
09:00 - 18:00

Exhibition hall

Other coinfections/Sexually transmitted infections

- PE24/2 **High rates of ocular and neurosyphilis in a large German, city-based university hospital: lessons learned on ocular syphilis**
Laura Franziska Wagner, Germany
- PE24/3 **Decreasing rate of HIV and HBV co-infection in nationwide Korean HIV/AIDS cohort and its meaning**
Yoonjung Kim, Korea, Republic of
- PE24/5 **Prevalence of syphilitic hepatitis among HIV-infected patients in Istanbul, Turkey, a region with increasing incidence of syphilis and HIV infection**
Ozlem Altuntas Aydin, Turkey
- PE24/6 **Seroconversion rate after yellow fever vaccine in HIV- positive patients**
Charlotte Martin, Belgium
- PE24/7 **Low seroprevalence of syphilis infection among key populations in Togo in 2017: a national cross-sectional survey**
Fifonsi Gbeasor, Togo
- PE24/8 **Socio demographics, sexual behavior and clinical manifestations of HIV+ and HIV- patients diagnosed with syphilis, Brussels 2017-2019**
Agnès Libois, Belgium
- PE24/9 **Risk factors and prevalence of syphilis, gonorrhea and chlamydia infections in the Swiss HIV cohort study**
Catrina Mugglin, Switzerland
- PE24/10 **Predictors of serofast state after treatment for syphilis in HIV-infected patients**
Gregor Paul, Germany
- PE24/11 **A proactive approach to assess rising STIs among different at-risk groups of MSM in the early era of PrEP: a real-world clinical care setting**
Christina Katerina Psomas, France

Scientific Programme

- PE24/12 **Profiles of multidrug resistant gonorrhea in HIV-infected patients attending an urban hospital in Uganda**
Christine Katusiime, Uganda
- PE24/13 **Sexually transmitted diseases clinic in a Portuguese Infectious Diseases unit**
Joana Fragoso, Portugal
- PE24/14 **Quantification of DNA human papillomavirus 16 and 18 in anal cells improves the prediction of high grade anal intraepithelial neoplasia in HIV patients**
Marcos Diez, Spain
- PE24/15 **Primary prophylaxis against *Pneumocystis jirovecii* Pneumonia may be effective in preventing severe bacterial pneumonia in HIV-positive patients: findings from a large Italian center**
Alex Dusina, Italy
- PE24/16 **HHV-8 salivary shedding in individuals with different HIV status and sexual behaviour**
Elvira Domonova, Russian Federation
- PE24/17 **Insights into syphilis reinfection in HIV patients: predictors and role of serofast condition**
Chiara Picarelli, Italy
- PE24/18 **Infective endocarditis, a current health problem in Romanian injecting drug users**
Irina Cristiana Ianache, Romania
- PE24/19 **Preventable risk factors and predictors of hepatic and non-hepatic co-morbidities among PLHIV**
Oluwakemi Odukoya, Nigeria
- PE24/20 **Incidence of asymptomatic HAV infection among MSM living with HIV in South-Western Poland**
Aleksandra Szymczak, Poland
- PE24/21 **Behavioural patterns to identify key populations for syphilis prevention**
Sara Andresen, Switzerland
- PE24/22 **Evaluation of a systematic sexually transmitted infections screening pilot programme in HIV-positive men who have sex with men (MSM)**
Paula Prieto, Spain
- PE24/23 **Chemsex in Barcelona: a descriptive approach about men who have sex with men (MSM) who use recreational drugs in a sexual context**
Lorena De la Mora, Spain
- PE24/24 **Analysis of serum metabolite changes in early syphilis patients with or without serologic response after treatment**
Chia-Jui Yang, Taiwan, Republic of China
- PE24/25 **Stable transmission of amoebiasis among newly diagnosed HIV-positive patients in Taiwan, 2009-2018**
Sung-Hsi Huang, Taiwan, Republic of China
- PE24/26 ***Mycoplasma genitalium* resistance against macrolide antibiotics in the Berlin MSM cohort tested with the Allplex MG & AziR Assay (SeeGene)**
Martin Obermeier, Germany

Scientific Programme

- PE24/27 **Predictors of ureaplasma urealyticum urinary colonization in HIV+ pregnant women: a pilot study**
Iacopo Franconi, Italy
- PE24/28 **No indication of decreased syphilis susceptibility with repeated syphilis episodes in HIV-infected men who have sex with men: a multicentre prospective cohort study on risk factors and the potential role of syphilis immunity**
Jan Roth, Switzerland
- PE24/29 **The prevalence of high-risk anal HPV in HIV-positive MSM in Lebanon**
Nesrine Rizk, Lebanon

ePosters
09:00 - 18:00

Exhibition hall

Toxicities

- PE32/1 **Sleep and functional characteristics of Central London Outpatient HIV Cohort**
Ana Milinkovic, United Kingdom
- PE32/2 **Osteopenia and osteoporosis in young HIV-infected patients less than age of 40 years: incidence and risk factors**
Shu-Ying Chang, Taiwan, Republic of China
- PE32/3 **Predictors of weight gain in patients treated with dolutegravir**
Lucia Taramasso, Italy
- PE32/4 **Effects of lamivudine plus dolutegravir 2-drug-regimen on bone mineral density in a multicenter Italian cohort**
Arturo Ciccullo, Italy
- PE32/5 **Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) lowers alanine transaminase (ALT) and aspartate transaminase (AST) in patients with HIV infection with or without viral hepatitis co-infection**
Nicola Squillace, Italy
- PE32/6 **Weight gain in people living with HIV switched to dual therapy with dolutegravir plus rilpivirine: changes in body fat mass**
Pilar Vizcarra, Spain
- PE32/7 **Does switching to tenofovir alafenamide fumarate impair recovery of renal function in individuals newly diagnosed with tenofovir disoproxil fumarate induced renal tubular toxicity?**
John Booth, United Kingdom
- PE32/8 **Weight gain among HIV-positive persons treated with dolutegravir or elvitegravir**
Leïla Belkhir, Belgium
- PE32/9 **NRTI backbone modification impact on weight, lipids and cardiovascular risk**
Ana Milinkovic, United Kingdom
- PE32/10 **Comparative neuropsychiatric toxicity profile of dolutegravir (DTG) versus efavirenz (EFV) versus other antiretroviral third drugs used either in first-line or switch antiretroviral therapies (ART): data from Icona Foundation Study Cohort**
Annalisa Mondì, Italy

Scientific Programme

- PE32/11 **SWORD 1&2: maintenance or improvement in renal function in PLWH through 148 weeks after switch to the dolutegravir + rilpivirine 2-drug regimen**
Josep M Llibre, Spain
- PE32/12 **Neurotoxicity related to efavirenz does not predict neurotoxicity related to dolutegravir**
Sara de la Fuente, Spain
- PE32/13 **Human embryonic stem cells exposed to dolutegravir show decreased cellular proliferation, reduced pluripotency, and increased mitochondrial toxicity, in a dose-dependent manner: preliminary data**
Marie-Soleil R. Smith, Canada
- PE32/14 **Dolutegravir but not raltegravir reduces cell proliferation and increases mitochondrial toxicities in cultured fibroblasts; effects that are not mitigated by telomerase reverse transcriptase**
Helene Cote, Canada

ePosters
09:00 - 18:00

Exhibition hall

Tuberculosis and opportunistic infections

- PE35/1 **Nontuberculous mycobacteria infections in Russian HIV patients: clinical features and outcomes**
Mikhail Savchenko, Russian Federation
- PE35/2 **Human immunodeficiency virus and the outcome of treatment for pulmonary tuberculosis: a retrospective study in Tehran, Iran**
Mohammad Bagheri, Iran, Islamic Republic of
- PE35/3 **Rifampicin pharmacokinetics and pharmacogenetics in Ugandan patients with multi-drug resistant tuberculosis**
Jackson K. Mukonzo, Uganda
- PE35/4 **Mycobacteria-induced immune responses by mucosal-associated invariant T (MAIT) cells are impaired in patients with tuberculosis (TB) and HIV-associated TB**
Muki Shey, South Africa
- PE35/5 **Acute onset of cerebral toxoplasmosis in patients with HIV infection**
Tatiana Ermak, Russian Federation
- PE35/6 **Association between immunological status and TB disease development in HIV-infected individuals with LTBI**
Ngai Sze Wong, Hong Kong
- PE35/7 **Amoeba- a swiss army knife for diagnosis and mechanistic understanding of Legionella infection**
Breanne M Head, Canada
- PE35/8 **Causes and outcomes of hospitalizations among HIV positive persons in Georgia's referral institution, 2012-2017**
Nino Rukhadze, Georgia
- PE35/9 **Population pharmacokinetic analysis of dolutegravir in HIV/TB co-infected people with and without rifampicin**
Rajendra Singh, United States

Scientific Programme

- PE35/10 **Lung function and health-related quality of life among patients following pulmonary tuberculosis treatment in urban Uganda: a cross-sectional study**
Josephine Zawedde, Uganda
- PE35/11 **Clinical and laboratory characterization of progressive multifocal leukoencephalopathy in HIV-infected patients in the intensive care unit**
Anastasia Pokrovskaya, Russian Federation
- PE35/13 **Cryptococcal and tuberculosis coinfection: case series identified through the implementation of an advanced HIV disease package of care linked to a TB active case finding strategy in rural Mozambique**
Alejandro Blanco-Arévalo, Spain
- PE35/14 **Trends in latent tuberculosis screening in a cohort of HIV-infected patients from a low tuberculosis incidence country**
Pedro Palma, Portugal
- PE35/15 **Drug-induced hepatic injury developed in tuberculosis / HIV co-infection treatment**
Sarah Silva, Brazil

ePosters
09:00 - 18:00

Exhibition hall

NASH

- PE22/1 **Assessment of non alcoholic fatty liver disease in a cohort of HIV mono-infected patients**
Paola Columpsi, United Kingdom
- PE22/2 **Non-alcoholic fatty liver disease (NAFLD) and related metabolic disorders among HIV-infected patients in the country of Georgia**
Lali Sharvadze, Georgia
- PE22/3 **Non-alcoholic fatty liver disease is a significant predictor of cardiovascular risk in HIV-infected patients**
Adriana Cervo, Italy
- PE22/4 **Non alcoholic fatty liver disease diagnosed by non-invasive markers in HIV-infected patients**
Carmen Busca, Spain
- PE22/5 **Global prevalence of liver impairment in HIV population in direct antiviral agents (DAA) era: the role of fatty liver disease**
Matilde Sánchez-Conde, Spain

ePosters
09:00 - 18:00

Exhibition hall

Viral hepatitis

- PE37/1 **Acute hepatitis C infection in HIV-infected patients who achieved viral suppression: incidence and risk factors**
Hsin-Yen Ku, Taiwan, Republic of China

Scientific Programme

- PE37/2 **HBV infections among HIV infected HAART receiving mothers and their exposed infants in a tertiary hospital in Kenya**
James Kangethe, Kenya
- PE37/3 **Direct-acting antivirals (DAAs) improve liver stiffness measurements but do not improve the Veterans Aging Cohort Study (VACS) Index in HIV /HCV co-infected Egyptian patients: is improved discrimination needed?**
Ahmed Cordie, Egypt
- PE37/4 **HCV/HIV coinfection in the DAA era: which patients have not been treated for HCV?**
Fabian Dario Rodriguez-Monaco, Germany
- PE37/5 **Hepatitis E seroprevalence in HIV-positive patients**
Mustafa Altindis, Turkey
- PE37/6 **Success of unrestricted DAA therapy is limited by HCV reinfections and loss to follow-up in HIV-positive patients**
David Chromy, Austria
- PE37/7 **Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and Hepatitis B Virus (HBV) coinfection**
Yu-Shan Huang, Taiwan, Republic of China
- PE37/8 **Effectiveness of hepatitis a vaccination among people living with HIV in Taiwan: is one dose enough?**
Chia-Jui Yang, Taiwan, Republic of China
- PE37/9 **HIV patients remain at high risk for advanced liver fibrosis after curing HCV infection**
Natalia Bolokadze, Georgia
- PE37/10 **HIV/HCV coinfection in Spain: trouble will soon be over**
Juan Berenguer, Spain
- PE37/11 **Care cascade of incident HCV infection among HIV-positive patients in Taiwan**
Miao-Hui Huang, Taiwan, Republic of China
- PE37/12 **Current characteristics of HIV/HBV coinfecting patients in a single HIV reference centre of Madrid**
Luz Martín-Carbonero, Spain
- PE37/13 **High HCV reinfection rate in MSM living with HIV in Barcelona: the need to focus on high risk population to achieve HCV elimination**
Maria Martínez-Rebollar, Spain
- PE37/14 **Liver disease in HIV-infected subjects in the post-HCV DAA treatment era**
Carmen Busca, Spain
- PE37/15 **Seroprevalence of hepatitis E in a Portuguese cohort of human immunodeficiency virus infected patients**
André Silva-Pinto, Portugal
- PE37/16 **Loss of seroprotection against hepatitis B virus (HBV) was associated with lower CD4 counts among HIV-positive patients who were born in the era of nationwide neonatal HBV vaccination**
Yi-Chia Huang, Taiwan, Republic of China

Scientific Programme

- PE37/17 **Improvement of immunity and hepatic fibrosis after HCV treatment with DAA in people living with HIV and HCV**
Montserrat Laguno, Spain
- PE37/18 **DAA treating Hepatitis C in HIV/HCV coinfecting patients in two prisons of Rome: results and problems**
Sara Lardo, Italy
- PE37/19 **Progress towards eliminating mother-to-child transmission of HIV in the Macha area in Zambia from 2010-2018**
Mutinta Hamahuwa, Zambia
- PE37/20 **Evaluation of the hepatitis C care cascade in the country of Georgia: monitoring 4 years of progress towards elimination**
Tengiz Tsertsvadze, Georgia
- PE37/21 **Epidemiology of HIV, HBV and HCV co-infection in Israel**
Karen Olshtain-Pops, Israel
- PE37/22 **Hepatitis C treatment outcomes of HIV infected people who inject drugs in a real-world cohort**
Dimitris Basoulis, Greece
- PE37/23 **Treatment of acute HCV infection with direct acting antivirals (DAA) in HIV patients**
Cristina Gómez-Ayerbe, Spain
- PE37/24 **Hepatic fibrosis progression among HIV patients in Israel**
Karen Olshtain-Pops, Israel
- PE37/25 **Acute hepatitis B in persons living with HIV in a low hepatitis B prevalence area during the last two decades**
Luz Martín-Carbonero, Spain
- PE37/26 **Virological response to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients with lamivudine-resistant hepatitis B virus coinfection**
Yu-Shan Huang, Taiwan, Republic of China
- PE37/27 **Impact of direct-acting antiviral (DAA) agents on T cell counts and liver stiffness in HIV/HCV-coinfecting patients: a multicenter prospective observational cohort study**
David Dalmau, Spain
- PE37/28 **Trends of HCV infection among HCV-seronegative, HIV-positive patients in Taiwan between 2011-2018**
Li-Hsin Su, Taiwan, Republic of China
- PE37/29 **The micro-elimination approach to eliminating Hepatitis C: a Fast Track City project**
Franco Maggiolo, Italy
- PE37/30 **Road to HCV elimination in HIV/HCV coinfecting patients by screening and universal access to DAA: baseline data from the first screening of NoCo (No-Coinfection) study**
Antonella d'Arminio Monforte, Italy
- PE37/31 **HCV cascade of care for HIV/HCV coinfecting individuals in Greece and HCV treatment considerations in clinical practice**
Mina Psichogiou, Greece

Scientific Programme

- PE37/32 **Hepatitis B core-related antigen and anti-hepatitis B core antibody are not associated with liver fibrosis evolution in HIV-HBV co-infected patients during treatment with tenofovir**
Romuald Cruchet, France
- PE37/33 **Antiretroviral therapy: a possible role in lipid changes after HCV eradication by DAAs**
Alessandra Vergori, Italy
- PE37/34 **Treatment of cirrhotic monoinfected and HCV/HIV coinfecting patients with direct acting antivirals (DAAs)**
Fábio Videira Santos, Portugal
- PE37/35 **Predictors of vaccine efficacy after hepatitis B vaccination in people with HIV infection**
Gerardo Ibarra, Germany
- PE37/36 **Long term response to mandatory anti-HBV vaccination: risks for disease acquisition and opportunities for re-vaccination within the ICONA cohort**
Roberto Rossotti, Italy
- PE37/37 **The assessment of HBsAg serum concentration during chronic hepatitis B phases' identification among HIV/HBV coinfecting patients before antiviral therapy prescription**
Tetiana Melnyk, Ukraine
- PE37/38 **Predictors of liver fibrosis improvement after HCV eradication in HIV+ patients: data from an Italian cohort**
Alessandra Vergori, Italy
- PE37/39 **Long-term follow-up of people who use drugs (PWUD) following HCV infection therapy: drug use patterns among HIV co-infected versus mono-infected patients**
Astou Thiam, Canada
- PE37/40 **Treatment outcome of HCV single vs multi tablet regimen in mono and HIV co-infected people who use drugs (PWUD): a long-term follow-up analysis**
Astou Thiam, Canada

ePosters
09:00 - 18:00

Exhibition hall

Gender issues

- PE10/1 **Patient, clinical and virus genetic characteristics of migrants from Eastern, Central and Western Africa enrolled in the SHCS**
Nadine Bachmann, Switzerland
- PE10/2 **Menopause impacts drug use and mental health in women with HIV in Switzerland**
Anna Hachfeld, Switzerland
- PE10/3 **Gender-specific analysis of a German cohort of HIV-infected patients on Raltegravir-based therapy shows distinctive baseline co-morbidity profiles of women versus men but no impact on treatment outcomes**
Karen Martin, Germany
- PE10/4 **Menopausal symptoms, sleep disorders and anxiety/depression among premenopausal and postmenopausal HIV-infected women: a multicenter cohort study in Spain**
Ines Suarez, Spain

Scientific Programme

- PE10/5 **An evaluation of the care given to older women attending an HIV clinic in London**
Claire Williams, United Kingdom
- PE10/6 **Anti-Mullerian hormone a plausible indicator of cardiometabolic risk in HIV-infected women**
Umbelina Caixas, Portugal
- PE10/7 **Differences in sexual health among HIV infected and uninfected women of child-bearing age**
Raffaella Marocco, Italy

ePosters
09:00 - 18:00

Exhibition hall

Mother-to-child transmission

- PE21/1 **HIV infection in pregnant women and children in Switzerland: how effective are measures for preventing mother-to-child transmission?**
Martin Gebhardt, Switzerland
- PE21/2 **No evidence for induced glucuronidation of dolutegravir in HIV-infected pregnant women**
Vera Bukkems, Netherlands
- PE21/3 **Comparative analysis of clinic and laboratory parameters and frequency of mother-to-child transmission of HIV among HIV-positive pregnant women with marked immunodeficiency and normal immunological status**
Olga Mozaleva, Russian Federation
- PE21/4 **Analysis of perinatal HIV transmission cases in St. Petersburg**
Anna Samarina, Russian Federation
- PE21/5 **Geopolitical assessment and relevance for acceptance of vaginal delivery in good controlled HIV-infected pregnant women in Japan**
Kimikazu Hayashi, Japan
- PE21/6 **Pregnancy outcomes in HIV-positive women: a retrospective national cohort study from the "Grigorios AIDS Clinic" in Cyprus**
Georgios Siakallis, Cyprus
- PE21/7 **New-born infants from HIV positive women: five years experience of Infectious Diseases Hospital Iasi**
Alexandra Largu, Romania
- PE21/8 **Risk factors for peripartum virological failure in South African pregnant women on anti-retroviral therapy: East London Prospective Cohort Study**
Oladele Vincent Adeniyi, South Africa

ePosters
09:00 - 18:00

Exhibition hall

Paediatric, adolescent

- PE25/1 **Effect of cluster of differentiation (CD4) on viral respiratory infection in children, between 0-5 years of age. A study conducted in Kwazulu-Natal, South Africa**
Temitayo Famoroti, South Africa

Scientific Programme

- PE25/2 **Adolescent HIV and asymptomatic malaria parasitemia (AMP) co-infection**
David Segun Adeniyi, Nigeria
- PE25/3 **Clinical features of viral diarrhea in the children of HIV**
Marufjon Salokhiddinov, Uzbekistan
- PE25/4 **High rate of rubella seronegativity in perinatally-infected HIV women of childbearing age: a case-control study**
Nicolas Dauby, Belgium
- PE25/5 **Health outcomes in adolescents and young adults living with HIV before and after transition to adult care in Barcelona**
Josep Ferrer Arbaizar, Spain
- PE25/6 **Correction of lipid abnormality by integrase inhibitor among children taking ART**
Anna Samarina, Russian Federation
- PE25/7 **Increasing contribution of sexually-transmitted HIV diagnoses in adolescents in Spain**
Enrique Bernal, Spain
- PE25/8 **Factors associated to late presentation of HIV newly diagnosed adolescents in Spain**
Enrique Bernal, Spain
- PE25/9 **Comparison of antiretroviral treatment initiation in HIV newly diagnosed adolescents in Spain**
Melchor Riera Jaume, Spain
- PE25/10 **Oral self-testing for adolescents and young adults absent or declining to test during home-based HIV testing - a mixed-method study embedded in a cluster-randomized trial in Lesotho (ADORE study)**
Alain Amstutz, Switzerland
- PE25/11 **Preterm births in women living with HIV in Switzerland: a 13-year evaluation**
Christian R Kahlert, Switzerland
- PE25/12 **Poor clinical outcomes in HIV-infected children who start antiretroviral therapy at an older age**
Kevin P. McKenzie, United States
- PE25/13 **Prevalence and predictors of unintended pregnancies among HIV positive young adults (14-24 years) attending an urban HIV clinic in Uganda**
Mackline Hope, Uganda
- PE25/14 **Microbiota composition in a cohort of underweight HIV-positive children aged 24-72 months in Cape Town, South Africa**
Margaret Van Niekerk, South Africa
- PE25/15 **Influence of maternal parameters on birth outcome in HIV-exposed newborns - 11 year observation**
Karolina Nowicka, Poland

ePosters
09:00 - 18:00

Exhibition hall

Cascade of care

Scientific Programme

- PE6/1 **Self-reported non-receipt of HIV test results: a silent barrier to HIV epidemic control in Mozambique**
Didier Mugabe, Mozambique
- PE6/2 **Improvement in ART initiation in different regions of Ukraine from 2010 to 2014**
Tetiana Salyuk, Ukraine
- PE6/3 **The HIV treatment cascade in Azerbaijan, 2018**
Natig Zulfugarov, Azerbaijan
- PE6/4 **Seven years of European Testing Week: impact of a regional awareness campaign on increase in awareness and testing activities in Europe**
Lauren Combs, Denmark
- PE6/5 **Impact of integrated family planning and HIV services on early postpartum contraceptive use among women with HIV in the Eastern Cape, South Africa**
Oladele Vincent Adeniyi, South Africa
- PE6/6 **The first report of Prevention of Mother-to-Child Transmission (PMTCT) of HIV in Islamic Republic of Iran**
Ebrahim Ghaderi, Iran, Islamic Republic of
- PE6/7 **New HIV diagnosis and linkage to care in two outpatient units in South Europe**
Alessio Pampaloni, Italy
- PE6/8 **The HIV- and HCV-cascade in Swiss opioid agonist treatment (OAT) patients - the SAMMSU-cohort**
Andrea Bregenzer, Switzerland
- PE6/9 **Increased Integrated testing for HIV and HCV in health care facilities: examples from the INTEGRATE activities in Lithuania and Romania**
Raimonda Matulionyte, Lithuania
- PE6/10 **AIDS and late presentation follows testing gaps in Poland - data from Test and Keep in care (TAK) Polska project**
Justyna Kowalska, Poland
- PE6/11 **Loss to follow-up and re-linkage to care in a single cohort study: who do we re-link to care?**
Laura Magnasco, Italy
- PE6/12 **Expanding access to HIV tests in 13 cities in Indonesia: an interrupted time series investigating effect of HIV policy intervention using six years population data**
Yane Tarigan, Australia
- PE6/13 **Link HIV-infected injection drug users after the imprisonment to continuum of HIV care program in Taiwan**
Wei-Wei Wu, Taiwan, Republic of China
- PE6/14 **HIV continuum of care by sex and mode of transmission in Spain, 2016: use of different sources of information**
Victoria Hernando, Spain
- PE6/15 **Temporal trends in time from HIV diagnosis to viral load suppression in CoRIS**
Belén Alejos, Spain
- PE6/16 **Navigation of HIV positive clients. Reasons of gaps in HIV cascade among PWID**
Oksana Pashchuk, Ukraine

Scientific Programme

- PE6/17 **Tracing the patterns of HIV-1 transmission among individuals with different time to diagnosis in Greece**
Evangelia-Georgia Kostaki, Greece
- PE6/18 **Late diagnosis and delayed presentation in Korean HIV/AIDS cohort**
Shin Woo Kim, Korea, Republic of
- PE6/19 **Interruption of HIV care: understanding the predictors and outcomes in the Belgian national HIV cohort**
Dominique Van Beckhoven, Belgium
- PE6/20 **The HIV continuum of care: current situation and advances. A systematic review**
Georgia Vourli, Greece
- PE6/21 **The contribution of a partnership with a civil society organization (SCO) to early HIV diagnosis and UNAIDS goals**
Antonio Diniz, Portugal
- PE6/22 **HIV cascade of care in Turkey: data from the HIV-TR cohort**
Deniz Gökengin, Turkey
- PE6/23 **Cascade analysis of anonymous voluntary HIV counseling and testing among HIV-infected patients in Taiwan**
Chun-Yuan Lee, Taiwan, Republic of China
- PE6/24 **Late presentation of HIV in Armenia**
Trdat Grigoryan, Armenia
- PE6/25 **Oral self-testing for individuals absent or refusing testing during home-based HIV testing - a cluster-randomized trial in Lesotho (HOSENG trial)**
Tracy R Glass, Switzerland
- PE6/26 **Acceptability of rapid tests for migrants during the medical consultation at the migration point**
Martin Duracinsky, France
- PE6/27 **Evaluation of the “test and treat” strategy in an high-income setting: data from a multicenter Italian cohort**
Gianmaria Baldin, Italy
- PE6/28 **Pill box return as a predictor of treatment outcome to antiretroviral therapy in PLHIV: a prospective cohort study**
Robert Ndege, Tanzania, United Republic of
- PE6/29 **Potentially missed opportunity to diagnose HIV with standard testing algorithm among adult patients with ongoing mononucleosis-like illness**
Anna Vassilenko, Belarus
- PE6/30 **HIV Continuum of Care Cascade in Cluj County, Romania. Comparative situation of the years 2016, 2017, 2018**
Adriana Topan, Romania
- PE6/31 **People living with HIV lost to follow up in the Paris region area and actions carried out by HIV care centers**
Nicolas Vignier, France
- PE6/32 **Far from 90-90-90 goals in Latin America**
Maria Greco, Argentina

Scientific Programme

- PE6/33 **Barriers to involving patients in ART as a challenge to the national health system in Ukraine**
Serhii Riabokon, Ukraine
- PE6/34 **Index testing and intensified case finding for efficiency in HIV testing in Rwanda**
Eric Remera, Switzerland

ePosters
09:00 - 18:00

Exhibition hall

Morbidity/mortality in the era of cART

- PE20/1 **The association of rare HLA alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies**
Christina Ekenberg, Denmark
- PE20/2 **Neutrophil-to-lymphocyte ratio compared to CD4+:CD8+ T-cell ratio as a predictor of non-AIDS events in treated people living with HIV**
Nick Power, Ireland
- PE20/3 **Factors associated with virologic failure in women with HIV: Condesa specialized clinics, Mexico City**
Teresita De Jesús Cabrera Lòpez, Mexico
- PE20/4 **Causes of death among a cohort of HIV-infected adults in rural Tanzania**
Fiona Vanobberghen, Switzerland
- PE20/5 **Predictors of early mortality among adult HIV-infected patients on antiretroviral therapy in a Kenyan pastoralist community: a retrospective cohort study**
Paul Yonga, Kenya
- PE20/6 **Trends in underlying causes of death in HIV - infected patients from 2016 to 2018 in Ukraine: a cohort study**
Tetiana Kyrychenko, Ukraine
- PE20/7 **Dynamic of CD4+/CD8+ ratio in late presenters: impact on clinical outcomes**
Marta Rava, Spain
- PE20/8 **Retrospective investigation into the causes of death in HIV-infected patients from Bonn in the era of combined Anti-Retroviral Therapy**
Lukas Knieps, Germany
- PE20/9 **Reduced utility of early procalcitonin in HIV febrile patients admitted to the emergency department**
Chiara Picarelli, Italy
- PE20/10 **Patients with HIV and HCV in intensive care treatment: admission criteria and trends in the intensive care unit (ICU) at the University Hospital of Bonn 2014-2019**
Stefan Schlabe, Germany
- PE20/11 **Burden of disease in PLWH harboring a 4-class drug resistant virus: data from PRESTIGIO Registry**
Maria Rita Parisi, Italy
- PE20/12 **Changing pattern of hospital admissions due to medical conditions in HIV-infected subjects in a European public health care system with free access to antiretroviral treatment**
Joan Raga Almudéver, Spain

Scientific Programme

- PE20/13 **Association of non-adherence to antiretroviral therapy with cardiovascular outcomes in virologically suppressed persons living with HIV: the Swiss HIV Cohort Study**
Tracy R Glass, Switzerland
- PE20/14 **Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980 - 201**
Katharina Kusejko, Switzerland
- PE20/15 **Low pre-ART CD4 count is associated with increased risk of clinical progression or death even after reaching 500 CD4 cells/ μ L on ART**
Nikos Pantazis, Greece
- PE20/16 **A comparative analysis on blood pressure in HIV-infected individuals versus uninfected controls residing in Sub-Saharan Africa: a narrative review**
Edith Phalane, South Africa
- PE20/17 **Causes of death in AIDS/HIV-infected patients at the hospital of infectious diseases in St. Petersburg, Russia**
Olga Sokolova, Russian Federation
- PE20/18 **Dynamics and structure of mortality of HIV-positive people in Ukraine**
Nataliia Bugaienko, Ukraine

ePosters
09:00 - 18:00

Exhibition hall

Prevalence, incidence and dynamics of HIV epidemics

- PE29/1 **Monitoring rates and accessibility of HIV and STI's testing, HAV and HBV vaccination among men who have sex with men in Slovenia**
Miran Solinc, Slovenia
- PE29/2 **Data triangulation to re-shape interventions to improve the HIV response: compering data from estimates, case reporting, and sentinel surveillance in Ukraine**
Tetiana Salyuk, Ukraine
- PE29/3 **The impact of frequent cannabis use on injection drug use patterns among people who use drugs in a Canadian setting**
Hudson Reddon, Canada
- PE29/4 **Predicting early loss to follow-up on ART: a retrospective review of clients' retention on ART in North-western Nigeria**
Johnson Okolie, Nigeria
- PE29/5 **The increasing number of late HIV diagnosis among men having sex with men and transgender women in a key population-led HIV testing and treatment facility and its societal implication in the Philippines**
Patrick Eustaquio, Philippines
- PE29/6 **HIV transmission network in a cohort of subjects with primary infection in a single clinical center in Rome**
Lavinia Fabeni, Italy
- PE29/7 **Evaluation of a multiassay approach for determination recent HIV infection in the Russian Federation**
Anastasia Murzakova, Russian Federation

Scientific Programme

- PE29/8 **Ongoing spread of HIV subtype A in Tel Aviv, Israel**
Dan Turner, Israel
- PE29/9 **Simple clinical and laboratory based score may identify HIV infection recency and subsidize HIV surveillance in low and middle-income countries (LMIC), Santo André/Brazil experience**
Elaine Monteiro Matsuda, Brazil
- PE29/10 **Clinical, epidemiological & virological features of primary HIV-1 infection in an HIV reference center in Brussels: a ten years' review**
Arthur Poncelet, Belgium
- PE29/11 **Current trends in HIV genetic diversity in Russia: increase of the unique recombinants prevalence**
Anastasiia Antonova, Russian Federation
- PE29/12 **Analysis of risk factors in HIV/AIDS patients**
Esra Zerdali, Turkey
- PE29/13 **Tracing the first HIV-1 epidemics in the Milan area**
Alessia Lai, Italy
- PE29/14 **Analysis of the local HIV-1 epidemic in Vologda region, Russia: predominance of CRF03_AB and rapid expansion of URFs**
Ekaterina Ozhmegova, Russian Federation
- PE29/15 **Identification of first near full length recombinant genome of HIV-1 in Korea**
Mee-Kyung Kee, Korea, Republic of
- PE29/16 **Characteristics of HIV infection among children in Georgia, 1989-2018**
Natela Chokoshvili, Georgia
- PE29/17 **HIV infection in older patients**
Barbara Belfiori, Italy
- PE29/18 **Seroincidence of the human herpesvirus 8 (HHV 8) infection among HIV-positive patients in Taiwan, 2016-2019**
Yi-Ching Su, Taiwan, Republic of China
- PE29/19 **Risk factors for late presentation for HIV care in 2019 in Ukraine**
Maryna Sukach, Ukraine
- PE29/20 **Incidence of hepatitis C virus infection among people living with HIV(PLHIV): an Egyptian Cohort Study**
Rahma Mohamed, Egypt
- PE29/21 **High HIV prevalence following screening of subjects with HIV indicator conditions in a hospital setting**
Camilla Tincati, Italy
- PE29/22 **First decrease in new HIV diagnoses in 2018 among men who have sex with men (MSM), in the East PACA (Provence Alpes Côte-d'Azur) area in France**
Philippe Bouvet de la Maisonneuve, France
- PE29/23 **The collision of public health interventions on HIV-1 spread in Albania by molecular epidemiology**
Shkurti Enkelejda, Albania

Scientific Programme

- PE29/24 **Two decades of HIV infection late diagnosis: the experience of a Portuguese Hospital**
Sofia Jordão, Portugal
- PE29/25 **Characterization of HIV patients followed in a specialist consultation at a tertiary and university centre**
Fábio Videira Santos, Portugal
- PE29/26 **Trends in epidemiology and clinical picture of late presentation among patients of the Hospital for Infectious Diseases in Warsaw**
Joanna Pula, Poland
- PE29/27 **An evolutionary insight into a growing HIV subtype A epidemic in Serbia**
Marina Siljic, Serbia
- PE29/28 **Change of prevalence, diseases distribution and factors associated with the risk of AIDS presentation in Italy over last decade (2009-2018)**
Andrea Antinori, Italy
- PE29/29 **The effect of gender on late diagnosis of HIV infection in a high incidence European population**
Rita Filipe, Portugal
- PE29/30 **Two decades surveillance of HIV-1 transmitted drug resistance in Serbia**
Valentina Cirkovic, Serbia
- PE29/31 **3M-BRiHT - Manchester Cohort. Investigation of the feasibility and acceptability of rapid HIV testing in a European Emergency Department setting**
Molly M. O'Kane, Ireland
- PE29/32 **HIV-1 A6 subtype: its challenging identification and Southern Russian molecular epidemiology**
Saleta Sierra, Germany
- PE29/33 **Neurodevelopmental assessments to screen for HIV encephalopathy in newly diagnosed infants not on ART in Mozambique**
Jyodi Mohole, United States

ePosters
09:00 - 18:00

Exhibition hall

Prevention of horizontal transmission, cART as prevention

- PE30/1 **Tolerability and treatment completion of tenofovir alafenamide/emtricitabine/rilpivirine (TAF/FTC/RPV) as HIV postexposure prophylaxis**
Marie Chauveau, France

ePosters
09:00 - 18:00

Exhibition hall

Standard of care

- PE31/1 **Exploring the attitudes of HIV-positive patients on single-tablet antiretroviral regimens towards generic de-simplification**
Ciara Levey, Ireland

Scientific Programme

- PE31/2 **Comparison of Immunological and virological response to cART between HIV-1/O and HIV-1/M patients followed-up in France: the ANRS ORIVAO and COPANA studies**
Guillemette Unal, France
- PE31/3 **From HIV diagnosis to antiretroviral therapy initiation in Croatia from 2013 to 2018**
Nikolina Bogdanić, Croatia
- PE31/5 **Tetanus seroprotection in HIV-positive subjects living in Belgium: risk factors for seronegativity, evaluation of medical history and a rapid dipstick test**
Nicolas Dauby, Belgium
- PE31/6 **The prevalence of virologic failure and resistance associated mutations in single and multi-tablet HIV treatment regimens**
Chien-Yu Cheng, Taiwan, Republic of China
- PE31/7 **Development and validation of a risk score for predicting non-adherence to antiretroviral therapy**
Hernando Knobel, Spain
- PE31/8 **Measles seroprevalence among HIV infected patients in central part of Poland - vaccination proposal**
Ewa Siwak, Poland
- PE31/9 **Nurse-led annual health review - one year follow up**
Marie-Pierre Klein, United Kingdom
- PE31/11 **Viral hepatitis in HIV-positive patients - testing, prophylaxis and treatment in Central and Eastern Europe**
Kerstin Kase, Estonia
- PE31/12 **Evaluating a national pilot process for reviewing late HIV diagnoses in England and Wales**
Ming Jie Lee, United Kingdom
- PE31/13 **GESIDA quality of care indicators for PLWH: report from two Spanish hospitals 2009-2017**
Francisco Fanjul, Spain
- PE31/14 **Late presentation and barriers to the early HIV diagnosis in Central part of Ukraine**
Tetiana Koval, Ukraine
- PE31/15 **Operational research of barriers and facilitators to harm reduction services for intravenous drug users (including female IDUs)**
Tamar Zurashvili, Georgia
- PE31/16 **A seven-month prospective review of HIV admissions to a regional infectious disease unit in Manchester, UK**
Hamzah Zahid Farooq, United Kingdom
- PE31/17 **Annual health review for people living with HIV - an evaluation**
Sarah Edwards, United Kingdom
- PE31/18 **Analysis of adherence to HIV-positive quality of care indicators and their impact of service quality perceptions in patient: a Spanish cross-sectional study**
Alejandra Gimeno García, Spain

Scientific Programme

ePosters
09:00 - 18:00

Exhibition hall

Behavioural interventions

- PE5/1 **Close group social media network and social gatherings for comprehensive HIV services among adolescent MSM in Lagos Nigeria**
Orobosa Enadeghe, Nigeria
- PE5/2 **Good hygiene practices post circumcision: a case for low adverse events in VMMC**
Timothy Kipkosgei, Kenya
- PE5/3 **Challenges of implementing HIV counselling and testing (HCT) campaigns for higher education distance learning students at University of South Africa**
Nkay Pascal Kiabilua, South Africa
- PE5/4 **Enhancing effective HIV prevention among girls by fighting child marriage and sexual and gender based violence in Karonga district, Malawi**
Shora Manuel Kauluka, Malawi
- PE5/5 **Effectiveness of rapid HIV and HCV testing programmes based on mobile units**
Ekaterina Zinger, Russian Federation
- PE5/6 **It can't happen to me - tackling cognitive mistakes and HIV using a national campaign**
Arian Diskovic, Croatia
- PE5/7 **Is mobility still a HIV/STI associated vulnerable factor in the changing sex work dynamics among female sex workers in India? - Emerging evidence**
Priyanka Dixit, India
- PE5/8 **"Amare con Sapienza": an Italian digital ambient media prevention campaign in one of the largest European University to increase U=U, PreP, TasP knowledge**
Serena Vita, Italy
- PE5/9 **Assessing high risky sexual behaviors in vulnerable women in northern Uganda: baseline results of "Pe Atye Kena, no longer alone" study**
Antonella Cingolani, Italy
- PE5/10 **HIV/AIDS educational program for secondary school female students in Iran: a school-based randomized controlled trial**
Farid Yousefi, Iran, Islamic Republic of

ePosters
09:00 - 18:00

Exhibition hall

Clinical trials of vaccines

- PE8/1 **Seroprevalence of vaccine preventable viral diseases and vaccine response among HIV positive patients**
Fatma Sebnem Erdinc, Turkey
- PE8/2 **Could we recommend the current herpes zoster vaccine for patients living with HIV (PLHIV)?**
Thomas Huleux, France

Scientific Programme

ePosters
09:00 - 18:00

Exhibition hall

PrEP

- | | |
|---------|---|
| PE28/1 | Establishment of the service system of HIV pre-exposure prophylaxis/post exposure prophylaxis (PrEP/PEP) in a certain area of Southern Taiwan
Kuei Ying Wang, Taiwan, Republic of China |
| PE28/2 | Systematic review of post-migration HIV acquisition within Europe: the case for PrEP interventions for migrants
Simran Mann, United Kingdom |
| PE28/3 | Self-reported STI history and associated factors among German PrEP users
Uwe Koppe, Germany |
| PE28/4 | PrEP implementation among MSM in Ukraine: results of pilot project in Kyiv
Roman Marchenko, Ukraine |
| PE28/5 | Emergency post-exposure prophylaxis (PEP) seeking behaviors among men who have sex with men (MSM) with recent HIV risk exposure in Thailand
Tarandeep Anand, Thailand |
| PE28/6 | The back side: Lymphogranuloma venereum in PrEP-users and PLWH
Sven Schellberg, Germany |
| PE28/7 | Awareness and interest in pre-exposure prophylaxis (PrEP) among MSM population in Serbia
Vanja Subotic, Serbia |
| PE28/8 | PrEP reimbursement and access in Europe: 2019 update
Krzysztof Tronczyński, Poland |
| PE28/9 | Users' perspective of an ideal service model for delivering pre-exposure prophylaxis (PrEP) to men who have sex with men
Shui Shan Lee, Hong Kong |
| PE28/10 | Assessment of the trough concentrations of tenofovir in HIV-negative subjects on pre-exposure prophylaxis: a single center, real-life experience
Dario Cattaneo, Italy |
| PE28/11 | No new HIV infections, but high incidence of syphilis among Pre-exposure Prophylaxis (PrEP) users in Georgia
Ekaterine Karkashadze, Georgia |
| PE28/12 | Feasibility and acceptability of an oral pre-exposure prophylaxis (PrEP) program against HIV targeting female sex workers in Belgium
Florence Deneumoustier, Belgium |
| PE28/13 | First results after 52 weeks of informal PrEP use in a cohort of MSM in Southern Spain
Alejandro Berto Moran, Spain |
| PE28/14 | Clinical outcomes of pre-exposure prophylaxis from clinical center in Warsaw, Poland
Iwona Cielniak, Poland |
| PE28/15 | Where are we with PrEP use in Central and Eastern Europe? - data from the ECEE Network Group
Josip Begovac, Croatia |

Scientific Programme

- PE28/16 **Sexual risk and HIV preventative behaviours among men who have sex in men in London in the era of HIV pre-exposure prophylaxis, 2019**
Fiona Burns, United Kingdom
- PE28/17 **Chemsex and mood disorders under HIV pre-exposure prophylaxis**
Helene Peyriere, France
- PE28/18 **Pre-exposure prophylaxis one year after implementation in Portugal - the reality of a central hospital**
Diogo Guerra, Portugal
- PE28/19 **DISCOVER in Europe: a sub-analysis of the phase 3 randomized, controlled trial of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP)**
Frank Post, United States
- PE28/20 **The Good and Bad of PrEP: a 14 month follow up on awareness, adherence, efficacy and sexually transmitted diseases at Hospital de Curry Cabral**
Marta Leal dos Santos, Portugal
- PE28/21 **PrEP for life: new challenges and barriers in PrEP uptake among men who have sex with men (MSM) and transgender people (TG) in Kyiv, Ukraine**
Dzmitry Filippau, Ukraine
- PE28/22 **Analysis of the need for pre-exposure prophylaxis of HIV among people that have high risk to be infected**
Vitaliy Andres, Ukraine
- PE28/23 **Lesson learnt from a combined HIV prevention using HIV self-testing and oral pre-exposure prophylaxis (PrEP) demonstration project in the United Republic of Tanzania**
Neema Makyo, Tanzania, United Republic of

ePosters
09:00 - 18:00

Exhibition hall

Treatment as prevention

- PE33/1 **HIV-1 viral load quantification using Aptima HIV-1 Quant Dx assay in Kenya: a diagnostic accuracy study**
Geoffrey Kangogo, Kenya
- PE33/3 **Rapid ART start in primary HIV infection: time to viral suppression in a London cohort**
Nicolo Girometti, United Kingdom
- PE33/4 **Reality check: HIV post-exposure prophylaxis (PEP) in real-life at a tertiary care centre prior to the PrEP era**
Lina Thewes, Germany

ePosters
09:00 - 18:00

Exhibition hall

Access to and models of care

Scientific Programme

- PE1/1 **Barriers in TB services for people living with HIV and overcoming them according to the health care workers opinion in the TB facilities in Russia (sociological study)**
Zinaida Zagdyn, Russian Federation
- PE1/2 **Investigating the impact of peer counseling intervention on access and use of sexual and reproductive health services in women Living with HIV in Nepal: a prospective cohort study**
Khem Pokhrel, Nepal
- PE1/3 **Health care delivery for HIV-positive people with tuberculosis in Europe**
Adrian Bentzon, Denmark
- PE1/4 **A survey of physicians on circumstances and factors influencing testing for HIV in Lithuania**
Raimonda Matulionyte, Lithuania
- PE1/5 **Experiences of forgiveness and unforgiveness of HIV-specific offenses among people living with HIV/AIDS in Ghana**
Judith A. Osae-Larbi, Ghana
- PE1/6 **Time to antiretroviral therapy: service model adaptation during an outbreak of HIV in people who inject drugs (PWIDs)**
Harrison Stubbs, United Kingdom
- PE1/7 **HIV infection hospital-based active case finding in Sardinia, Italy: results from the SHOT project**
Maria Sabrina Mameli, Italy
- PE1/8 **Retention activities based on home visits as a tool of return and keeping in care of low adhered patients. Results of work 2016-2019 Krasnoyarsk AIDS clinic**
Konstantin Kandlen, Russian Federation
- PE1/9 **Pilot project of shared assistance with primary care for patients with HIV infection**
Adrián Ferre, Spain

ePosters
09:00 - 18:00

Exhibition hall

HIV and marginalised groups

- PE11/1 **Sexual behaviors and seroprevalence of HIV, HBV, and HCV among hill tribe youths of Northern Thailand**
Tawatchai Apidechkul, Thailand
- PE11/3 **The blind spot: high HIV burden among slum-dwelling school-age girls in Kampala, Uganda**
Jude Thaddeus Ssensamba, Uganda
- PE11/4 **Research of behavioral models of transgender people leading to high rates of HIV prevalence in Ukraine**
Igor Medvid, Ukraine
- PE11/5 **Outreach services for HIV testing and prevention among female transgender commercial sex workers in Milan: different approaches for different populations?**
Giuseppe Lapadula, Italy
- PE11/6 **The impact of unstable housing on HIV treatment outcomes in people living with HIV/AIDS in an urban setting of Southern Europe**
Hernando Knobel, Spain

Scientific Programme

- PE11/7 **Reflection of sex work criminalization in court judgements targeting to protect health, sanitary and epidemiological well-being**
Marina Avramenko, Russian Federation
- PE11/8 **Caring for the Transgender HIV-positive patient**
Chiara Picarelli, Italy
- PE11/9 **Association of current Estradiol use with carotid intimal media thickness among transgender women: a cross-sectional study**
Rodrigo Moreira, Brazil
- PE11/10 **HIV and migrants: a demographic and clinical characterization of migrants under follow up at an Infectious Diseases Department in Lisbon, Portugal**
Marta Leal dos Santos, Portugal

ePosters
09:00 - 18:00

Exhibition hall

Novel consultations, remote care - telemedicine, mobile applications

- PE23/1 **Harnessing mobile technology for health worker capacity building to improve quality of care in resource-constrained settings**
Walter Joseph Arinaitwe, Uganda
- PE23/2 **Feasibility, uptake and acceptability of the EmERGE mHealth app in individuals living with stable HIV in five European countries**
Jenny Whetham, United Kingdom
- PE23/3 **Attracting people who use drugs to HIV prevention and care programs via darknet and messengers: evidence from St. Petersburg, Russia**
Aleksey Lakhov, Russian Federation
- PE23/4 **People living with HIV (PLHIV) and their doctors: adopters and sceptics, and those opened to e-health**
Christine Jacomet, France
- PE23/5 **Fitness tracking wearable devices and a dedicated smart phone app (MySAwH App) to predict quality of life in PLWH: a multi-centre prospective study**
Giovanni Guaraldi, Italy
- PE23/6 **The efficiency of introducing the EmERGE Pathway of care for stable Croatian PLHIV**
Eduard J. Beck, United Kingdom
- PE23/7 **‘The 4th 90’: a preliminary assessment of change in quality of life over 1 year of the EmERGE study: PROQOL-HIV and EQ-5D-5L, a descriptive analysis**
Christopher Jones, United Kingdom
- PE23/8 **Measuring empowerment in EmERGE mHealth platform users: a descriptive analysis of interim data**
Stephen Bremner, United Kingdom

Scientific Programme

ePosters
09:00 - 18:00

Exhibition hall

Social and behavioural science

- PE30/2 **Priorities for behavioral interventions in a group of long term PLWHA - the experience of the Baylor Clinical Centre of Excellence in Constanta, Romania**
Ana-Maria Schweitzer, Romania
- PE30/3 **Will HIV-infected patients taking oral ARV switch to long-acting injectable ART when it become available?**
Marie-Aude Khuong-Josses, France
- PE30/4 **Time perspectives as predictors of depression and suicidal ideation amongst adolescents and young adults with HIV: the moderating role of resilience**
Oluwapelumi Ashamu, Nigeria
- PE30/5 **Social support and quality of life of people living with AIDS receiving ART at BPKIHS**
Ram Sharan Mehta, Nepal
- PE30/7 **Knowledge, attitudes, beliefs and HIV-related behaviour in metropolitan France: investigation in a festive place**
Fernanda Medina, France
- PE30/9 **Injectable long acting antiretrovirals for HIV treatment or prevention: the ANRS CLAPT study**
Laurence Slama, France
- PE30/10 **Quality of life in people living with HIV: a regional survey in Flanders**
Gert Scheerder, Belgium
- PE30/11 **Innovative strategies to sustain community participation in HIV vaccine trials, experience of Makerere University Walter Reed Project (MUWRP) in Kampala, Uganda**
Jauhara Nanyondo, Uganda
- PE30/12 **Stigma among healthcare providers towards people living with HIV/AIDS in India**
Akanksha Rathi, India
- PE30/13 **"I love my life, I don't want to miss a thing": motivators and Barriers to ART adherence among women living with HIV/AIDS in Iran**
Nooshin Amirisani, Iran, Islamic Republic of
- PE30/14 **Medical students as potential sources of information about HIV/AIDS**
Mykola Haras, Ukraine
- PE30/15 **Gender violence, intimate partner violence and domestic violence among HIV-positive patients in Alicante (Spain). Preliminary results of the VIHOLETA study**
Jara Llenas-García, Spain
- PE30/16 **Influence of stigma and discrimination on psychosocial health in children affected by AIDS in Nepal: a cross-sectional study**
Kalpana Gaulee Pokhrel, Nepal
- PE30/17 **The quality of life among people living with HIV in Taiwan in the era of STR**
Chung-Ching Shih, Taiwan, Republic of China
- PE30/18 **Experiences of and factors influencing physical activity in people living with HIV: a qualitative systematic review**
Megan Davies, United Kingdom

Scientific Programme

- PE30/20 **Perception of condom use in the era of pre-exposure prophylaxis (PrEP): a qualitative analysis**
Shui Shan Lee, Hong Kong
- PE30/21 **Recommendations for enabling timely pregnancy disclosure to clinical staff of women living with HIV**
Stefania Mihale, Romania
- PE30/22 **Health-related quality of life in a single center cohort of people living with chronic diseases: comparison between HIV and other clinical conditions**
Antonella Cingolani, Italy
- PE30/23 **Experiences of Dutch obstetric healthcare providers with HIV-positive pregnant women: a qualitative study**
Carlijn Damsté, Netherlands
- PE30/24 **Evaluation of knowledge, attitudes and practices among HIV positive pregnant women and their partners in four healthcare facilities in Malawi**
Isotta Triulzi, Italy
- PE30/25 **Towards the 4th 90, measuring multi-dimensional quality of life in people living with HIV in Aquitaine, France: psychometric properties of the French version of the WHOQOL-HIV BREF**
Diana Barger, France
- PE30/26 **Body size modifies the relationship between internalized HIV stigma and pain in people with HIV in the Southeastern USA**
Kaylee Crockett, United States

ePosters
09:00 - 18:00

Exhibition hall

Treatment in resource-constrained settings

- PE34/2 **Optimizing clients linkage into ART using family-centered differentiated approach (FCDA) in Kebbi state, northwestern Nigeria: successes and challenges**
Johnson Okolie, Nigeria
- PE34/3 **A multi-stakeholder evaluation of the early implementation experiences of differentiated anti-retroviral therapy (ART) delivery roll-out across Uganda: a qualitative analysis**
Henry Zakumumpa, Uganda
- PE34/5 **Evaluation of the financial cost of treating people living with human immunodeficiency virus in the United Kingdom versus matched HIV-negative controls in 2004, 2010 and 2017**
Scott Francis, United Kingdom
- PE34/6 **Continuous quality improvement across the viral load testing spectrum at the Infectious Diseases Institute, Uganda**
Harriet Tibakabikoba, Uganda
- PE34/7 **Pediatric HIV viral load suppression: qualitative insights of barriers and facilitators among caregivers of children on ART in high volume sites in Kisumu County, Kenya**
Nicollate Okoko, Kenya

Scientific Programme

- PE34/8 **Boosting economic affordability of HIV medicines while considering safety and effectiveness within transition from donor funding. Enabling access to TAF regime with better safety profile in Ukraine through advocacy campaign of community organization**
Zoia Zamikhovska, Ukraine

ePosters
09:00 - 18:00

Exhibition hall

Vulnerable groups

- PE39/1 **Boys having sex with boys: CD4 count as parameter to estimate the time of infection among HIV seropositive men having sex with men and its societal implications in the Philippines**
Patrick Eustaquio, Philippines
- PE39/2 **Evaluating factors increasing the vulnerability of adolescent girls and young women to HIV/AIDS infection in selected communities, Akwa Ibom State**
Jessie Inyang, Nigeria
- PE39/3 **Men's perspectives on HIV self-testing in sub-Saharan Africa: a systematic review and meta-synthesis**
Mbuzeleni Hlongwa, South Africa
- PE39/4 **Molecular-biological methods of diagnostics in the investigation of the case of transmission of HIV-infection**
Diana Valutite, Russian Federation
- PE39/5 **Implementation of demedicalized and decentralized HIV testing project in Brussels: action test, project for vulnerable populations at high HIV risk in Brussels, including Subsaharan African Migrants (SAM)**
Tresors Kouadio, Belgium
- PE39/6 **HIV prevalence, risk-taking behavior and self-testing potential among men who have sex with men and transgender people**
Evgeniy Pisemskiy, Russian Federation
- PE39/7 **Political commitment matters in the elimination of the threat of HIV and HCV and TB among people who use drugs**
Gefra Fulane, Portugal
- PE39/8 **Challenges in health and social care for migrant HIV patients in the Czech Republic**
Elena Tulupova, Czech Republic
- PE39/9 **Integration of hepatitis C cure in housing facility Soleil Evant: health cost implications**
Erika Castro, Switzerland
- PE39/10 **The role of sexual partners of people who inject drugs in better uptake of retention in HIV services**
Marine Gogia, Georgia
- PE39/11 **Male sex workers and ICT: anthropological approach of male sex workers and the different practices online: bareback, PrEP and chemsex**
Maxime Maes, Belgium
- PE39/12 **Portuguese League Against AIDS - mobile screening unit**
Maria Eugénia Saraiva, Portugal

Scientific Programme

- PE39/13 **Detectable viraemia in the era of successful antiretroviral therapy; engagement with multi-disciplinary services**
Shimu Khamlichi, United Kingdom
- PE39/14 **Optimal HIV self-testing, potential strategies to increase HIV diagnosis in Tanzania**
Neema Makyao, Tanzania, United Republic of

ePosters
09:00 - 18:00

Exhibition hall

Clinical case

- PE7/1 **Disseminated histoplasmosis in HIV, a key point of interest in Latin America**
Nelson Delgado, Ecuador
- PE7/2 **H-ART to Heart: a 43 year old body builder with HIV on anti-retroviral therapy with recurrent myocardial infarctions (5 heart attacks)**
Gavin Paul Raphael Manmathan, United Kingdom
- PE7/3 **Immune reconstitution inflammatory syndrome presenting as toxoplasma macular retinochoroiditis of eyes**
Dombu Guiafaing Reine Charlye, Cameroon
- PE7/4 **Invasive pulmonary aspergillosis and pulmonary tuberculosis in newly HIV diagnosed patients without prior ART exposure: differential diagnosis difficulties, treatment strategy**
Katerina Lytvin, Ukraine
- PE7/5 **Pseudotumor mimicking lung malignancy as a clinical presentation of Mycobacterium Avium infection in AIDS patient**
Luka Jovanovic, Serbia
- PE7/6 **Use of ibalizumab in a heavily treatment-experienced HIV-1-infected subject harbouring a multidrug-resistant virus**
Diana Canetti, Italy
- PE7/7 **Successful use of long-acting injectable cabotegravir and rilpivirine combination therapy in a patient with HIV-1 infection unable to absorb oral medication**
Razan Saman, United Kingdom
- PE7/8 **Cutaneous malignancy in a Romanian HIV-infected patient: diagnosis and treatment challenges**
Irina Cristiana Ianache, Romania
- PE7/9 **Autoantibodies, drugs and a failing liver**
Sonia Raffe, United Kingdom

ePosters
09:00 - 18:00

Exhibition hall

HIV cure

- PE12/1 **Comparison of three commercial kits for quantitative analysis of HIV-1 RNA produced in Russia**
Ilya Lapovok, Russian Federation

Scientific Programme

PE12/2 **Optimization of genotyping by phenotypic analysis of clinical HIV-1 subtype CRF01_AE isolates from South-East Asia**
Nina Marty, Switzerland

Parallel session
10:00 - 12:00

Event Hall

PS1, Women, pregnancy and children - Pharmacokinetics, injectables, endocrinology

Access to the webcasted session:

[ML1](http://resourcelibrary.eacs.cyim.com?mediald=78017)
[PS1/1](http://resourcelibrary.eacs.cyim.com?mediald=78023)
[PS1/2](http://resourcelibrary.eacs.cyim.com?mediald=78029)
[PS1/3](http://resourcelibrary.eacs.cyim.com?mediald=78031)
[PS1/4](http://resourcelibrary.eacs.cyim.com?mediald=78036)

[PS1/5](http://resourcelibrary.eacs.cyim.com?mediald=78043)

[ML2](http://resourcelibrary.eacs.cyim.com?mediald=78047)

Chairs:

Mariana Mardarescu, Romania
Sharon Walmsley, Canada

ML1	Are there gender and age differences in ARV PK? Felix Stader, Switzerland	10:00 - 10:20
PS1/1	Outcomes for women in phase 3 trials of long-acting cabotegravir + rilpivirine: pooled ATLAS and FLAIR week 48 results Romina Quercia, United Kingdom	10:20 - 10:35
PS1/2	Dolutegravir (DTG) use during pregnancy and birth outcomes: data from the Antiretroviral Pregnancy Registry (APR) Vani Vannappagari, United States	10:35 - 10:50
PS1/3	Prevalence and outcomes of pregnancies over a 20 year period: the EuroSIDA study Justyna Kowalska, Poland	10:50 - 11:05
PS1/4	Does menopause affect treatment response in HIV-infected women? a multicenter cohort in Spain Victoria Hernando, Spain	11:05 - 11:20
PS1/5	Discontinuation of neonatal postexposure prophylaxis in infants born to HIV-infected mothers with suppressed plasma viral load: safety and implementation of the new Swiss recommendations Paolo Paioni, Switzerland	11:20 - 11:35
ML2	Effects of obesity and hormones on the immune system - Implications for women with HIV Donal O'Shea, Ireland	11:35 - 11:55

Scientific Programme

Parallel session
10:00 - 12:00

San Francisco

PS2, Social and implementation science

Session interpreted in Russian

Access to the webcasted session:

[ML1](http://resourcelibrary.eacs.cyim.com?mediald=78019)
[PS2/1](http://resourcelibrary.eacs.cyim.com?mediald=78024)
[ML2](http://resourcelibrary.eacs.cyim.com?mediald=78030)
[PS2/2](http://resourcelibrary.eacs.cyim.com?mediald=78037)
[ML3](http://resourcelibrary.eacs.cyim.com?mediald=78038)

[ML4](http://resourcelibrary.eacs.cyim.com?mediald=78044)

[ML5](http://resourcelibrary.eacs.cyim.com?mediald=78048)

Chairs:

Esther Dixon-Williams, United Kingdom
Niklaus Daniel Labhardt, Switzerland

ML1	Treatment access, optimisation and community monitoring in Russia Sergey Golovin, Russian Federation	10:00 - 10:15
PS2/1	Empowering home visiting nurses as leaders in the response to the HIV epidemic in Central Asia Yelena Kudusova, Kazakhstan	10:15 - 10:30
ML2	Innovative approaches in improving access to care in Ukraine Valeriia Rachynska, Ukraine	10:30 - 10:45
PS2/2	Extension of HIV treatment coverage in Ukraine through advocating access of dolutegravir generics to market Zoia Zamikhovska, Ukraine Sergey Dmitriev, Ukraine	10:45 - 11:00
ML3	PLWHIV 3.0. - Technology makes life easier Alex Schneider, Switzerland	11:00 - 11:15
ML4	EmERGE: mHealth supported pathways of care for people living with stable HIV Jenny Whetham, United Kingdom	11:15 - 11:30
ML5	Innovations in sub-Saharan Africa - May some of these approaches be transferred to Europe? Helen Ayles, United Kingdom	11:30 - 11:45
	Panel discussion	11:45 - 12:00

Scientific Programme

Parallel session
10:00 - 12:00

Sydney

PS3, Weight gain under integrase inhibitors: Is this real?

Access to the webcasted session:

[ML1](http://resourcelibrary.eacs.cyim.com?mediald=78021)
[PS3/2](http://resourcelibrary.eacs.cyim.com?mediald=78032)
[PS3/3](http://resourcelibrary.eacs.cyim.com?mediald=78033)
[PS3/5](http://resourcelibrary.eacs.cyim.com?mediald=78040)
[PS3/6](http://resourcelibrary.eacs.cyim.com?mediald=78045)

Chairs:

Rui Sarmiento e Castro, Portugal
Laura Waters, United Kingdom

ML1	Are new antiretroviral treatments increasing the risks of clinical obesity? Andrew Hill, United Kingdom	10:00 - 10:15
PS3/1	Antiretroviral therapy and body weight in the START (Strategic Timing of Antiretroviral Treatment) trial Kasper Sommerlund Moestrup, Denmark	10:15 - 10:30
PS3/2	Effect of doravirine on body weight and body mass index in treatment naïve adults with HIV-1 Chloe Orkin, United Kingdom	10:30 - 10:45
PS3/3	The ADVANCE clinical trial: changes from baseline to week 96 in DXA-assessed body composition in TAF/FTC +DTG compared to TDF/FTC+DTG, and TDF/FTC/EFV Michelle Moorhouse, South Africa	10:45 - 11:00
PS3/4	Integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in adipose tissue and adipocytes Jennifer Gorwood, France	11:00 - 11:15
PS3/5	Changes in weight after switching to dolutegravir containing antiretroviral therapy in the Swiss HIV cohort study Catrina Mugglin, Switzerland	11:15 - 11:30
PS3/6	Switching to an integrase inhibitor containing antiretroviral regimen is not associated with above-average weight gain in middle-aged people living with HIV on long-term suppressive antiretroviral therapy, the AGEHIV cohort study Sebastiaan Verboeket, Netherlands	11:30 - 11:45

Scientific Programme

Special session
10:00 - 12:00

Boston 1-3

Cure symposium co-organised with the National Agency for AIDS Research (ANRS)

Access to the webcasted session:

[ML2](http://resourcelibrary.eacs.cyim.com?mediald=78027)
[PS14/1](http://resourcelibrary.eacs.cyim.com?mediald=78035)
[PS14/2](http://resourcelibrary.eacs.cyim.com?mediald=78041)

[PS14/3](http://resourcelibrary.eacs.cyim.com?mediald=78042)

[PS14/4](http://resourcelibrary.eacs.cyim.com?mediald=78046)

Chairs:

François Dabis, France
Annemarie Wensing, Netherlands

ML1	Mechanisms of HIV persistence Maria Jose Buzón, Spain	10:00 - 10:15
ML2	Cell metabolism and HIV pathogenesis Asier Sáez-Cirión, France	10:15 - 10:30
ML3	Antiviral NK cells and HIV-1 immunotherapy Marcus Altfeld, Germany	10:30 - 10:45
PS14/1	HIV reservoir in gut from PHI treated individuals is stable over time and correlates with blood markers of HIV reservoir and inflammation-findings from the HEATHER gut study John Patrick Thornhill, United Kingdom	10:45 - 11:00
PS14/2	Effects of long-term ART on integrated and intact HIV-DNA in acutely treated vs chronically infected patients: is there a real advantage of treating early? Manuela Ceccarelli, Italy	11:00 - 11:15
PS14/3	Increased frequency of cytotoxic CXCR5+ effector memory CD8+ T cells during natural control of HIV-1 infection Philipp Adams, Luxembourg	11:15 - 11:30
PS14/4	HIV-1 reservoir formation, stability and dynamics during cART Fabian Otte, Switzerland	11:30 - 11:45

Industry sponsored session
12:15 - 13:45

San Francisco

Industry sponsored session

(For more details, please visit the [conference website](https://eacs-conference2019.com/index.php?article_id=166))

Scientific Programme

Industry sponsored session
12:15 - 13:45

Sydney

Industry sponsored session

(For more details, please visit the [conference website](https://eacs-conference2019.com/index.php?article_id=166))

Workshop/Symposium
12:15 - 13:15

Shanghai 3

Migration and HIV Session convened by EATG

Convener: EATG

Chairs:

Tristan Barber, United Kingdom
Esther Dixon-Williams, United Kingdom

Introduction	12:15 - 12:19
Tristan Barber, United Kingdom Esther Dixon-Williams, United Kingdom	
Migrant access to HIV treatment in 15 countries across WHO Europe and in closed settings/refugee camps	12:19 - 12:28
Ferenc Bagyinszky, Germany	
Migration and religion: The intersection between Religion, Migration and treatment and care for Black MSM?	12:28 - 12:37
Jide Macaulay, United Kingdom	
Migration and Women	12:37 - 12:46
Maryan Said, Norway	
Migration during war in Ukraine	12:46 - 12:55
Valeriia Rachynska, Ukraine	
Panel discussion	12:55 - 13:10
Dennis Onyango, United Kingdom Tristan Barber, United Kingdom Maryan Said, Norway Jide Macaulay, United Kingdom Ferenc Bagyinszky, Germany Valeriia Rachynska, Ukraine	
Summary	13:10 - 13:15
Tristan Barber, United Kingdom Esther Dixon-Williams, United Kingdom	

Scientific Programme

ePosters
12:30 - 13:15

ePosters area

Moderated ePosters II: Clinical science

Chairs:

Giovanni Guaraldi, Italy
Annette Haberl, Germany

- PE18/1 **Are women living with HIV in increased risk of complications to birth when planning elective caesarean section? A Danish nation wide population based study**
Mathilde Ørbæk, Denmark
- PE18/2 **Cesarean section is still the most common mode of delivery among HIV-positive women in Central Poland**
Justyna Kowalska, Poland
- PE18/3 **The Swiss Mother and Child HIV Cohort Study (MoCHiV), a unique opportunity to monitor and adapt measures to prevent HIV mother to child transmission**
Christian R Kahlert, Switzerland
- PE18/4 **Influence of HCV co-infection and hepatitis C treatment on risk of chronic kidney disease in HIV positive persons**
Lars Peters, Denmark
- PE18/5 **The hepatitis C continuum of care among HIV-infected individuals in Austria**
David Chromy, Austria

ePosters
12:30 - 13:15

ePosters area

Moderated ePosters I: Basic science

Chairs:

Hendrik Streeck, Germany

- PE17/1 **Abdominal adipose tissue is associated with alterations in tryptophan-kynurenine metabolism and markers of systemic inflammation in people living with HIV**
Marco Gelpi, Denmark
- PE17/2 **Integrase inhibitor negatively affects CD8 T-cell function**
Enrico Richter, Germany
- PE17/3 **The evolution of HIV-1 drug resistance during the 3-month WHO-recommended enhanced adherence counselling period**
Jennifer Anne Brown, Switzerland
- PE17/4 **Replication-competent HIV-1 reservoirs form in mucosal tissue macrophages of patients under antiretroviral therapy**
Morgane Bomsel, France
- PE17/5 **Skin tissue resident memory T cells (TRMs) are depleted in HIV infection and reconstituted by an early begin of ART**
Simona Saluzzo, Austria

Scientific Programme

- PE17/6 **Baseline and emergent genotypic and phenotypic results in HIV-1-infected, heavily treatment-experienced (HTE) participants meeting protocol-defined virologic failure (PDVF) criteria through week 96 in the fostemsavir (FTR) phase 3 BRIGHT study**
Peter Ackerman, United States

ePosters
12:30 - 13:15

ePosters area

Moderated ePosters III: Social and implementation sciences

Chairs:

Niklaus Daniel Labhardt, Switzerland

- PE19/1 **Untreated HCV in HIV/HCV-coinfected US population remains common despite the availability of curative therapies**
Rick Elion, United States
- PE19/2 **HepCare Europe - a model of integrated care in Romanian HCV/HIV co-infected patients from key populations**
Cristiana Oprea, Romania
- PE19/3 **Prélib: evaluating a newly launched Canadian provider of innovative internet-based services for self-directed HIV and STI screening**
Khadija Benomar, Canada
- PE19/4 **Employment of people living with HIV approaching that of the HIV-negative population irrespective of migrant status and sexual orientation**
Christina Carlander, Sweden
- PE19/5 **Retention in care and virological suppression in naïve HIV-infected transgender women initiating treatment in Argentina: 48-week results (TRANSViiV study)**
Claudia Frola, Argentina
- PE19/6 **Addressing the needs of female sex workers in Switzerland: model of care beyond STI testing**
Karoline Aepli-Popp, Switzerland

Scientific Programme

Parallel session
14:00 - 16:00

Event Hall

PS4, More than the sum of its parts? Multimorbidity in PLWH

Session interpreted in Russian

Access to the webcasted session:

[ML1](http://resourcelibrary.eacs.cyim.com?mediald=78055)
[PS4/1](http://resourcelibrary.eacs.cyim.com?mediald=78056)
[PS4/2](http://resourcelibrary.eacs.cyim.com?mediald=78072)
[PS4/3](http://resourcelibrary.eacs.cyim.com?mediald=78073)

[PS4/4](http://resourcelibrary.eacs.cyim.com?mediald=78074)

[PS4/7](http://resourcelibrary.eacs.cyim.com?mediald=78081)

Chairs:

Stefan Mauss, Germany
Peter Reiss, Netherlands

ML1	Neighbours visiting: Update from the 2019 co-morbidity workshop Judith Currier, United States	14:00 - 14:15
PS4/1	AIDS defining and non-defining cancers in persons living with HIV in a single center cohort followed since 1986 Rocio Montejano Sanchez, Spain	14:15 - 14:30
PS4/2	Incidence of CKD with TDF and non-TDF containing antiretroviral regimens by baseline D:A:D CKD risk in people living with HIV (PLWH) Ricky Hsu, United States	14:30 - 14:45
PS4/3	The ADVANCE trial: the impact of DXA-assessed bone mineral density of TDF/FTC/EFV and TDF/FTC+DTG versus TAF/FTC+DTG Michelle Moorhouse, South Africa	14:45 - 15:00
PS4/4	Pericardial adipose tissue volume is independently associated with HIV status Andreas Dehlbæk Knudsen, Denmark	15:00 - 15:15
PS4/6	Comparing a risk score against physiological markers for predicting diabetes incidence in HIV+ individuals Karla I Galaviz, United States	15:15 - 15:30
PS4/7	Development and validation of a comorbidity index for people living with HIV and its ability to predict frailty and mortality Davide De Francesco, United Kingdom	15:30 - 15:45

Scientific Programme

Parallel session
14:00 - 16:00

San Francisco

PS5, Basic and translational HIV biology

Access to the webcasted session:

[ML1](http://resourcelibrary.eacs.cyim.com?mediald=78051)
[ML2](http://resourcelibrary.eacs.cyim.com?mediald=78065)
[PS5/1](http://resourcelibrary.eacs.cyim.com?mediald=78066)
[PS5/2](http://resourcelibrary.eacs.cyim.com?mediald=78075)
[PS5/3](http://resourcelibrary.eacs.cyim.com?mediald=78076)
[PS5/4](http://resourcelibrary.eacs.cyim.com?mediald=78078)

[PS5/5](http://resourcelibrary.eacs.cyim.com?mediald=78082)

[PS5/6](http://resourcelibrary.eacs.cyim.com?mediald=78085)

Chairs:

Huldrych Günthard, Switzerland
Michaela Müller-Trutwin, France

ML1	Inflammation, the microbiome and HIV Here the interaction between the microbiome and inflammation should be discussed in HIV-infected individuals and whether this has clinical implications to date and what could be future avenues of microbiome research Roger Paredes, Spain	14:00 - 14:15
ML2	Phylogenetics as a tool in HIV research <i>To explain to physicians what can be done with phylogenetics and how these data can be interpreted and improve our understanding of spread of HIV and pathogenesis</i> Roger Kouyos, Switzerland	14:15 - 14:30
PS5/1	Stem-cell-like CD4+ memory T cells expand during the acute HIV-1 infection accelerating disease progression Jernej Pušnik, Germany	14:30 - 14:45
PS5/2	Correlation between cerebrospinal fluid (CSF) and plasma concentrations of neurofilament light protein (NFL) in treated HIV infection in the COMorBidity in Relation to AIDS (COBRA) study Jasmini Alagaratnam, United Kingdom	14:45 - 15:00
PS5/3	TET2 genetic variation affects HIV viral load in ART-naïve persons Daniel D. Murray, Denmark	15:00 - 15:15
PS5/4	Temporal evolution of a unique N332 supersite directed bnAb lineage in slow progressing HIV-1 infection Merle Schanz, Switzerland	15:15 - 15:30
PS5/5	Prevalence of InSTI resistance and effectiveness of InSTI-based regimens in HIV-infected patients: results from a European cohort study Barbara Rossetti, Italy	15:30 - 15:45
PS5/6	In vitro analysis of doravirine activity on HIV-1 clones harboring multiple NNRTI resistance mutations Francesco Saladini, Italy	15:45 - 16:00

Scientific Programme

Parallel session
14:00 - 16:00

Sydney

PS6, Addressing the HIV and STI syndemics co-organised with the International AIDS Society (IAS)

Access to the webcasted session:

[ML1](http://resourcelibrary.eacs.cyim.com?mediald=78058)
[ML2](http://resourcelibrary.eacs.cyim.com?mediald=78059)
[ML3](http://resourcelibrary.eacs.cyim.com?mediald=78060)
[ML4](http://resourcelibrary.eacs.cyim.com?mediald=78067)
[ML5](http://resourcelibrary.eacs.cyim.com?mediald=78068)

[PS6/2](http://resourcelibrary.eacs.cyim.com?mediald=78080)

[PS6/3](http://resourcelibrary.eacs.cyim.com?mediald=78083)

Chairs:

Ken Mayer, United States
Fiona Mulcahy, Ireland

ML1	Global epidemiology of HIV and STI Teodora Elvira Wi, Switzerland	14:00 - 14:15
ML2	Framing the clinical issues Henry de Vries, Netherlands	14:15 - 14:30
ML3	STI in the era of PrEP and U=U Jean-Michel Molina, France	14:30 - 14:45
ML4	New and emerging STI concerns Nicola Low, Switzerland	14:45 - 15:00
ML5	Considerations for key populations Ken Mayer, United States	15:00 - 15:15
PS6/1	The natural history of anal high grade squamous intraepithelial lesions in HIV positive and HIV negative gay and bisexual men David James Templeton, Australia	15:15 - 15:30
PS6/2	The role of E6/7 mRNA for anal cancer screening in HIV-infected men who have sex with men Ana Silva-Klug, Spain	15:30 - 15:45
PS6/3	Modelling the syphilis epidemic among HIV-positive and negative MSM in Switzerland Suraj Balakrishna, Switzerland	15:45 - 16:00

Scientific Programme

Parallel session
14:00 - 16:00

Boston 1-3

PS7, Antiretroviral therapy in special populations

Access to the webcasted session:

[PS7/1](http://resourcelibrary.eacs.cyim.com?mediald=78062)
[PS7/2](http://resourcelibrary.eacs.cyim.com?mediald=78063)
[PS7/3](http://resourcelibrary.eacs.cyim.com?mediald=78069)
[PS7/4](http://resourcelibrary.eacs.cyim.com?mediald=78070)
[PS7/5](http://resourcelibrary.eacs.cyim.com?mediald=78071)
[PS7/6](http://resourcelibrary.eacs.cyim.com?mediald=78084)

Chairs:

Carlo Federico Perno, Italy
Caroline Sabin, United Kingdom

PS7/1	RPV+DRV/cobi as 2DR option in HIV-infected subjects on virologic suppression Franco Maggiolo, Italy	14:00 - 14:20
PS7/2	Switching to DTG/3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) through 48 weeks: subgroup analyses from the TANGO study Jean van Wyk, United Kingdom	14:20 - 14:40
PS7/3	Safety and efficacy of triple therapy with Dolutegravir plus 2 NRTIs, in treatment-naïve HIV-2 infected patients - 48 weeks results from a phase II study Patricia Pacheco, Portugal	14:40 - 15:00
PS7/4	HIV-1-RNA kinetics in blood plasma and in seminal plasma of men starting a dolutegravir-based regimen at the time of primary HIV-1 infection Jade Ghosn, France	15:00 - 15:20
PS7/5	Dolutegravir and lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a pilot clinical trial (ART-PRO) Rosa De Miguel Buckley, Spain	15:20 - 15:40
PS7/6	Efficacy and safety of bicitegravir/emtricitabine/tenofovir alafenamide vs comparators in cis-women and girls (living with HIV): an analysis of 5 clinical trials Chloe Orkin, United Kingdom	15:40 - 16:00

Scientific Programme

Special session
16:30 - 17:30

Event Hall

EACS Guidelines session

Session interpreted in Russian

Access to the webcasted session:

[Welcome](http://resourcelibrary.eacs.cyim.com?mediald=78087)
[Introduction](http://resourcelibrary.eacs.cyim.com?mediald=78088)
[ART panel](http://resourcelibrary.eacs.cyim.com?mediald=78089)
[Drug-drug interaction panel](http://resourcelibrary.eacs.cyim.com?mediald=78090)
[Co-morbidity panel](http://resourcelibrary.eacs.cyim.com?mediald=78185)
[Co-infection panel](http://resourcelibrary.eacs.cyim.com?mediald=78186)
[Opportunistic infections panel](http://resourcelibrary.eacs.cyim.com?mediald=78187)

[Community perspective](http://resourcelibrary.eacs.cyim.com?mediald=78188)

[Closing](http://resourcelibrary.eacs.cyim.com?mediald=78189)

[](http://resourcelibrary.eacs.cyim.com?mediald=78188)

[>](http://resourcelibrary.eacs.cyim.com?mediald=78188)

Chairs:

Andri Rauch, Switzerland
Lene Ryom, Denmark

Welcome

Andri Rauch, Switzerland
Lene Ryom, Denmark

Introduction

Manuel Battegay, Switzerland

16:30 - 16:40

ART panel

Jose Arribas, Spain

16:40 - 16:48

Drug-drug interaction panel

Catia Marzolini, Switzerland

16:48 - 16:56

Paddy Mallon, Ireland

16:56 - 17:04

Charles Béguelin, Switzerland

17:04 - 17:12

Ole Kirk, Denmark

17:12 - 17:20

Simon Collins, United Kingdom

17:20 - 17:26

Closing

Andri Rauch, Switzerland
Lene Ryom, Denmark

Scientific Programme

Special session
17:30 - 18:30

San Francisco

EuroSIDA 25 years: What have we learned from cohort studies?

Access to the webcasted session:

[Welcome](http://resourcelibrary.eacs.cyim.com?mediald=78190)

[Major achievements in EuroSIDA: Perspective from invited expert](http://resourcelibrary.eacs.cyim.com?mediald=78191)

[The role of EuroSIDA in HIV, HCV and TB research in Central East and Eastern Europe](http://resourcelibrary.eacs.cyim.com?mediald=78193)

[What HIV observational cohorts have brought to the field](http://resourcelibrary.eacs.cyim.com?mediald=78219)

[Adapting HIV cohorts to future challenges in HIV research](http://resourcelibrary.eacs.cyim.com?mediald=78220)

[Questions/Wrap-up](http://resourcelibrary.eacs.cyim.com?mediald=78221)

Chairs:

Amanda Mocroft, United Kingdom
Jürgen Rockstroh, Germany
Gilles Wandeler, Switzerland

Welcome	17:30 - 17:35
Amanda Mocroft, United Kingdom Jürgen Rockstroh, Germany Gilles Wandeler, Switzerland	
Major achievements in EuroSIDA : Perspective from invited expert	17:35 - 17:45
Alison Rodger, United Kingdom	
The role of EuroSIDA in HIV, HCV and TB research in Central East and Eastern Europe	17:45 - 17:55
Daria Podlekareva, Denmark	
What HIV observational cohorts have brought to the field	17:55 - 18:10
Bruno Ledergerber, Switzerland	
Adapting HIV cohorts to future challenges in HIV research	18:10 - 18:25
Jens D. Lundgren, Denmark	
Questions/Wrap-up	18:25 - 18:30
Gilles Wandeler, Switzerland	

Workshop/Symposium
17:30 - 18:30

Boston 1-3

EACS Regional Representatives

Chairs:

Cristiana Oprea, Romania
Ann Sullivan, United Kingdom

Welcome and introduction	17:30 - 17:35
Cristiana Oprea, Romania	

Scientific Programme

Update on new structure of EACS - Regional Representatives and Governing Board, Q&A on EACS activities Sanjay Bhagani, United Kingdom	17:35 - 17:45
Feedback on the Standard of Care meeting in Bucharest Cristiana Oprea, Romania	17:45 - 17:55
Euroguidelines in Central and Eastern Europe network update Andrzej Horban, Poland	17:55 - 18:05
To be announced Cristina Mussini, Italy	18:05 - 18:15
Roundtable	18:15 - 18:25

Industry sponsored session
17:45 - 18:45

Sydney

Industry sponsored session

(For more details, please visit the [conference website](https://eacs-conference2019.com/index.php?article_id=166))

Industry sponsored session
17:45 - 19:15

Samarkand + Osaka

Industry sponsored session

(For more details, please visit the [conference website](https://eacs-conference2019.com/index.php?article_id=166))

Scientific Programme

Friday, 08 November 2019

Meet-the-expert/Clinical cases
07:30 - 08:30

Sydney

Clinical cases I

Chairs:

Sanjay Bhagani, United Kingdom
Yvonne Gilleece, United Kingdom

CC1/1	Cutaneous and asymptomatic visceral leishmaniasis in late-stage HIV infection Daniela Lages, Portugal	07:30 - 07:50
CC1/2	An unusual neurologic manifestation Luba Tau, Israel	07:50 - 08:10
CC1/3	Treatment with DAA HIV-HCV coinfectd patient with XDR-tuberculosis Narina Sargsyants, Armenia	08:10 - 08:30

Meet-the-expert/Clinical cases
07:30 - 08:30

Shanghai 3

HIV-associated neurocognitive disorders and neurological complications - An update

Chairs:

Andrea Calcagno, Italy
Matthias Cavassini, Switzerland

Special session
07:30 - 08:30

Shanghai 1-2

Ageing with HIV

Access to the webcasted session:

[Introduction](http://resourcelibrary.eacs.cyim.com?mediald=78700)
[Do we need models of care for older people with HIV?](http://resourcelibrary.eacs.cyim.com?mediald=78701)
[Examples of models of care for older people with HIV in Europe](http://resourcelibrary.eacs.cyim.com?mediald=78702)
[Italy](http://resourcelibrary.eacs.cyim.com?mediald=78703)
[Poland](http://resourcelibrary.eacs.cyim.com?mediald=78704)
[Norway](http://resourcelibrary.eacs.cyim.com?mediald=78705)
[Community perspective](http://resourcelibrary.eacs.cyim.com?mediald=78709)
[Closing](http://resourcelibrary.eacs.cyim.com?mediald=78710)

Chairs:

Tristan Barber, United Kingdom
Jaime Vera, United Kingdom

Scientific Programme

Introduction	07:30 - 07:32
Tristan Barber, United Kingdom Jaime Vera, United Kingdom	
Do we need models of care for older people with HIV?	07:32 - 07:40
Jaime Vera, United Kingdom	
Examples of models of care for older people with HIV in Europe	
Italy	07:40 - 07:48
Giovanni Guaraldi, Italy	
Poland	07:48 - 07:56
Justyna Kowalska, Poland	
Norway	07:56 - 08:04
Maryan Said, Norway	
Community perspective	08:04 - 08:12
EATG Susan Cole, NAM aidsmap, United Kingdom	
Panel discussion and audience questions	08:12 - 08:22
Closing	08:22 - 08:27
Tristan Barber, United Kingdom Jaime Vera, United Kingdom	

Workshop/Symposium
07:30 - 08:30

Boston 1-3

Euroguidelines in Central and Eastern Europe Symposium

Chairs:

Josip Begovac, Croatia
Andrzej Horban, Poland
Vadim Pokrovsky, Russian Federation

Who we are and what we do?	07:30 - 07:35
Justyna Kowalska, Poland	
ECEE Workshop in Lviv - clinicians' perspective on HIV care in Ukraine	07:35 - 07:50
Marta Vasylyev, Ukraine	
Access to new cART components, new treatment strategies and clinical trials in CEE	07:50 - 08:05
Josip Begovac, Croatia	
HIV care in CEE - what is changing, what is not	08:05 - 08:20
Mike Youle, United Kingdom	
Discussion on future perspectives and action points	08:20 - 08:30

Scientific Programme

Meet-the-expert/Clinical cases
07:30 - 08:30

Darwin

HIV and the liver

Chairs:

Christoph Boesecke, Germany
Marina Klein, Canada

CC4/1	Hepatitis B reactivation after tenofovir cessation in an HIV-infected patient with poor immunological status	07:30 - 07:50
	Luz Martin, Spain	

Meet-the-expert/Clinical cases
07:30 - 08:30

Kairo 2

Vaccination in HIV: Which vaccine for whom?

Chairs:

Christoph Fux, Switzerland
Carolynne Schwarze-Zander, Germany

Plenary lecture
08:30 - 09:00

Event Hall

PL3, Precision medicine in HIV

Session interpreted in Russian

Access to the webcasted session:

[Precision medicine in HIV](http://resourcelibrary.eacs.cyim.com?mediald=78707)

Chairs:

Cristina Mussini, Italy

Precision medicine in HIV	08:30 - 08:55
Amalio Telenti, United States	

European Hector Research Award in HIV 2019 ceremony - Best clinical science and/or epidemiological paper	08:55 - 09:00
Esteban Martínez, Spain	

Scientific Programme

Plenary lecture
09:00 - 09:30

Event Hall

PL4, Whole genome sequencing for tuberculosis treatment and control: A game changer?

Session interpreted in Russian

Access to the webcasted session:

[Whole genome sequencing for tuberculosis treatment and control: A game changer?](http://resourcelibrary.eacs.cyim.com?mediaId=78724)

Chairs:

Paddy Mallon, Ireland

Whole genome sequencing for tuberculosis treatment and control: A game changer?

09:00 - 09:30

Iñaki Comas, Spain

ePosters
09:00 - 16:00

Exhibition hall

HIV cure

PE12/1 **Comparison of three commercial kits for quantitative analysis of HIV-1 RNA produced in Russia**
Ilya Lapovok, Russian Federation

PE12/2 **Optimization of genotyping by phenotypic analysis of clinical HIV-1 subtype CRF01_AE isolates from South-East Asia**
Nina Marty, Switzerland

ePosters
09:00 - 16:00

Exhibition hall

Antiretroviral therapy preclinical

PE4/3 **In vivo dissection of the effects of HIV and antivirals on mitochondrial function in chronic treated HIV**
Theodoros Kelesidis, United States

PE4/4 **The main barriers to "Test and Start" in Central Asia from the service providers' and patients' point of view**
Yelena Kudusova, Kazakhstan

PE4/5 **Preclinical aspects of an anti-HIV molecule targeting vimentin**
Celia Berta Fernandez-Ortega, Cuba

PE4/6 **PK/PD modelling of bnAbs for HIV treatments identifying knowledge gaps**
Mark Baker, Switzerland

PE4/7 **A new inhibitor of HIV-1 infection exploiting host intracellular signaling to alter viral RNA processing**
Raymond Waiman Wong, Canada

Scientific Programme

ePosters
09:00 - 16:00

Exhibition hall

HIV drug resistance

- PE13/1 **Darunavir resistance among patients exposed to protease inhibitors failing ARV therapy**
Luis Fernando Brigido, Brazil
- PE13/2 **Prevalence and factors associated to the detection (population and next generation sequencing) of archived 3TC resistance mutations in aviremic HIV-infected adults (GEN-PRO)**
Lourdes Domínguez-Domínguez, Spain
- PE13/4 **Monitoring the prevalence of transmitted HIV drug resistance in Hungary**
Eva Ay, Hungary
- PE13/5 **Predominant reverse transcriptase resistance mutations as barriers to achieving elimination of mother-to-child transmission of HIV in South Africa**
Oladele Vincent Adeniyi, South Africa
- PE13/6 **Virologic failure and human immunodeficiency virus drug resistance in adolescents on antiretroviral therapy in Yaounde and Douala**
Magaly Jeanne Estelle Moukoko Mbonjo, Cameroon
- PE13/7 **Selection of integrase inhibitor (INI) resistance mutations in an INI experienced patient treated by Bictegravir**
Thanes Vanig, United States
- PE13/8 **Impact of HIV-1 subtypes and integrase natural polymorphisms on virological response to first-line integrase inhibitors based regimens**
Daniele Armenia, Italy
- PE13/9 **HIV-1 integrase inhibitor resistance associated mutations defined by majority and minority populations among individuals failing therapy**
Smitha Gudipati, United States
- PE13/10 **HIV-1 diversity and antiretroviral resistance among bulgarian citizens infected abroad and foreigners registered with HIV/AIDS in bulgaria from 2012 to 2017 (preliminary analysis)**
Ivailo Alexiev, Bulgaria
- PE13/11 **Analytical treatment interruption and its association with rearrangement of peripheral archived resistance mutations**
Claudia Alteri, Italy
- PE13/12 **A low level of darunavir resistance-associated mutation emergence in patients with virological failure during long term use of darunavir in people living with HIV, the French ANRS CO3 Aquitaine cohort**
Fabrice Bonnet, France
- PE13/13 **Patients infected with multi-class resistant HIV-1 and with viral suppression treated with no more than one active drug: comparison of historical resistance reports and drug resistance in proviral DNA**
Christian Hoffmann, Germany
- PE13/14 **Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance in people living with HIV-1 (PLWH) subtype non-B from the Swiss HIV Cohort Study (SHCS)**
Martina L. Reichmuth, Switzerland

Scientific Programme

- PE13/15 **HIV-1 from antiretroviral-naïve and experienced patients lack capsid substitutions associated with GS-6207 in vitro resistance**
Anne-Geneviève Marcelin, France
- PE13/16 **Long-term efficacy, safety and durability of ibalizumab in expanded access study**
Graeme Moyle, United Kingdom
- PE13/17 **Clinical impact of minority mutations in patients failing an integrase inhibitor-based regimen: what do clinicians do?**
Smitha Gudipati, United States
- PE13/18 **Identification of HIV-1 transmission clusters in Croatia, 2014 - 2017: evidence for the forward spread of HIV-1 resistant variants**
Josip Begovac, Croatia
- PE13/19 **High levels of resistance among HIV-1 treatment naive patients in Greece, a nationwide study: evidence for country and regional level transmission networks**
Dimitris Chatzidimitriou, Greece
- PE13/20 **A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring NRTI resistance mutations M184V/I +/- TAMs (GS-US-292-1824): week 24 results**
Ignacio Pérez-Valero, Spain
- PE13/21 **Sustained viral suppression among participants with pre-existing M184V/I who switched to bictegravir/emtricitabine/tenofovir alafenamide**
Kristen Andreatta, United States
- PE13/22 **Absence of naturally existing resistance against the HIV-1 capsid inhibitor GS-6207 in HIV-1 primary isolates**
Christian Callebaut, United States
- PE13/23 **Impacts assessment of home based care program over adherence to ART among adolescence living with HIV and AIDS in Blantyre Malawi**
Lesily Samson Kapile, Malawi
- PE13/24 **Correlation of results analysis drug resistance of HIV-1 among patients with virological failure by next-generation sequencing and traditional population sequencing**
Alina Kirichenko, Russian Federation
- PE13/25 **Analysis of the latent reservoir of a patient infected with HIV under PrEP by single full-length HIV-1 amplification**
Maximilian Damagnez, Germany
- PE13/26 **Drug resistance profile according to HIV-1 viral load after long-term exposure to antiretroviral treatment in the absence of routine virological monitoring: results from a programmatic cohort in sub-Saharan Africa**
Giovanni Villa, United Kingdom
- PE13/27 **In vitro analysis of replicative capacity and phenotypic susceptibility of integrase mutant HIV-2 viruses**
Quentin Le Hingrat, France
- PE13/28 **Treatment simplification with two-drug regimens: impact of transmitted drug resistance mutations in residents of South-East Austria**
Evelyn Stelzl, Austria

Scientific Programme

- PE13/29 **Baseline resistance to Doravirine depends on the algorithm used for interpretation**
Carlos Guerrero Beltrán, Spain
- PE13/30 **Baseline resistance to EACS first line recommended antiretroviral regimens in newly diagnosed patients in Spain**
Federico García, Spain
- PE13/31 **A retrospective evaluation of a national home infusion provider's approach to medication adherence of parenteral ibalizumab-uiyk in the alternate-site and homecare setting**
Kathryn Andrusko-Furphy, United States
- PE13/32 **Prevalence of HIV-1 drug resistance among patients with antiretroviral therapy failure in Moscow region, Russia**
Natalya Lebedeva, Russian Federation
- PE13/33 **HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa: implications for elimination of mother-to-child transmission**
Oladele Vincent Adeniyi, South Africa
- PE13/34 **Antiretroviral Resistance patterns in HIV-1 infected patients failing to second-line in Bamako, Mali**
Almoustapha Issiaka Maiga, Mali

ePosters
09:00 - 16:00

Exhibition hall

Human genomics

- PE15/1 **Genetic characterization of the near full-length genome of an HIV-1 A1/C/D/K/B unique recombinant form from the Eastern Cape, South Africa: a case report**
Oladele Vincent Adeniyi, South Africa
- PE15/2 **Impact of KIR and their ligands (HLA allele) on susceptibility to selected viral opportunistic conditions and HIV plasma viral load in HIV+ patients**
Magdalena Leszczyszyn-Pynka, Poland
- PE15/3 **The identification and causal analysis of aberrant CD4 counts in an HIV cohort in Southern Alberta, Canada**
Raynell Lang, Canada
- PE15/4 **Placental gene expression profiles and pathways in HIV-1 positive Cameroonian women under ART**
Forgu Esemu Livo, Cameroon
- PE15/5 **Functional clustering and association of HLA class I alleles to viral load in HIV-positive and ART-naïve participants from the INSIGHT START study**
Adrian Gabriel Zucco, Denmark
- PE15/6 **miRNA expression profiling in subcutaneous adipose tissue of monozygotic twins discordant for HIV infection: validation of differentially expressed miRNA and bioinformatic analysis**
Nicola Squillace, Italy
- PE15/7 **Factors influencing late presentation into care of HIV disease**
Bogusz Aksak-Wąs, Poland

Scientific Programme

ePosters
09:00 - 16:00

Exhibition hall

Immunology

- PE16/1 **Immunological and metabolic effects of dasatinib treatment in IL7-stimulated CD4+ T-cells subpopulations**
Humberto Erick De La Torre Tarazona, Spain
- PE16/2 **New T- and B-lymphocytes production and T-cell receptor diversity in young adults perinatally infected by HIV**
Martina Properzi, Italy
- PE16/3 **In Vivo modelling of mechanisms of HIV-1-related monocyte dysfunction**
Theodoros Kelesidis, United States
- PE16/4 **Lectin-like oxidized low-density lipoprotein (LOX-1) is elevated in proinflammatory monocytes in chronic treated HIV**
Theodoros Kelesidis, United States
- PE16/5 **In vivo dissection of the impact of HIV-1 versus antivirals on immune activation in chronic treated HIV**
Theodoros Kelesidis, United States
- PE16/6 **Differential impact of HIV-1 versus antivirals on systemic inflammation in chronic treated HIV**
Theodoros Kelesidis, United States
- PE16/7 **Correlation between blood telomere length and CD4+ CD8+ T-cell subsets in HIV-1-positive individuals with long-term virological suppression on antiretroviral therapy**
Javier Rodríguez-Centeno, Spain
- PE16/9 **Phenotypical recovery of the T-cell pool following switch to dual and triple INSTI-based cART**
Camilla Tincati, Italy
- PE16/11 **Expression of PD-1 in a population of double-negative T cells (CD3+CD4-CD8-) in HIV-infected patients - the preliminary study results**
Weronika Rymer, Poland
- PE16/12 **Targeting inflammation in chronic treated HIV with oral ApoA-I mimetics**
Theodoros Kelesidis, United States
- PE16/13 **Poor recovery of T-cell receptor repertoire despite long-term antiretroviral therapy**
James Brown, United Kingdom

ePosters
09:00 - 16:00

Exhibition hall

Pathogenesis and immunopathogenesis

- PE26/2 **Colonic microbiota exhibits disparate associations with HIV-infection and sexual practices**
Eveline Verheij, Netherlands
- PE26/3 **Zonulin indicates loss of intestinal integrity and microbial translocation in HIV+ patients**
Max Augustin, Germany

Scientific Programme

- PE26/4 **Distinct pro-inflammatory and cardio-protective effects of antiretroviral drugs in vascular endothelial cells**
Akif A. Khawaja, United Kingdom
- PE26/5 **Bacterial translocation kinetics in HIV-1 infection: from acute to chronic stages**
Paula Aranguren-Rivas, Spain
- PE26/6 **Mitochondrial antioxidants attenuate In vivo liver fibrosis in chronic treated HIV**
Theodoros Kelesidis, United States
- PE26/7 **Mitochondrial antioxidants attenuate In vivo mitochondrial dysfunction and exhaustion in T cells in chronic treated HIV**
Theodoros Kelesidis, United States
- PE26/8 **Inhibition of caspase 1 reduces viral load, CD4 T cell depletion and immune activation in HIV-1 infected humanized mice**
Philipp Adams, Luxembourg
- PE26/9 **Effect of early initiation of ART on alterations in natural killer cells in HIV infected pediatric patients**
Romsha Kumar, India
- PE26/10 **HIV-DNA levels, HLA-B*27 and HLA-DRB1*13 among LTNPs, ECs and HIV controllers**
Arianna Gabrieli, Italy
- PE26/11 **Macromolecule uptake across intestinal epithelia in HIV infection**
Carolin Grünhagen, Germany
- PE26/12 **Immune cell activation as a risk factor for hypertension in people living with HIV in Sub-Saharan Africa using the recent American Heart Association and American College of Cardiology Guidelines**
Sepiso Masenga, Zambia

ePosters
09:00 - 16:00

Exhibition hall

Vaccines and immune based therapies

- PE36/2 **Development of engineered nanocarrier for controlled delivery of a protease inhibitor**
Saurabh Bhargava, India

ePosters
09:00 - 16:00

Exhibition hall

Virology

- PE38/1 **Identification of an HIV-1 BC intersubtype recombinant form, which is circulating in Spain**
Javier Enrique Cañada García, Spain
- PE38/2 **Viral reservoir dynamics in very early primary HIV infection (PHI) patients receiving an intensified antiretroviral regimen (ART): a pilot clinical trial**
Juan Ambrosioni, Spain

Scientific Programme

- PE38/3 **Lamivudine-based two-drug regimens are not associated with an increased risk of detectable rectal HIV-RNA**
Alberto Borghetti, Italy
- PE38/4 **Comparison of HIV-1 viral load and drug resistance mutations between cerebrospinal fluid and plasma in patients with HIV and Cryptococcal meningitis co-infection in Botswana**
Nametso Kelentse, Botswana
- PE38/5 **HTLV-II antisense protein Aph-2 negatively regulates HIV-1 transcription**
Rajkumar Londhe, India
- PE38/6 **HIV compartmentalization between plasma and CSF and association with neurocognitive disorders**
Alessandro Lazzaro, Italy
- PE38/7 **Determinants of neurocognitive impairments in a Romanian cohort of young adults with chronic HIV infection**
Simona Ruta, Romania
- PE38/8 **Reconstruction of phylogeography for Indian HIV-1 sub-subtype A1**
Ajit Patil, India
- PE38/9 **Broad and potent neutralizing antibody responses in HIV-1 infected Angolan patients: implications for vaccine design and efficacy**
Francisco Martin, Portugal
- PE38/10 **The XbnAb cohort: a HIV-1 cohort of 304 bnAb inducers and matched controls tailored to study determinants of bnAb induction**
Irene Abela, Switzerland
- PE38/11 **Performance of 'Xpert® HIV-1 Qual assay' for diagnosis of HIV-1 infection using Dried Blood Spot specimens**
Swarali Kurle, India
- PE38/12 **HIV-1 infections belonging to transmission clusters originating in different countries are frequently detected in Spain among newly diagnosed individuals**
Javier Cañada, Spain

ePosters
09:00 - 16:00

Exhibition hall

Antiretroviral observational studies

- PE2/1 **A study of the effect of antiretroviral therapy on sexual risk behavior in a high-risk cohort of Congolese women**
Samuel Bitá, Congo, the Democratic Republic of the
- PE2/2 **Coagulation system and HIV infection: a review**
Nnamdi Nwachukwu, Nigeria
- PE2/3 **Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-naïve HIV-1 infected patients - 24-month results from the German TAFNES cohort study**
Hans-Jürgen Stellbrink, Germany

Scientific Programme

- PE2/4 **“Attracting men” - extended clinic hours as differentiated model of care in an urban Malawian cohort**
Sam Phiri, Malawi
- PE2/5 **HIV care in India: a systematic review of barriers to anti-retroviral therapy adherence**
Charu Kohli, India
- PE2/6 **Comparing NRTI-sparing dual regimens using data from the Swiss HIV cohort study**
Jim Young, Switzerland
- PE2/7 **Physicians' opinions on generic antiretroviral drugs and single tablet regimen (STR) de-simplification for the treatment of HIV infection: a multicentre survey in Spain**
Inés Suárez-García, Spain
- PE2/8 **Simplifying salvage regimens with darunavir-based dual therapy in HIV-infected individuals harboring multidrug-resistance**
Pilar Vizcarra, Spain
- PE2/9 **Clinical outcomes among HIV-infected Africans with advanced disease in Spain**
Adrià Ramírez-Mena, Switzerland
- PE2/10 **The Treatment of Primary HIV (TopHIV) cohort: a prospective multicenter cohort in Germany**
Melanie Stecher, Germany
- PE2/11 **No decrease in CD4/CD8 ratio after 36 months therapy in patients who were switched to two dual regimens containing rilpivirine**
Cecilia Tortajada, Spain
- PE2/12 **Clinical experience of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in real life practice: data from the Turkish HIV-TR cohort**
Volkan Korten, Turkey
- PE2/13 **Real world utilisation of raltegravir 1200mg once daily (The RETRO Study)**
Christine Mackay, United Kingdom
- PE2/14 **Effectiveness, persistence and safety in treatment-naïve and treatment-experienced HIV-1 infected patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) - 12-month evaluation of the French TARANIS cohort**
Jean-Luc Meynard, France
- PE2/15 **24-month evaluation of the German TAFNES cohort - Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF + 3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-experienced HIV-1 infected patients**
Heribert Knechten, Germany
- PE2/16 **Effectiveness, safety and tolerability of bictegrovir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected adult patients in routine clinical practice - 6 months results of the BICSTaR cohort**
Stefan Esser, Germany
- PE2/17 **Short-term increase in Body Mass Index and systolic blood pressure elevation in treatment naïve persons starting INSTI-based antiretroviral therapy**
Ronald Galdamez, Spain
- PE2/18 **Baseline characteristics in JUNGLE, a German observational cohort study of Juluca as 2-drug Regimen in virologically suppressed patients, compared to the phase-3 SWORD 1 & 2 study populations**
F. Schabaz, Germany

Scientific Programme

- PE2/19 **Examining the efficacy in clinical practice of the dual antiretroviral therapy regimen of boosted protease inhibitors with maraviroc**
Abhishek Katiyar, United Kingdom
- PE2/20 **Good efficacy but side effects including hypercholesterolemia and body weight gain after switching to dolutegravir plus booster protease inhibitor regimen among treatment experienced HIV-positive patients**
Yu-Lin Lee, Taiwan, Republic of China
- PE2/21 **Rates of DTG/ABC/3TC discontinuation in a real-life setting: no surprises found in reported adverse events**
Ana Gorgulho, Portugal
- PE2/22 **Low baseline HIV viral loads with a history of PrEP use - how should these patients be managed?**
Victoria Tittle, United Kingdom
- PE2/23 **Lamivudine-based maintenance 2-drugs regimens: an algorithm for the estimation of 2-years risk of virological failure in clinical practice**
Alberto Borghetti, Italy
- PE2/24 **Adding raltegravir to a bPI failing regimen was not associated with higher virologic suppression**
Monica Maria Gomes-da-Silva, Brazil
- PE2/25 **Neuropsychiatric tolerability of bictegrovir combined with FTC/TAF in clinical practice**
Christian Hoffmann, Germany
- PE2/26 **Real-world clinical outcomes of patients switched from complex multi-tablet regimens to TAF-based single-tablet regimens plus a boosted protease inhibitor**
Charlotte-Paige Rolle, United States
- PE2/27 **Dual therapy with fixed dose combination of darunavir/ritonavir plus raltegravir in HIV-infected patients in Argentina**
Diego Martin Cecchini, Argentina
- PE2/28 **Detectability of HIV residual viremia despite therapy is highly associated with treatment with protease inhibitor**
Gilles Darcis, Belgium
- PE2/29 **Prediction of virological failure in patients with low level HIV-1 viremia using a joint latent class model**
Enrique Bernal, Spain
- PE2/30 **Comparing effectiveness and tolerability of emtricitabine/tenofovir alafenamide (F/TAF) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV-1 infected adult patients in routine clinical practice: a cross cohort analysis**
Stefan Esser, Germany
- PE2/31 **Effectiveness of Dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients**
Rakan Nasreddine, Belgium
- PE2/32 **Characterizations of weight gain following antiretroviral regimen initiation in treatment-naïve individuals living with HIV**
Ricky Hsu, United States

Scientific Programme

- PE2/33 **How to RESPOND to modern challenges for people living with HIV: a new cohort collaboration**
Bastian Neesgaard, Denmark
- PE2/34 **ART simplification: use of dual therapy for HIV in a public health reference center (CRT-DST/Aids) in São Paulo, Brazil**
Roberta Schiavon Nogueira, Brazil
- PE2/35 **Simplification to dual (2D) antiretroviral therapy (ART) with lamivudine and dolutegravir in HIV-infected patients with solid organ transplantation (SOT): a preliminary single-center experience**
Juan Ambrosioni, Spain
- PE2/36 **Comparable effectiveness of Raltegravir-based dual therapy versus other regimens in patients switched for maintenance**
Karen Martin, Germany
- PE2/37 **Comparison of a two-drug regimen (dolutegravir/rilpivirine) to standard three-drug regimens in virologically suppressed, treatment experienced individuals in the real world**
Gerald Pierone, United States
- PE2/38 **Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir in treatment-experienced patients: a multicentre cohort study**
Inés Suárez-García, Spain
- PE2/39 **High persistence of dolutegravir-containing 2-drug regimens in routine clinical care**
Sebastian Noe, Germany
- PE2/40 **Virologic, immunologic and clinical outcomes in antiretroviral treatment (ART) naïve individuals in the RESPOND cohort collaboration**
Amanda Mocroft, United Kingdom
- PE2/41 **A retrospective analysis of the EuResist data set assessing HIV dual therapy success in a real-life context**
Michael Böhm, Germany
- PE2/42 **The real-world impact of switching to tenofovir-alafenamide (TAF) on metabolic co-morbidities in PLWH aged over 60s**
Ming Jie Lee, United Kingdom
- PE2/43 **Effect of simplification to INSTI-based dual therapy on residual inflammation and viral reservoir**
Giulia Marchetti, Italy
- PE2/44 **Changes in LDL after switch from TDF to TAF in the U.S.**
Paddy Mallon, Ireland
- PE2/45 **A retrospective analysis of the EuResist data set assessing if NRTI resistance impairs INSTI based treatment with NRTI backbone**
Michael Böhm, Germany
- PE2/46 **Impact of archived M184V/I mutations on the effectiveness of switching to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide among virologically suppressed HIV-positive patients**
Chien-Ching Hung, Taiwan, Republic of China

Scientific Programme

- PE2/47 **Central nervous system (CNS) side effects and viral blips post cART switch from atazanavir boosted with ritonavir (ATZ/r) to atazanavir boosted with cobicistat (ATZ/c)**
Stephanie Tyler, United Kingdom
- PE2/48 **Quantitation of cellular HIV-1 DNA levels by droplet digital PCR in virologically-suppressed patients switching to dolutegravir plus lamivudine: a prospective study**
Francesca Lombardi, Italy
- PE2/49 **Evaluation of weight gain in incarcerated individuals living with HIV/AIDS after switching to a raltegravir-based regimen**
Melissa Badowski, United States
- PE2/50 **Determinants of viral non-suppression among people living with HIV (PLHIV) in rural setting, Neno: a retrospective cohort study**
Potiphar Damiano, Malawi
- PE2/51 **Risk of developing HIV resistance in patients with low level viraemia in a large London cohort**
Naomi Fitzgerald, United Kingdom
- PE2/52 **Virological outcomes of first line regimens in women living with HIV from Icona cohort: comparison with clinical trial data**
Cristina Mussini, Italy
- PE2/53 **Well-being in people living with HIV/AIDS (PLWHA) according to cART exposure: data from IOCONA cohort**
Antonella Cingolani, Italy
- PE2/54 **Body composition changes in HIV: do INSTI matter?**
Giovanni Guaraldi, Italy
- PE2/55 **Dolutegravir-based regimens are associated with weight gain over two years following ART-initiation in ART-naïve people living with HIV (PLWH)**
Heidi Crane, United States
- PE2/56 **Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in combination with boosted darunavir (DRV) in treatment experienced patients with HIV**
Lucas Hill, United States
- PE2/57 **Real world data of using Triumeq (dolutegravir/abacavir/lamivudine; DTG/ABC/3TC): final outcomes of the 3-year German TRIUMPH cohort show good virologic effectiveness and safety in clinical routine**
Nils Postel, Germany
- PE2/58 **The effectiveness of E/C/F/TAF in treatment-naïve (TN) or treatment-experienced (TE) adult HIV-infected patients in a real-world setting, results from southern Turkey**
Dilara Inan, Turkey
- PE2/59 **Comparison of efficacy and safety of a switch to fixed-dose combination FTC/TDF-TAF/RPV versus fixed-dose combination 3TC/ABC/DTG in HIV-1-infected, treatment experienced and virologically suppressed patients: a cohort study**
Gaetana Sterrantino, Italy
- PE2/60 **COPEDOL: a 2-year French multicentric, observational, longitudinal retro-prospective study, in pretreated HIV-1-infected patients starting dolutegravir based regimen due to treatment failure**
Roland Landman, France

Scientific Programme

- PE2/61 **Drug-drug interactions with recommended first-line antiretroviral therapy in real-world settings**
Wang-Huei Sheng, Taiwan, Republic of China
- PE2/62 **Determinants of switching to TAF-based cART or dual combinations (DC) from TDF-based regimens in a cohort of HIV-infected individuals with controlled viral load ≤ 50 copies/mL**
Alessandra Vergori, Italy
- PE2/63 **An early proactive switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) is effective in maintaining virologic control and improving quality of life (QoL) in patients with a primary HIV-1 infection (PHI). An interim analysis of a phase IV clinical trial (ESTER study)**
Marta Camici, Italy
- PE2/64 **Prevalence of neuropsychiatric conditions in patients living with HIV-1 treated with antiretroviral therapies - a perspective from US Medicaid**
Wing Chow, United States
- PE2/65 **Switch to dolutegravir dual regimens and inflammation mediated by annexin**
Claudio Ucciferri, Italy
- PE2/66 **Efficacy of dual antiretroviral therapy (ART) as intermittent short cycle regimen in virologically suppressed HIV-infected patients: an observational cohort**
Romain Palich, France
- PE2/67 **Modelling time varying viral load and CD4 cell counts response to antiretroviral therapy in a cohort of HIV naive patients**
Margarida Tavares, Portugal
- PE2/68 **Impact of switching to E/C/F/TAF on lipid profile and renal function in HIV-infected patients**
Bilgul Mete, Turkey

ePosters
09:00 - 16:00

Exhibition hall

Antiretroviral randomized clinical trials

- PE3/1 **Genital HIV-1 RNA and DNA shedding in virologically suppressed individuals switching from triple- to dual- or monotherapy: pooled results from two randomized controlled trials**
Laurent Hocqueloux, France
- PE3/2 **Comparison of the Ease of Swallowability of B/F/TAF placebo compared to DTG/ABC/3TC placebo**
John Ernest McKinnon, United States
- PE3/3 **Evaluation of total HIV-DNA changes in HIV-1 infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-One Study**
Maria Mercedes Santoro, Italy
- PE3/4 **Phase-3 trials of new antiretrovirals are not representative of the global HIV epidemic**
Toby Pepperrell, United Kingdom

Scientific Programme

- PE3/5 **Impact of susceptibility scoring on virologic response in heavily treatment-experienced participants with HIV-1 receiving a fostemsavir-based antiretroviral regimen: results through week 96 from the randomized cohort of the Phase 3 BRIGHT study**
Peter Ackerman, United States
- PE3/6 **Reversibility of dolutegravir/lamivudine/abacavir neuropsychiatric toxicity after 24 weeks of switching to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (EVG/c/FTC/TAF). The DREAM Clinical Trial**
Ignacio Pérez-Valero, Spain
- PE3/7 **A switch to dolutegravir in combination with boosted darunavir is safe and effective in suppressed patients with HIV - a predefined psychosocial subanalysis of the DUALIS study**
Christoph Spinner, Germany
- PE3/8 **Tenofovir alafenamide versus tenofovir disoproxil fumarate - is there a true difference in safety?**
Toby Pepperrell, United Kingdom
- PE3/9 **Biologic sex is not the only difference between men and women: data from the Doravirine phase 2/3 clinical trials**
Sharon Walmsley, Canada
- PE3/10 **No metabolic or renal benefits when switching to an NRTI-free dolutegravir-containing 2 drug regimen (2DR) - a subanalysis of the DUALIS study**
Christoph Boesecke, Germany
- PE3/11 **Sustained viral suppression with dolutegravir monotherapy during 9,899 patient weeks of follow-up in individuals starting combination antiretroviral therapy during primary HIV infection (EARLY SIMPLIFIED): a randomized, controlled, multi-site, non-inferiority trial**
Dominique Laurent Braun, Switzerland
- PE3/12 **Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in patients with human immunodeficiency virus (HIV)-1 infection: age, race/ethnicity, and gender subgroup analyses from the DIAMOND study**
David Anderson, United States
- PE3/13 **A systematic review and meta-analysis evaluating the risk of central nervous system adverse events in randomised controlled trials of dolutegravir**
Khadija Muniath Chowdhury, United Kingdom
- PE3/14 **Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naïve adults**
Chloe Orkin, United Kingdom
- PE3/15 **Switching from a 3-drug tenofovir alafenamide (TAF)-based regimen (TBR) to a 2-drug dolutegravir/lamivudine (2DR, DTG/3TC FDC) was not associated with a higher frequency of intermittent viremia in suppressed patients in the TANGO study**
Ruolan Wang, United States
- PE3/16 **Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): week 96 results**
Peter J Ruane, United States
- PE3/17 **Single doses of long-acting capsid inhibitor GS-6207 administered by subcutaneous injection are safe and efficacious in people living with HIV**
Eric S Daar, United States

Scientific Programme

- PE3/18 **Long-term safety and efficacy of rilpivirine plus nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 7-year roll-over study from phase 2 and 3 clinical studies**
Jean-Michel Molina, France
- PE3/20 **Prevalence of archived HIV-1 DNA resistance-associated mutations (RAMs) and their lack of effect on virologic outcome at week 96 in antiretroviral treatment (ART)-experienced, virologically suppressed patients receiving the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in the EMERALD phase III trial**
Erkki Lathouwers, Belgium
- PE3/21 **Islatravir efficacy and safety for selected demographic and baseline subgroups from a Phase 2 trial in treatment naïve adults with HIV-1 infection**
Jean-Michel Molina, France

ePosters
09:00 - 16:00

Exhibition hall

Pharmacology, pharmacogenomics and drug interactions

- PE27/1 **Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz based antiretroviral therapy in Zambia: an open label non-randomized interventional trial**
Mike Chaponda, Zambia
- PE27/2 **Ritonavir-boosted darunavir plus two nucleoside reverse transcriptase inhibitors versus other regimens for initial antiretroviral therapy for people with HIV infection: a systematic review**
Tatevik Balayan, Armenia
- PE27/3 **Towards individualization of antiretroviral therapy - more cost-effective than dose intensification in patients**
Bhavik Dalal, India
- PE27/4 **The valproic acid - dolutegravir drug-drug interaction is based on displacement of protein binding and unlikely to be clinically relevant**
Henriette Prins, Netherlands
- PE27/5 **BESIDE - clinical relevance and implications for management of antiretroviral therapy due to recreational drug use in PLWH in Germany**
Karen Martin, Germany
- PE27/6 **Drug-drug interactions between antiretrovirals and carbamazepine or oxcarbazepine: a real-life investigation**
Cristina Gervasoni, Italy
- PE27/7 **Drug-drug interactions between dolutegravir (DTG) and immunosuppressant drugs (IS) in HIV-infected patients with solid organ transplantation (SOT): a single-arm clinical trial (DTGSOT)**
Christian Manzardo, Spain
- PE27/8 **Abacavir hypersensitivity reaction (HSR), associated to baseline false negative HLAB5701 screening, in antiretroviral treatment naïve HIV-1 patient**
Salvatore Martini, Italy

Scientific Programme

- PE27/9 **Central nervous system penetration of antiretroviral drugs in HIV-positive patients with neurocognitive impairment, assessed from paired plasma-CSF concentrations**
Perrine Courlet, Switzerland

ePosters

09:00 - 16:00

Exhibition hall

Co-morbidities, ageing

- PE9/1 **Detectable subclinical myocardial abnormalities in people living with HIV: insights from cardiac magnetic resonance imaging (MRI)**
Gavin Paul Raphael Manmathan, United Kingdom
- PE9/2 **Hypertension and ECG alterations in HIV positive patients in DREAM centres in Mozambique**
Isotta Triulzi, Italy
- PE9/3 **Cardiovascular events are declining in men with HIV aged 50 years or older in Austria**
Maria Kitchen, Austria
- PE9/4 **Prevalence of HIV-associated neurocognitive disorder (HAND) in Turkey and assessment of Addenbrooke's Cognitive Examination Revised (ACE-R) test as a screening tool**
Volkan Korten, Turkey
- PE9/5 **Pilot study assessing the Rotterdam Healthy Aging Score in a cohort of HIV-positive adults**
Sharon Walmsley, Canada
- PE9/6 **Obesity and HIV - the overlapping epidemics**
Justyna Kowalska, Poland
- PE9/7 **Exhaled nitric oxide levels are higher in people living with HIV compared to uninfected controls suggesting increased eosinophilic pulmonary inflammation**
Rebekka Faber Thudium, Denmark
- PE9/8 **Comparison of changes in bone microarchitecture with abacavir-lamivudine versus tenofovir disoproxil fumarate-emtricitabine in adults living with HIV**
Roger Bedimo, United States
- PE9/9 **Limitations of FRAX equation for predicting low bone mineral density or bone loss progression among people living with HIV: the role of secondary causes of osteoporosis**
Pilar Vizcarra, Spain
- PE9/10 **Elevated body mass index during pregnancy and gestational weight gain in HIV-infected women in Cape Town, South Africa: association with adverse birth outcomes**
Hlengi Madlala, South Africa
- PE9/11 **Facilitating primary care non-antiretroviral drug prescribing in people living with HIV: the Think ARV project**
Jaime Vera, United Kingdom
- PE9/12 **Characterization of moderate and severe anemia by peripheral blood smear in HIV infected patients in the Kilombero and Ulanga antiretroviral cohort**
Vanesa Anton-Vazquez, United Kingdom
- PE9/13 **HIV infection and smoking: PET imaging reveals early pulmonary perfusion abnormalities**
Puja Kohli, United States

Scientific Programme

- PE9/14 **Bariatric surgery in HIV obese patients: first results of the French ObéVIH ongoing study**
Valérie Pourcher, France
- PE9/16 **Plasma cotinine cut-off for distinguishing smokers from non-smokers among people living with HIV (PLWH)**
Omid Reza Hosseini, Denmark
- PE9/17 **An analysis of HIV and co-morbidity profiles for adults accessing health care in Khayelitsha, South Africa**
Richard Osei-Yeboah, South Africa
- PE9/18 **Femoral arteries better indicator than carotid arteries of cardiovascular risk in HIV/AIDS patients**
Gordana Dragovic Lukic, Serbia
- PE9/19 **Cardiovascular risk assessment in PLWH over 50: agreement between cardiovascular risk predictors and Coronary Artery Calcium CT Scoring (CACS)**
Branca Pereira, United Kingdom
- PE9/20 **Safety and tolerance of denosumab in HIV patients**
Sara Vela, Spain
- PE9/21 **Lower incidence of liver steatosis in patients treated with lamivudine plus dolutegravir dual therapy**
Davide Moschese, Italy
- PE9/22 **Correlations between computerised and standard cognitive testing in persons with HIV and controls**
Davide De Francesco, United Kingdom
- PE9/23 **Whole body MRI detects high prevalence of incidental findings in older HIV-1-infected patients participating in a randomised, controlled trial of maraviroc and/or metformin for non-alcoholic fatty liver disease**
Sarah Pett, United Kingdom
- PE9/24 **An analysis of potential drug-drug interactions in an aging HIV cohort**
Pádraig Gardiner, Ireland
- PE9/25 **A standardized comparison of cardiovascular risk factor prevalence between people living with HIV and general population in Spain**
Vicente Estrada, Spain
- PE9/26 **Subclinical atherosclerosis burden by ultrasound in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors**
Vicente Estrada, Spain
- PE9/27 **Subcutaneous adipose tissue modifications induced by a switch to dual raltegravir-maraviroc therapy in controlled HIV-infected patients: a sub-study of the ANRS-ROCNAL157 clinical trial**
Jacqueline Capeau, France
- PE9/28 **Results of 10 year experience of a specialist clinic for people living with HIV over 50 at Chelsea and Westminster Hospital**
Branca Pereira, United Kingdom
- PE9/29 **Discordance in diagnosis of osteoporosis in HIV-infected patients: prevalence, characteristics, and impact on FRAX equation**
Pilar Vizcarra, Spain

Scientific Programme

- PE9/30 **CD4/CD8 ratio is a better indicator of acute phase inflammation than absolute CD4 count during virally-suppressed HIV infection**
Rodney Rousseau, Canada
- PE9/31 **Immune activation and chronic inflammation: is there an additional effect of HIV in a geriatric population?**
Clotilde Allavena, France
- PE9/32 **Trends in cardiovascular risk factors and estimated 10-year cardiovascular risk score in a spanish cohort of PLWH: 2010-2018**
Francisco Fanjul, Spain
- PE9/33 **Prevalence of depression and associated psychosocial factors among HIV positive patients attending ART clinic at Gulu Regional Referral Hospital**
Ronald Kiyemba, Uganda
- PE9/34 **Potentially inappropriate medications in older adults with HIV in the region of Madrid, Spain**
Beatriz López-Centeno, Spain
- PE9/35 **Impact of the reproductive/hormonal status on weight, fat and insulin resistance in HIV-infected women switching from a PI regimen to dual raltegravir-etravirine therapy: results from the ANRS163-ETRAL trial at 48 and 96 weeks**
Jacqueline Capeau, France
- PE9/37 **Age- and sex-related differences in concomitant diseases and use of co-medication in patients with treated HIV-infection in Germany**
Karen Martin, Germany
- PE9/38 **Kidney transplantation in HIV-positive patients in Israel including the first case of HIV-positive living donor to HIV-positive recipient with a 7-year follow-up**
Eugene Katchman, Israel
- PE9/39 **Vitamin D deficiency and frailty phenotype in HIV-infected men**
Fiona Bhondoeckhan, United States
- PE9/40 **The UCSD performance-based skills assessment is associated to cognitive performance in HIV positive population with very good immunological condition**
Valentina Delle Donne, Italy
- PE9/41 **Alcohol, smoking and the association with HIV virological non-suppression among people living with HIV on ART**
Timothy Peter Wynne Jones, United Kingdom
- PE9/42 **Decreasing incidence of diabetes mellitus in HIV-positive Taiwanese patients on combination antiretroviral therapy from 2004 to 2011**
Pei-Ying Wu, Taiwan, Republic of China
- PE9/43 **Incidental findings in PLWH over 50 undergoing coronary artery calcium scoring (CACS) for cardiovascular risk assessment**
Maria Mazzitelli, United Kingdom
- PE9/44 **Aging biomarkers, inflammatory cytokines and development of cardiovascular ischemic events or diabetes in HIV-infected persons**
Jose I Bernardino, Spain
- PE9/45 **Falls but not frailty are common in people living with HIV using an mHealth platform: issues of ageing within the EmERGE cohort**
Tom Levett, United Kingdom

Scientific Programme

- PE9/46 **A standardized comparison of cardiovascular risk factor treatment in people living with HIV and general population**
Vicente Estrada, Spain
- PE9/48 **Perceptions of ageing and desire for ageing information amongst users of the EmERGE mHealth platform**
Tom Levett, United Kingdom
- PE9/49 **Switching to bicitgravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older: week 48 results from a phase 3b, open-label trial**
Franco Maggiolo, Italy
- PE9/50 **Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older**
Hans-Jürgen Stellbrink, Germany
- PE9/51 **HIV testing in patients diagnosed with community acquired pneumonia or primary lung cancer from 2014 to 2018 in a tertiary reference hospital in Northern Spain**
Teresa Rubio Obanos, Spain
- PE9/52 **Menopause in aging women living with HIV: changes in bone mineral density and trabecular bone score**
Giovanni Guaraldi, Italy
- PE9/53 **Higher anti-CMV IgG concentrations are not associated with longitudinal brain injury in virally suppressed people with HIV**
Jonathan Underwood, United Kingdom
- PE9/55 **Higher Prevalence of CKD in HIV+ individuals compared to the general population**
Stefan Esser, Germany
- PE9/56 **Effect of CMV viraemia on endothelial dysfunction over 42 weeks in Malawian adults initiating ART with advanced immune suppression**
Christine Kelly, Ireland
- PE9/57 **High prevalence of neurocognitive impairment in adults with perinatally acquired HIV infection**
Irene Portilla-Tamarit, Spain
- PE9/58 **Modeling 2018 AHA cholesterol guidelines in HIV**
Giacomo Ciusa, Italy
- PE9/59 **A multi-disciplinary Neuro-HIV Platform in managing patients with neurocognitive impairment**
Phanie Bidlingmeyer, Switzerland
- PE9/60 **Archi-Prevalent project. A national register of color-Doppler ultrasonography of the epi-aortic vessels in patients living with HIV**
Salvatore Martini, Italy
- PE9/61 **Preliminary results of a diagnostic-therapeutic work-up to early detect cardiovascular disease in HIV positive patients**
Giovanni Millotti, Italy
- PE9/62 **Bone mineral density changes in young African women on tenofovir disoproxil fumarate antiretroviral therapy and non-hormonal contraception**
Flavia Kiweewa Matovu, Uganda

Scientific Programme

- PE9/63 **Examination of HIV-infected patients regarding weight gain while using integrase inhibitors in Japan**
Ryoko Sekiya, Japan
- PE9/65 **Predictors of sarcopenia and its impact on components of the frailty phenotype in an Asian population living with HIV**
Grace Lui, Hong Kong
- PE9/66 **Failure to restore CD4 cell count with combination antiretroviral therapy is associated with increased systemic inflammation**
Rodney Rousseau, Canada
- PE9/67 **High prevalence of left ventricular systolic dysfunction assessed by speckle tracking in asymptomatic HIV patients**
Dimitris Basoulis, Greece
- PE9/68 **Polypharmacy and drug-drug interactions - prevalence in a Portuguese HIV Metabolic Clinic**
Joana Fragoso, Portugal
- PE9/69 **Bone density alterations in the HIV-infected patient - epidemiologic characterization of a Portuguese cohort**
Diogo Guerra, Portugal
- PE9/70 **Cigarette smoking disproportionately impairs nitric oxide signaling in pulmonary artery endothelial cells in HIV: role of viral and host factors**
Saurabh Aggarwal, United States
- PE9/71 **Frailty phenotype in older virologically suppressed PLWHIV is strongly correlated with specific comorbidities and tobacco use**
Christina Katerina Psomas, France
- PE9/72 **HIV-FUNCFRAIL study: differences between women and men aging with HIV**
Fátima Brañas, Spain
- PE9/73 **Prevalence, risk factors and outcomes of cardiovascular, metabolic and chronic kidney diseases in HIV-infected vs. uninfected adults in sub-Saharan Africa: a systematic review and meta-analysis**
Ajibola Awotiwon, South Africa
- PE9/74 **People living with HIV are more likely to be screened for cardiovascular disease risk factors than other members of the general population in Botswana - a community based study**
Onkabetse Julia Molefe-Baikai, Botswana
- PE9/75 **APOL1 high risk genotype has an adverse impact on kidney function in African HIV-infected patients with high viral load**
Nongodo Firmin Kabore, France
- PE9/76 **Comparison of 2 frailty scores in PLWHIV aged 50 and over: SOF index and FRIED phenotype**
Christina Katerina Psomas, France
- PE9/77 **Annexin V, Annexin A1 and cardiovascular risk in HIVpopulation**
Claudio Ucciferri, Italy
- PE9/78 **Could we consider the intima-media thickness (c-IMT) > 1mm as a risk factor for cardiovascular diseases in HIV+ subjects chronically treated with antiretrovirals?**
Alessio Pampaloni, Italy

Scientific Programme

- PE9/79 **Immune reconstitution inflammatory syndrome (IRIS) in HIV-infected hospitalized patients with advanced disease**
Alberto Díaz-de Santiago, Spain
- PE9/80 **Low Body Mass Index (BMI) in ART naïve HIV-positive subjects and risk of virological failure and drug discontinuation: data from the ICONA Foundation Cohort**
Roberto Rossotti, Italy
- PE9/81 **Sistatin C, KIM1 and NGAL as biological markers for detecting early kidney injury in HIV positive patients**
Aslıhan Ulu, Turkey
- PE9/82 **Long-term AIDS survivors: comorbidities and polypharmacy a new challenge**
María José Galindo Puerto, Spain
- PE9/83 **Risk Factors associated to immune reconstitution inflammatory syndrome (IRIS) in HIV-infected hospitalized patients with advanced disease**
Alberto Díaz-de Santiago, Spain
- PE9/84 **Sleep disorders and depression through efavirenz to dolutegravir transition in Brazil: what really changed after all**
Melissa Medeiros, Brazil
- PE9/85 **Patterns of inflammation and comorbidity in Human Immunodeficiency Virus (HIV) infection: a clustering analysis from the CARDAMONE study**
Sonia Zebachi, France
- PE9/86 **Cognitive impairment in patients with HIV in a Mexican hospital**
Lucia Carrazco Ibarra, Mexico
- PE9/87 **Clinical management of ageing people living with HIV in Europe: The view of the care providers**
Marta Boffito, United Kingdom
- PE9/88 **Real-world characterization of the Portuguese population living with HIV who initiated Raltegravir based-regimen in the last three years - REALITY Study**
Joana Almeida, Portugal
- PE9/89 **Long-term lipid-lowering-therapy in HIV is clinically effective**
Henning Drechsler, United States

ePosters
09:00 - 16:00

Exhibition hall

HIV-associated and non HIV-associated tumours

- PE14/1 **Prevalence of anal dysplasia among persons living with human immunodeficiency virus (HIV)**
Adelaine Lopez, Philippines
- PE14/2 **HIV infection is associated with reduced survival among hepatocellular carcinoma cases from an urban referral hospital: Kampala, Uganda**
Sara Nsibirwa, Uganda

Scientific Programme

- PE14/3 **High prevalence of anal and cervical dysplasia in a cohort of HIV-infected women, but low prevalence of concomitant lesions**
Ana Gomez, Ecuador
- PE14/4 **Malignant and benign skin lesions in HIV-1 infected people**
Alessandra Latini, Italy
- PE14/5 **Results of HPV-testing for anal screening in HIV-infected women**
Anna Popova, Russian Federation
- PE14/6 **COHORT SDT (Granada): decrease of the incidence of HSIL+ in the anal mucosa of HIV+ patients MSM after the performance of a screening, diagnostic and therapeutic program (2010-2018)**
Carmen Hidalgo-Tenorio, Spain
- PE14/7 **Prospective longitudinal study on immunogenicity and safety of vaccination against human papillomavirus (HPV) with the 9valent vaccine in HIV-positive women, the Papillon study: preliminary results on tolerance and safety**
Déborah Konopnicki, Belgium
- PE14/8 **Cancer trends and outcomes in a cohort of people living with HIV**
Andrea De Vito, Italy
- PE14/9 **Rate of HCC occurrence and associated risk factors in a multicentric cohort of HIV/HCV co-infected patients treated with DAAs**
Alice Toschi, Italy

ePosters
09:00 - 16:00

Exhibition hall

Other coinfections/Sexually transmitted infections

- PE24/2 **High rates of ocular and neurosyphilis in a large German, city-based university hospital: lessons learned on ocular syphilis**
Laura Franziska Wagner, Germany
- PE24/3 **Decreasing rate of HIV and HBV co-infection in nationwide Korean HIV/AIDS cohort and its meaning**
Yoonjung Kim, Korea, Republic of
- PE24/5 **Prevalence of syphilitic hepatitis among HIV-infected patients in Istanbul, Turkey, a region with increasing incidence of syphilis and HIV infection**
Ozlem Altuntas Aydin, Turkey
- PE24/6 **Seroconversion rate after yellow fever vaccine in HIV- positive patients**
Charlotte Martin, Belgium
- PE24/7 **Low seroprevalence of syphilis infection among key populations in Togo in 2017: a national cross-sectional survey**
Fifonsi Gbeasor, Togo
- PE24/8 **Socio demographics, sexual behavior and clinical manifestations of HIV+ and HIV- patients diagnosed with syphilis, Brussels 2017-2019**
Agnès Libois, Belgium

Scientific Programme

- PE24/9 **Risk factors and prevalence of syphilis, gonorrhea and chlamydia infections in the Swiss HIV cohort study**
Catrina Mugglin, Switzerland
- PE24/10 **Predictors of serofast state after treatment for syphilis in HIV-infected patients**
Gregor Paul, Germany
- PE24/11 **A proactive approach to assess rising STIs among different at-risk groups of MSM in the early era of PrEP: a real-world clinical care setting**
Christina Katerina Psomas, France
- PE24/12 **Profiles of multidrug resistant gonorrhea in HIV-infected patients attending an urban hospital in Uganda**
Christine Katusiime, Uganda
- PE24/13 **Sexually transmitted diseases clinic in a Portuguese Infectious Diseases unit**
Joana Fragoso, Portugal
- PE24/14 **Quantification of DNA human papillomavirus 16 and 18 in anal cells improves the prediction of high grade anal intraepithelial neoplasia in HIV patients**
Marcos Díez, Spain
- PE24/15 **Primary prophylaxis against *Pneumocystis jirovecii* Pneumonia may be effective in preventing severe bacterial pneumonia in HIV-positive patients: findings from a large Italian center**
Alex Dusina, Italy
- PE24/16 **HHV-8 salivary shedding in individuals with different HIV status and sexual behaviour**
Elvira Domonova, Russian Federation
- PE24/17 **Insights into syphilis reinfection in HIV patients: predictors and role of serofast condition**
Chiara Picarelli, Italy
- PE24/18 **Infective endocarditis, a current health problem in Romanian injecting drug users**
Irina Cristiana Ianache, Romania
- PE24/19 **Preventable risk factors and predictors of hepatic and non-hepatic co-morbidities among PLHIV**
Oluwakemi Odukoya, Nigeria
- PE24/20 **Incidence of asymptomatic HAV infection among MSM living with HIV in South-Western Poland**
Aleksandra Szymczak, Poland
- PE24/21 **Behavioural patterns to identify key populations for syphilis prevention**
Sara Andresen, Switzerland
- PE24/22 **Evaluation of a systematic sexually transmitted infections screening pilot programme in HIV-positive men who have sex with men (MSM)**
Paula Prieto, Spain
- PE24/23 **Chemsex in Barcelona: a descriptive approach about men who have sex with men (MSM) who use recreational drugs in a sexual context**
Lorena De la Mora, Spain
- PE24/24 **Analysis of serum metabolite changes in early syphilis patients with or without serologic response after treatment**
Chia-Jui Yang, Taiwan, Republic of China

Scientific Programme

- PE24/25 **Stable transmission of amoebiasis among newly diagnosed HIV-positive patients in Taiwan, 2009-2018**
Sung-Hsi Huang, Taiwan, Republic of China
- PE24/26 **Mycoplasma genitalium resistance against macrolide antibiotics in the Berlin MSM cohort tested with the Allplex MG & AziR Assay (SeeGene)**
Martin Obermeier, Germany
- PE24/27 **Predictors of ureaplasma urealyticum urinary colonization in HIV+ pregnant women: a pilot study**
Iacopo Franconi, Italy
- PE24/28 **No indication of decreased syphilis susceptibility with repeated syphilis episodes in HIV-infected men who have sex with men: a multicentre prospective cohort study on risk factors and the potential role of syphilis immunity**
Jan Roth, Switzerland
- PE24/29 **The prevalence of high-risk anal HPV in HIV-positive MSM in Lebanon**
Nesrine Rizk, Lebanon

ePosters
09:00 - 16:00

Exhibition hall

Toxicities

- PE32/1 **Sleep and functional characteristics of Central London Outpatient HIV Cohort**
Ana Milinkovic, United Kingdom
- PE32/2 **Osteopenia and osteoporosis in young HIV-infected patients less than age of 40 years: incidence and risk factors**
Shu-Ying Chang, Taiwan, Republic of China
- PE32/3 **Predictors of weight gain in patients treated with dolutegravir**
Lucia Taramasso, Italy
- PE32/4 **Effects of lamivudine plus dolutegravir 2-drug-regimen on bone mineral density in a multicenter Italian cohort**
Arturo Ciccullo, Italy
- PE32/5 **Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) lowers alanine transaminase (ALT) and aspartate transaminase (AST) in patients with HIV infection with or without viral hepatitis co-infection**
Nicola Squillace, Italy
- PE32/6 **Weight gain in people living with HIV switched to dual therapy with dolutegravir plus rilpivirine: changes in body fat mass**
Pilar Vizcarra, Spain
- PE32/7 **Does switching to tenofovir alafenamide fumarate impair recovery of renal function in individuals newly diagnosed with tenofovir disoproxil fumarate induced renal tubular toxicity?**
John Booth, United Kingdom
- PE32/8 **Weight gain among HIV-positive persons treated with dolutegravir or elvitegravir**
Leïla Belkhir, Belgium

Scientific Programme

- PE32/9 **NRTI backbone modification impact on weight, lipids and cardiovascular risk**
Ana Milinkovic, United Kingdom
- PE32/10 **Comparative neuropsychiatric toxicity profile of dolutegravir (DTG) versus efavirenz (EFV) versus other antiretroviral third drugs used either in first-line or switch antiretroviral therapies (ART): data from Icona Foundation Study Cohort**
Annalisa Mondì, Italy
- PE32/11 **SWORD 1&2: maintenance or improvement in renal function in PLWH through 148 weeks after switch to the dolutegravir + rilpivirine 2-drug regimen**
Josep M Llibre, Spain
- PE32/12 **Neurotoxicity related to efavirenz does not predict neurotoxicity related to dolutegravir**
Sara de la Fuente, Spain
- PE32/13 **Human embryonic stem cells exposed to dolutegravir show decreased cellular proliferation, reduced pluripotency, and increased mitochondrial toxicity, in a dose-dependent manner: preliminary data**
Marie-Soleil R. Smith, Canada
- PE32/14 **Dolutegravir but not raltegravir reduces cell proliferation and increases mitochondrial toxicities in cultured fibroblasts; effects that are not mitigated by telomerase reverse transcriptase**
Helene Cote, Canada

ePosters
09:00 - 16:00

Exhibition hall

Tuberculosis and opportunistic infections

- PE35/1 **Nontuberculous mycobacteria infections in Russian HIV patients: clinical features and outcomes**
Mikhail Savchenko, Russian Federation
- PE35/2 **Human immunodeficiency virus and the outcome of treatment for pulmonary tuberculosis: a retrospective study in Tehran, Iran**
Mohammad Bagheri, Iran, Islamic Republic of
- PE35/3 **Rifampicin pharmacokinetics and pharmacogenetics in Ugandan patients with multi-drug resistant tuberculosis**
Jackson K. Mukonzo, Uganda
- PE35/4 **Mycobacteria-induced immune responses by mucosal-associated invariant T (MAIT) cells are impaired in patients with tuberculosis (TB) and HIV-associated TB**
Muki Shey, South Africa
- PE35/5 **Acute onset of cerebral toxoplasmosis in patients with HIV infection**
Tatiana Ermak, Russian Federation
- PE35/6 **Association between immunological status and TB disease development in HIV-infected individuals with LTBI**
Ngai Sze Wong, Hong Kong
- PE35/7 **Amoeba- a swiss army knife for diagnosis and mechanistic understanding of Legionella infection**
Breanne M Head, Canada

Scientific Programme

- PE35/8 **Causes and outcomes of hospitalizations among HIV positive persons in Georgia's referral institution, 2012-2017**
Nino Rukhadze, Georgia
- PE35/9 **Population pharmacokinetic analysis of dolutegravir in HIV/TB co-infected people with and without rifampicin**
Rajendra Singh, United States
- PE35/10 **Lung function and health-related quality of life among patients following pulmonary tuberculosis treatment in urban Uganda: a cross-sectional study**
Josephine Zawedde, Uganda
- PE35/11 **Clinical and laboratory characterization of progressive multifocal leukoencephalopathy in HIV-infected patients in the intensive care unit**
Anastasia Pokrovskaya, Russian Federation
- PE35/13 **Cryptococcal and tuberculosis coinfection: case series identified through the implementation of an advanced HIV disease package of care linked to a TB active case finding strategy in rural Mozambique**
Alejandro Blanco-Arévalo, Spain
- PE35/14 **Trends in latent tuberculosis screening in a cohort of HIV-infected patients from a low tuberculosis incidence country**
Pedro Palma, Portugal
- PE35/15 **Drug-induced hepatic injury developed in tuberculosis / HIV co-infection treatment**
Sarah Silva, Brazil

ePosters
09:00 - 16:00

Exhibition hall

NASH

- PE22/1 **Assessment of non alcoholic fatty liver disease in a cohort of HIV mono-infected patients**
Paola Columpsi, United Kingdom
- PE22/2 **Non-alcoholic fatty liver disease (NAFLD) and related metabolic disorders among HIV-infected patients in the country of Georgia**
Lali Sharvadze, Georgia
- PE22/3 **Non-alcoholic fatty liver disease is a significant predictor of cardiovascular risk in HIV-infected patients**
Adriana Cervo, Italy
- PE22/4 **Non alcoholic fatty liver disease diagnosed by non-invasive markers in HIV-infected patients**
Carmen Busca, Spain
- PE22/5 **Global prevalence of liver impairment in HIV population in direct antiviral agents (DAA) era: the role of fatty liver disease**
Matilde Sánchez-Conde, Spain

Scientific Programme

ePosters
09:00 - 16:00

Exhibition hall

Viral hepatitis

- PE37/1 **Acute hepatitis C infection in HIV-infected patients who achieved viral suppression: incidence and risk factors**
Hsin-Yen Ku, Taiwan, Republic of China
- PE37/2 **HBV infections among HIV infected HAART receiving mothers and their exposed infants in a tertiary hospital in Kenya**
James Kangethe, Kenya
- PE37/3 **Direct-acting antivirals (DAAs) improve liver stiffness measurements but do not improve the Veterans Aging Cohort Study (VACS) Index in HIV /HCV co-infected Egyptian patients: is improved discrimination needed?**
Ahmed Cordie, Egypt
- PE37/4 **HCV/HIV coinfection in the DAA era: which patients have not been treated for HCV?**
Fabian Dario Rodriguez-Monaco, Germany
- PE37/5 **Hepatitis E seroprevalence in HIV-positive patients**
Mustafa Altindis, Turkey
- PE37/6 **Success of unrestricted DAA therapy is limited by HCV reinfections and loss to follow-up in HIV-positive patients**
David Chromy, Austria
- PE37/7 **Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and Hepatitis B Virus (HBV) coinfection**
Yu-Shan Huang, Taiwan, Republic of China
- PE37/8 **Effectiveness of hepatitis a vaccination among people living with HIV in Taiwan: is one dose enough?**
Chia-Jui Yang, Taiwan, Republic of China
- PE37/9 **HIV patients remain at high risk for advanced liver fibrosis after curing HCV infection**
Natalia Bolokadze, Georgia
- PE37/10 **HIV/HCV coinfection in Spain: trouble will soon be over**
Juan Berenguer, Spain
- PE37/11 **Care cascade of incident HCV infection among HIV-positive patients in Taiwan**
Miao-Hui Huang, Taiwan, Republic of China
- PE37/12 **Current characteristics of HIV/HBV coinfecting patients in a single HIV reference centre of Madrid**
Luz Martín-Carbonero, Spain
- PE37/13 **High HCV reinfection rate in MSM living with HIV in Barcelona: the need to focus on high risk population to achieve HCV elimination**
Maria Martínez-Rebollar, Spain
- PE37/14 **Liver disease in HIV-infected subjects in the post-HCV DAA treatment era**
Carmen Busca, Spain
- PE37/15 **Seroprevalence of hepatitis E in a Portuguese cohort of human immunodeficiency virus infected patients**
André Silva-Pinto, Portugal

Scientific Programme

- PE37/16 **Loss of seroprotection against hepatitis B virus (HBV) was associated with lower CD4 counts among HIV-positive patients who were born in the era of nationwide neonatal HBV vaccination**
Yi-Chia Huang, Taiwan, Republic of China
- PE37/17 **Improvement of immunity and hepatic fibrosis after HCV treatment with DAA in people living with HIV and HCV**
Montserrat Laguno, Spain
- PE37/18 **DAA treating Hepatitis C in HIV/HCV coinfectd patients in two prisons of Rome: results and problems**
Sara Lardo, Italy
- PE37/19 **Progress towards eliminating mother-to-child transmission of HIV in the Macha area in Zambia from 2010-2018**
Mutinta Hamahuwa, Zambia
- PE37/20 **Evaluation of the hepatitis C care cascade in the country of Georgia: monitoring 4 years of progress towards elimination**
Tengiz Tsertsvadze, Georgia
- PE37/21 **Epidemiology of HIV, HBV and HCV co-infection in Israel**
Karen Olshtain-Pops, Israel
- PE37/22 **Hepatitis C treatment outcomes of HIV infected people who inject drugs in a real-world cohort**
Dimitris Basoulis, Greece
- PE37/23 **Treatment of acute HCV infection with direct acting antivirals (DAA) in HIV patients**
Cristina Gómez-Ayerbe, Spain
- PE37/24 **Hepatic fibrosis progression among HIV patients in Israel**
Karen Olshtain-Pops, Israel
- PE37/25 **Acute hepatitis B in persons living with HIV in a low hepatitis B prevalence area during the last two decades**
Luz Martín-Carbonero, Spain
- PE37/26 **Virological response to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients with lamivudine-resistant hepatitis B virus coinfection**
Yu-Shan Huang, Taiwan, Republic of China
- PE37/27 **Impact of direct-acting antiviral (DAA) agents on T cell counts and liver stiffness in HIV/HCV-coinfectd patients: a multicenter prospective observational cohort study**
David Dalmau, Spain
- PE37/28 **Trends of HCV infection among HCV-seronegative, HIV-positive patients in Taiwan between 2011-2018**
Li-Hsin Su, Taiwan, Republic of China
- PE37/29 **The micro-elimination approach to eliminating Hepatitis C: a Fast Track City project**
Franco Maggiolo, Italy
- PE37/30 **Road to HCV elimination in HV/HCV coinfectd patients by screening and universal access to DAA: baseline data from the first screening of NoCo (No-Coinfection) study**
Antonella d'Arminio Monforte, Italy

Scientific Programme

- PE37/31 **HCV cascade of care for HIV/HCV coinfecting individuals in Greece and HCV treatment considerations in clinical practice**
Mina Psichogiou, Greece
- PE37/32 **Hepatitis B core-related antigen and anti-hepatitis B core antibody are not associated with liver fibrosis evolution in HIV-HBV co-infected patients during treatment with tenofovir**
Romuald Cruchet, France
- PE37/33 **Antiretroviral therapy: a possible role in lipid changes after HCV eradication by DAAs**
Alessandra Vergori, Italy
- PE37/34 **Treatment of cirrhotic monoinfected and HCV/HIV coinfecting patients with direct acting antivirals (DAAs)**
Fábio Videira Santos, Portugal
- PE37/35 **Predictors of vaccine efficacy after hepatitis B vaccination in people with HIV infection**
Gerardo Ibarra, Germany
- PE37/36 **Long term response to mandatory anti-HBV vaccination: risks for disease acquisition and opportunities for re-vaccination within the ICONA cohort**
Roberto Rossotti, Italy
- PE37/37 **The assessment of HBsAg serum concentration during chronic hepatitis B phases' identification among HIV/HBV coinfecting patients before antiviral therapy prescription**
Tetiana Melnyk, Ukraine
- PE37/38 **Predictors of liver fibrosis improvement after HCV eradication in HIV+ patients: data from an Italian cohort**
Alessandra Vergori, Italy
- PE37/39 **Long-term follow-up of people who use drugs (PWUD) following HCV infection therapy: drug use patterns among HIV co-infected versus mono-infected patients**
Astou Thiam, Canada
- PE37/40 **Treatment outcome of HCV single vs multi tablet regimen in mono and HIV co-infected people who use drugs (PWUD): a long-term follow-up analysis**
Astou Thiam, Canada

ePosters
09:00 - 16:00

Exhibition hall

Gender issues

- PE10/1 **Patient, clinical and virus genetic characteristics of migrants from Eastern, Central and Western Africa enrolled in the SHCS**
Nadine Bachmann, Switzerland
- PE10/2 **Menopause impacts drug use and mental health in women with HIV in Switzerland**
Anna Hachfeld, Switzerland
- PE10/3 **Gender-specific analysis of a German cohort of HIV-infected patients on Raltegravir-based therapy shows distinctive baseline co-morbidity profiles of women versus men but no impact on treatment outcomes**
Karen Martin, Germany

Scientific Programme

- PE10/4 **Menopausal symptoms, sleep disorders and anxiety/depression among premenopausal and postmenopausal HIV-infected women: a multicenter cohort study in Spain**
Ines Suarez, Spain
- PE10/5 **An evaluation of the care given to older women attending an HIV clinic in London**
Claire Williams, United Kingdom
- PE10/6 **Anti-Mullerian hormone a plausible indicator of cardiometabolic risk in HIV-infected women**
Umbelina Caixas, Portugal
- PE10/7 **Differences in sexual health among HIV infected and uninfected women of child-bearing age**
Raffaella Marocco, Italy

ePosters
09:00 - 16:00

Exhibition hall

Mother-to-child transmission

- PE21/1 **HIV infection in pregnant women and children in Switzerland: how effective are measures for preventing mother-to-child transmission?**
Martin Gebhardt, Switzerland
- PE21/2 **No evidence for induced glucuronidation of dolutegravir in HIV-infected pregnant women**
Vera Bukkems, Netherlands
- PE21/3 **Comparative analysis of clinic and laboratory parameters and frequency of mother-to-child transmission of HIV among HIV-positive pregnant women with marked immunodeficiency and normal immunological status**
Olga Mozaleva, Russian Federation
- PE21/4 **Analysis of perinatal HIV transmission cases in St. Petersburg**
Anna Samarina, Russian Federation
- PE21/5 **Geopolitical assessment and relevance for acceptance of vaginal delivery in good controlled HIV-infected pregnant women in Japan**
Kimikazu Hayashi, Japan
- PE21/6 **Pregnancy outcomes in HIV-positive women: a retrospective national cohort study from the "Grigorios AIDS Clinic" in Cyprus**
Georgios Siakallis, Cyprus
- PE21/7 **New-born infants from HIV positive women: five years experience of Infectious Diseases Hospital Iasi**
Alexandra Largu, Romania
- PE21/8 **Risk factors for peripartum virological failure in South African pregnant women on anti-retroviral therapy: East London Prospective Cohort Study**
Oladele Vincent Adeniyi, South Africa

ePosters
09:00 - 16:00

Exhibition hall

Paediatric, adolescent

Scientific Programme

- PE25/1 **Effect of cluster of differentiation (CD4) on viral respiratory infection in children, between 0-5 years of age. A study conducted in Kwazulu-Natal, South Africa**
Temitayo Famoroti, South Africa
- PE25/2 **Adolescent HIV and asymptomatic malaria parasitemia (AMP) co-infection**
David Segun Adeniyi, Nigeria
- PE25/3 **Clinical features of viral diarrhea in the children of HIV**
Marufjon Salokhiddinov, Uzbekistan
- PE25/4 **High rate of rubella seronegativity in perinatally-infected HIV women of childbearing age: a case-control study**
Nicolas Dauby, Belgium
- PE25/5 **Health outcomes in adolescents and young adults living with HIV before and after transition to adult care in Barcelona**
Josep Ferrer Arbaizar, Spain
- PE25/6 **Correction of lipid abnormality by integrase inhibitor among children taking ART**
Anna Samarina, Russian Federation
- PE25/7 **Increasing contribution of sexually-transmitted HIV diagnoses in adolescents in Spain**
Enrique Bernal, Spain
- PE25/8 **Factors associated to late presentation of HIV newly diagnosed adolescents in Spain**
Enrique Bernal, Spain
- PE25/9 **Comparison of antiretroviral treatment initiation in HIV newly diagnosed adolescents in Spain**
Melchor Riera Jaume, Spain
- PE25/10 **Oral self-testing for adolescents and young adults absent or declining to test during home-based HIV testing - a mixed-method study embedded in a cluster-randomized trial in Lesotho (ADORE study)**
Alain Amstutz, Switzerland
- PE25/11 **Preterm births in women living with HIV in Switzerland: a 13-year evaluation**
Christian R Kahlert, Switzerland
- PE25/12 **Poor clinical outcomes in HIV-infected children who start antiretroviral therapy at an older age**
Kevin P. McKenzie, United States
- PE25/13 **Prevalence and predictors of unintended pregnancies among HIV positive young adults (14-24 years) attending an urban HIV clinic in Uganda**
Mackline Hope, Uganda
- PE25/14 **Microbiota composition in a cohort of underweight HIV-positive children aged 24-72 months in Cape Town, South Africa**
Margaret Van Niekerk, South Africa
- PE25/15 **Influence of maternal parameters on birth outcome in HIV-exposed newborns - 11 year observation**
Karolina Nowicka, Poland

Scientific Programme

ePosters
09:00 - 16:00

Exhibition hall

Cascade of care

- PE6/1 **Self-reported non-receipt of HIV test results: a silent barrier to HIV epidemic control in Mozambique**
Didier Mugabe, Mozambique
- PE6/2 **Improvement in ART initiation in different regions of Ukraine from 2010 to 2014**
Tetiana Salyuk, Ukraine
- PE6/3 **The HIV treatment cascade in Azerbaijan, 2018**
Natig Zulfugarov, Azerbaijan
- PE6/4 **Seven years of European Testing Week: impact of a regional awareness campaign on increase in awareness and testing activities in Europe**
Lauren Combs, Denmark
- PE6/5 **Impact of integrated family planning and HIV services on early postpartum contraceptive use among women with HIV in the Eastern Cape, South Africa**
Oladele Vincent Adeniyi, South Africa
- PE6/6 **The first report of Prevention of Mother-to-Child Transmission (PMTCT) of HIV in Islamic Republic of Iran**
Ebrahim Ghaderi, Iran, Islamic Republic of
- PE6/7 **New HIV diagnosis and linkage to care in two outpatient units in South Europe**
Alessio Pampaloni, Italy
- PE6/8 **The HIV- and HCV-cascade in Swiss opioid agonist treatment (OAT) patients - the SAMMSU-cohort**
Andrea Bregenzer, Switzerland
- PE6/9 **Increased Integrated testing for HIV and HCV in health care facilities: examples from the INTEGRATE activities in Lithuania and Romania**
Raimonda Matulionyte, Lithuania
- PE6/10 **AIDS and late presentation follows testing gaps in Poland - data from Test and Keep in care (TAK) Polska project**
Justyna Kowalska, Poland
- PE6/11 **Loss to follow-up and re-linkage to care in a single cohort study: who do we re-link to care?**
Laura Magnasco, Italy
- PE6/12 **Expanding access to HIV tests in 13 cities in Indonesia: an interrupted time series investigating effect of HIV policy intervention using six years population data**
Yane Tarigan, Australia
- PE6/13 **Link HIV-infected injection drug users after the imprisonment to continuum of HIV care program in Taiwan**
Wei-Wei Wu, Taiwan, Republic of China
- PE6/14 **HIV continuum of care by sex and mode of transmission in Spain, 2016: use of different sources of information**
Victoria Hernando, Spain
- PE6/15 **Temporal trends in time from HIV diagnosis to viral load suppression in CoRIS**
Belén Alejos, Spain

Scientific Programme

- PE6/16 **Navigation of HIV positive clients. Reasons of gaps in HIV cascade among PWID**
Oksana Pashchuk, Ukraine
- PE6/17 **Tracing the patterns of HIV-1 transmission among individuals with different time to diagnosis in Greece**
Evangelia-Georgia Kostaki, Greece
- PE6/18 **Late diagnosis and delayed presentation in Korean HIV/AIDS cohort**
Shin Woo Kim, Korea, Republic of
- PE6/19 **Interruption of HIV care: understanding the predictors and outcomes in the Belgian national HIV cohort**
Dominique Van Beckhoven, Belgium
- PE6/20 **The HIV continuum of care: current situation and advances. A systematic review**
Georgia Vourli, Greece
- PE6/21 **The contribution of a partnership with a civil society organization (SCO) to early HIV diagnosis and UNAIDS goals**
Antonio Diniz, Portugal
- PE6/22 **HIV cascade of care in Turkey: data from the HIV-TR cohort**
Deniz Gökengin, Turkey
- PE6/23 **Cascade analysis of anonymous voluntary HIV counseling and testing among HIV-infected patients in Taiwan**
Chun-Yuan Lee, Taiwan, Republic of China
- PE6/24 **Late presentation of HIV in Armenia**
Trdat Grigoryan, Armenia
- PE6/25 **Oral self-testing for individuals absent or refusing testing during home-based HIV testing - a cluster-randomized trial in Lesotho (HOSENG trial)**
Tracy R Glass, Switzerland
- PE6/26 **Acceptability of rapid tests for migrants during the medical consultation at the migration point**
Martin Duracinsky, France
- PE6/27 **Evaluation of the “test and treat” strategy in an high-income setting: data from a multicenter Italian cohort**
Gianmaria Baldin, Italy
- PE6/28 **Pill box return as a predictor of treatment outcome to antiretroviral therapy in PLHIV: a prospective cohort study**
Robert Ndege, Tanzania, United Republic of
- PE6/29 **Potentially missed opportunity to diagnose HIV with standard testing algorithm among adult patients with ongoing mononucleosis-like illness**
Anna Vassilenko, Belarus
- PE6/30 **HIV Continuum of Care Cascade in Cluj County, Romania. Comparative situation of the years 2016, 2017, 2018**
Adriana Topan, Romania
- PE6/31 **People living with HIV lost to follow up in the Paris region area and actions carried out by HIV care centers**
Nicolas Vignier, France

Scientific Programme

- PE6/32 **Far from 90-90-90 goals in Latin America**
Maria Greco, Argentina
- PE6/33 **Barriers to involving patients in ART as a challenge to the national health system in Ukraine**
Serhii Riabokon, Ukraine
- PE6/34 **Index testing and intensified case finding for efficiency in HIV testing in Rwanda**
Eric Remera, Switzerland

ePosters
09:00 - 16:00

Exhibition hall

Morbidity/mortality in the era of cART

- PE20/1 **The association of rare HLA alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies**
Christina Ekenberg, Denmark
- PE20/2 **Neutrophil-to-lymphocyte ratio compared to CD4+:CD8+ T-cell ratio as a predictor of non-AIDS events in treated people living with HIV**
Nick Power, Ireland
- PE20/3 **Factors associated with virologic failure in women with HIV: Condesa specialized clinics, Mexico City**
Teresita De Jesús Cabrera Lòpez, Mexico
- PE20/4 **Causes of death among a cohort of HIV-infected adults in rural Tanzania**
Fiona Vanobberghen, Switzerland
- PE20/5 **Predictors of early mortality among adult HIV-infected patients on antiretroviral therapy in a Kenyan pastoralist community: a retrospective cohort study**
Paul Yonga, Kenya
- PE20/6 **Trends in underlying causes of death in HIV - infected patients from 2016 to 2018 in Ukraine: a cohort study**
Tetiana Kyrychenko, Ukraine
- PE20/7 **Dynamic of CD4+/CD8+ ratio in late presenters: impact on clinical outcomes**
Marta Rava, Spain
- PE20/8 **Retrospective investigation into the causes of death in HIV-infected patients from Bonn in the era of combined Anti-Retroviral Therapy**
Lukas Knieps, Germany
- PE20/9 **Reduced utility of early procalcitonin in HIV febrile patients admitted to the emergency department**
Chiara Picarelli, Italy
- PE20/10 **Patients with HIV and HCV in intensive care treatment: admission criteria and trends in the intensive care unit (ICU) at the University Hospital of Bonn 2014-2019**
Stefan Schlabe, Germany
- PE20/11 **Burden of disease in PLWH harboring a 4-class drug resistant virus: data from PRESTIGIO Registry**
Maria Rita Parisi, Italy

Scientific Programme

- PE20/12 **Changing pattern of hospital admissions due to medical conditions in HIV-infected subjects in a European public health care system with free access to antiretroviral treatment**
Joan Raga Almudéver, Spain
- PE20/13 **Association of non-adherence to antiretroviral therapy with cardiovascular outcomes in virologically suppressed persons living with HIV: the Swiss HIV Cohort Study**
Tracy R Glass, Switzerland
- PE20/14 **Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980 - 201**
Katharina Kusejko, Switzerland
- PE20/15 **Low pre-ART CD4 count is associated with increased risk of clinical progression or death even after reaching 500 CD4 cells/ μ L on ART**
Nikos Pantazis, Greece
- PE20/16 **A comparative analysis on blood pressure in HIV-infected individuals versus uninfected controls residing in Sub-Saharan Africa: a narrative review**
Edith Phalane, South Africa
- PE20/17 **Causes of death in AIDS/HIV-infected patients at the hospital of infectious diseases in St. Petersburg, Russia**
Olga Sokolova, Russian Federation
- PE20/18 **Dynamics and structure of mortality of HIV-positive people in Ukraine**
Nataliia Bugaienko, Ukraine

ePosters
09:00 - 16:00

Exhibition hall

Prevalence, incidence and dynamics of HIV epidemics

- PE29/1 **Monitoring rates and accessibility of HIV and STI's testing, HAV and HBV vaccination among men who have sex with men in Slovenia**
Miran Solinc, Slovenia
- PE29/2 **Data triangulation to re-shape interventions to improve the HIV response: compering data from estimates, case reporting, and sentinel surveillance in Ukraine**
Tetiana Salyuk, Ukraine
- PE29/3 **The impact of frequent cannabis use on injection drug use patterns among people who use drugs in a Canadian setting**
Hudson Reddon, Canada
- PE29/4 **Predicting early loss to follow-up on ART: a retrospective review of clients' retention on ART in North-western Nigeria**
Johnson Okolie, Nigeria
- PE29/5 **The increasing number of late HIV diagnosis among men having sex with men and transgender women in a key population-led HIV testing and treatment facility and its societal implication in the Philippines**
Patrick Eustaquio, Philippines
- PE29/6 **HIV transmission network in a cohort of subjects with primary infection in a single clinical center in Rome**
Lavinia Fabeni, Italy

Scientific Programme

- PE29/7 **Evaluation of a multiassay approach for determination recent HIV infection in the Russian Federation**
Anastasia Murzakova, Russian Federation
- PE29/8 **Ongoing spread of HIV subtype A in Tel Aviv, Israel**
Dan Turner, Israel
- PE29/9 **Simple clinical and laboratory based score may identify HIV infection recency and subsidize HIV surveillance in low and middle-income countries (LMIC), Santo André/Brazil experience**
Elaine Monteiro Matsuda, Brazil
- PE29/10 **Clinical, epidemiological & virological features of primary HIV-1 infection in an HIV reference center in Brussels: a ten years' review**
Arthur Poncelet, Belgium
- PE29/11 **Current trends in HIV genetic diversity in Russia: increase of the unique recombinants prevalence**
Anastasiia Antonova, Russian Federation
- PE29/12 **Analysis of risk factors in HIV/AIDS patients**
Esra Zerdali, Turkey
- PE29/13 **Tracing the first HIV-1 epidemics in the Milan area**
Alessia Lai, Italy
- PE29/14 **Analysis of the local HIV-1 epidemic in Vologda region, Russia: predominance of CRF03_AB and rapid expansion of URFs**
Ekaterina Ozhmegova, Russian Federation
- PE29/15 **Identification of first near full length recombinant genome of HIV-1 in Korea**
Mee-Kyung Kee, Korea, Republic of
- PE29/16 **Characteristics of HIV infection among children in Georgia, 1989-2018**
Natela Chokoshvili, Georgia
- PE29/17 **HIV infection in older patients**
Barbara Belfiori, Italy
- PE29/18 **Seroincidence of the human herpesvirus 8 (HHV 8) infection among HIV-positive patients in Taiwan, 2016-2019**
Yi-Ching Su, Taiwan, Republic of China
- PE29/19 **Risk factors for late presentation for HIV care in 2019 in Ukraine**
Maryna Sukach, Ukraine
- PE29/20 **Incidence of hepatitis C virus infection among people living with HIV(PLHIV): an Egyptian Cohort Study**
Rahma Mohamed, Egypt
- PE29/21 **High HIV prevalence following screening of subjects with HIV indicator conditions in a hospital setting**
Camilla Tincati, Italy
- PE29/22 **First decrease in new HIV diagnoses in 2018 among men who have sex with men (MSM), in the East PACA (Provence Alpes Côte-d'Azur) area in France**
Philippe Bouvet de la Maisonneuve, France

Scientific Programme

- PE29/23 **The collision of public health interventions on HIV-1 spread in Albania by molecular epidemiology**
Shkurti Enkelejda, Albania
- PE29/24 **Two decades of HIV infection late diagnosis: the experience of a Portuguese Hospital**
Sofia Jordão, Portugal
- PE29/25 **Characterization of HIV patients followed in a specialist consultation at a tertiary and university centre**
Fábio Videira Santos, Portugal
- PE29/26 **Trends in epidemiology and clinical picture of late presentation among patients of the Hospital for Infectious Diseases in Warsaw**
Joanna Pula, Poland
- PE29/27 **An evolutionary insight into a growing HIV subtype A epidemic in Serbia**
Marina Siljic, Serbia
- PE29/28 **Change of prevalence, diseases distribution and factors associated with the risk of AIDS presentation in Italy over last decade (2009-2018)**
Andrea Antinori, Italy
- PE29/29 **The effect of gender on late diagnosis of HIV infection in a high incidence European population**
Rita Filipe, Portugal
- PE29/30 **Two decades surveillance of HIV-1 transmitted drug resistance in Serbia**
Valentina Cirkovic, Serbia
- PE29/31 **3M-BRIHT - Manchester Cohort. Investigation of the feasibility and acceptability of rapid HIV testing in a European Emergency Department setting**
Molly M. O'Kane, Ireland
- PE29/32 **HIV-1 A6 subtype: its challenging identification and Southern Russian molecular epidemiology**
Saleta Sierra, Germany
- PE29/33 **Neurodevelopmental assessments to screen for HIV encephalopathy in newly diagnosed infants not on ART in Mozambique**
Jyodi Mohole, United States

ePosters
09:00 - 16:00

Exhibition hall

Prevention of horizontal transmission, cART as prevention

- PE30/1 **Tolerability and treatment completion of tenofovir alafenamide/emtricitabine/rilpivirine (TAF/FTC/RPV) as HIV postexposure prophylaxis**
Marie Chauveau, France

ePosters
09:00 - 16:00

Exhibition hall

Standard of care

Scientific Programme

- PE31/1 **Exploring the attitudes of HIV-positive patients on single-tablet antiretroviral regimens towards generic de-simplification**
Ciara Levey, Ireland
- PE31/2 **Comparison of Immunological and virological response to cART between HIV-1/O and HIV-1/M patients followed-up in France: the ANRS ORIVAO and COPANA studies**
Guillemette Unal, France
- PE31/3 **From HIV diagnosis to antiretroviral therapy initiation in Croatia from 2013 to 2018**
Nikolina Bogdanić, Croatia
- PE31/5 **Tetanus seroprotection in HIV-positive subjects living in Belgium: risk factors for seronegativity, evaluation of medical history and a rapid dipstick test**
Nicolas Dauby, Belgium
- PE31/6 **The prevalence of virologic failure and resistance associated mutations in single and multi-tablet HIV treatment regimens**
Chien-Yu Cheng, Taiwan, Republic of China
- PE31/7 **Development and validation of a risk score for predicting non-adherence to antiretroviral therapy**
Hernando Knobel, Spain
- PE31/8 **Measles seroprevalence among HIV infected patients in central part of Poland - vaccination proposal**
Ewa Siwak, Poland
- PE31/9 **Nurse-led annual health review - one year follow up**
Marie-Pierre Klein, United Kingdom
- PE31/11 **Viral hepatitis in HIV-positive patients - testing, prophylaxis and treatment in Central and Eastern Europe**
Kerstin Kase, Estonia
- PE31/12 **Evaluating a national pilot process for reviewing late HIV diagnoses in England and Wales**
Ming Jie Lee, United Kingdom
- PE31/13 **GESIDA quality of care indicators for PLWH: report from two Spanish hospitals 2009-2017**
Francisco Fanjul, Spain
- PE31/14 **Late presentation and barriers to the early HIV diagnosis in Central part of Ukraine**
Tetiana Koval, Ukraine
- PE31/15 **Operational research of barriers and facilitators to harm reduction services for intravenous drug users (including female IDUs)**
Tamar Zurashvili, Georgia
- PE31/16 **A seven-month prospective review of HIV admissions to a regional infectious disease unit in Manchester, UK**
Hamzah Zahid Farooq, United Kingdom
- PE31/17 **Annual health review for people living with HIV - an evaluation**
Sarah Edwards, United Kingdom
- PE31/18 **Analysis of adherence to HIV-positive quality of care indicators and their impact of service quality perceptions in patient: a Spanish cross-sectional study**
Alejandra Gimeno García, Spain

Scientific Programme

ePosters
09:00 - 16:00

Exhibition hall

Behavioural interventions

- PE5/1 **Close group social media network and social gatherings for comprehensive HIV services among adolescent MSM in Lagos Nigeria**
Orobosa Enadeghe, Nigeria
- PE5/2 **Good hygiene practices post circumcision: a case for low adverse events in VMMC**
Timothy Kipkosgei, Kenya
- PE5/3 **Challenges of implementing HIV counselling and testing (HCT) campaigns for higher education distance learning students at University of South Africa**
Nkay Pascal Kiabilua, South Africa
- PE5/4 **Enhancing effective HIV prevention among girls by fighting child marriage and sexual and gender based violence in Karonga district, Malawi**
Shora Manuel Kauluka, Malawi
- PE5/5 **Effectiveness of rapid HIV and HCV testing programmes based on mobile units**
Ekaterina Zinger, Russian Federation
- PE5/6 **It can't happen to me - tackling cognitive mistakes and HIV using a national campaign**
Arian Diskovic, Croatia
- PE5/7 **Is mobility still a HIV/STI associated vulnerable factor in the changing sex work dynamics among female sex workers in India? - Emerging evidence**
Priyanka Dixit, India
- PE5/8 **"Amare con Sapienza": an Italian digital ambient media prevention campaign in one of the largest European University to increase U=U, PreP, TasP knowledge**
Serena Vita, Italy
- PE5/9 **Assessing high risky sexual behaviors in vulnerable women in northern Uganda: baseline results of "Pe Atye Kena, no longer alone" study**
Antonella Cingolani, Italy
- PE5/10 **HIV/AIDS educational program for secondary school female students in Iran: a school-based randomized controlled trial**
Farid Yousefi, Iran, Islamic Republic of

ePosters
09:00 - 16:00

Exhibition hall

Clinical trials of vaccines

- PE8/1 **Seroprevalence of vaccine preventable viral diseases and vaccine response among HIV positive patients**
Fatma Sebnem Erdinc, Turkey
- PE8/2 **Could we recommend the current herpes zoster vaccine for patients living with HIV (PLHIV)?**
Thomas Huleux, France

Scientific Programme

ePosters
09:00 - 16:00

Exhibition hall

Treatment as prevention

- PE33/1 **HIV-1 viral load quantification using Aptima HIV-1 Quant Dx assay in Kenya: a diagnostic accuracy study**
Geoffrey Kangogo, Kenya
- PE33/3 **Rapid ART start in primary HIV infection: time to viral suppression in a London cohort**
Nicolo Girometti, United Kingdom
- PE33/4 **Reality check: HIV post-exposure prophylaxis (PEP) in real-life at a tertiary care centre prior to the PrEP era**
Lina Thewes, Germany

ePosters
09:00 - 16:00

Exhibition hall

Access to and models of care

- PE1/1 **Barriers in TB services for people living with HIV and overcoming them according to the health care workers opinion in the TB facilities in Russia (sociological study)**
Zinaida Zagdyn, Russian Federation
- PE1/2 **Investigating the impact of peer counseling intervention on access and use of sexual and reproductive health services in women Living with HIV in Nepal: a prospective cohort study**
Khem Pokhrel, Nepal
- PE1/3 **Health care delivery for HIV-positive people with tuberculosis in Europe**
Adrian Bentzon, Denmark
- PE1/4 **A survey of physicians on circumstances and factors influencing testing for HIV in Lithuania**
Raimonda Matulionyte, Lithuania
- PE1/5 **Experiences of forgiveness and unforgiveness of HIV-specific offenses among people living with HIV/AIDS in Ghana**
Judith A. Osae-Larbi, Ghana
- PE1/6 **Time to antiretroviral therapy: service model adaptation during an outbreak of HIV in people who inject drugs (PWIDs)**
Harrison Stubbs, United Kingdom
- PE1/7 **HIV infection hospital-based active case finding in Sardinia, Italy: results from the SHOT project**
Maria Sabrina Mameli, Italy
- PE1/8 **Retention activities based on home visits as a tool of return and keeping in care of low adhered patients. Results of work 2016-2019 Krasnoyarsk AIDS clinic**
Konstantin Kandlen, Russian Federation
- PE1/9 **Pilot project of shared assistance with primary care for patients with HIV infection**
Adrián Ferre, Spain

Scientific Programme

ePosters
09:00 - 16:00

Exhibition hall

HIV and marginalised groups

- PE11/1 **Sexual behaviors and seroprevalence of HIV, HBV, and HCV among hill tribe youths of Northern Thailand**
Tawatchai Apidechkul, Thailand
- PE11/3 **The blind spot: high HIV burden among slum-dwelling school-age girls in Kampala, Uganda**
Jude Thaddeus Ssensamba, Uganda
- PE11/4 **Research of behavioral models of transgender people leading to high rates of HIV prevalence in Ukraine**
Igor Medvid, Ukraine
- PE11/5 **Outreach services for HIV testing and prevention among female transgender commercial sex workers in Milan: different approaches for different populations?**
Giuseppe Lapadula, Italy
- PE11/6 **The impact of unstable housing on HIV treatment outcomes in people living with HIV/AIDS in an urban setting of Southern Europe**
Hernando Knobel, Spain
- PE11/7 **Reflection of sex work criminalization in court judgements targeting to protect health, sanitary and epidemiological well-being**
Marina Avramenko, Russian Federation
- PE11/8 **Caring for the Transgender HIV-positive patient**
Chiara Picarelli, Italy
- PE11/9 **Association of current Estradiol use with carotid intimal media thickness among transgender women: a cross-sectional study**
Rodrigo Moreira, Brazil
- PE11/10 **HIV and migrants: a demographic and clinical characterization of migrants under follow up at an Infectious Diseases Department in Lisbon, Portugal**
Marta Leal dos Santos, Portugal

ePosters
09:00 - 16:00

Exhibition hall

Social and behavioural science

- PE30/2 **Priorities for behavioral interventions in a group of long term PLWHA - the experience of the Baylor Clinical Centre of Excellence in Constanta, Romania**
Ana-Maria Schweitzer, Romania
- PE30/3 **Will HIV-infected patients taking oral ARV switch to long-acting injectable ART when It become available?**
Marie-Aude Khuong-Josses, France
- PE30/4 **Time perspectives as predictors of depression and suicidal ideation amongst adolescents and young adults with HIV: the moderating role of resilience**
Oluwapelumi Ashamu, Nigeria

Scientific Programme

- PE30/5 **Social support and quality of life of people living with AIDS receiving ART at BPKIHS**
Ram Sharan Mehta, Nepal
- PE30/7 **Knowledge, attitudes, beliefs and HIV-related behaviour in metropolitan France: investigation in a festive place**
Fernanda Medina, France
- PE30/9 **Injectable long acting antiretrovirals for HIV treatment or prevention: the ANRS CLAPT study**
Laurence Slama, France
- PE30/10 **Quality of life in people living with HIV: a regional survey in Flanders**
Gert Scheerder, Belgium
- PE30/11 **Innovative strategies to sustain community participation in HIV vaccine trials, experience of Makerere University Walter Reed Project (MUWRP) in Kampala, Uganda**
Jauhara Nanyondo, Uganda
- PE30/12 **Stigma among healthcare providers towards people living with HIV/AIDS in India**
Akanksha Rathi, India
- PE30/13 **"I love my life, I don't want to miss a thing": motivators and Barriers to ART adherence among women living with HIV/AIDS in Iran**
Nooshin Amirisani, Iran, Islamic Republic of
- PE30/14 **Medical students as potential sources of information about HIV/AIDS**
Mykola Haras, Ukraine
- PE30/15 **Gender violence, intimate partner violence and domestic violence among HIV-positive patients in Alicante (Spain). Preliminary results of the VIHOLETA study**
Jara Llenas-García, Spain
- PE30/16 **Influence of stigma and discrimination on psychosocial health in children affected by AIDS in Nepal: a cross-sectional study**
Kalpana Gaulee Pokhrel, Nepal
- PE30/17 **The quality of life among people living with HIV in Taiwan in the era of STR**
Chung-Ching Shih, Taiwan, Republic of China
- PE30/18 **Experiences of and factors influencing physical activity in people living with HIV: a qualitative systematic review**
Megan Davies, United Kingdom
- PE30/20 **Perception of condom use in the era of pre-exposure prophylaxis (PrEP): a qualitative analysis**
Shui Shan Lee, Hong Kong
- PE30/21 **Recommendations for enabling timely pregnancy disclosure to clinical staff of women living with HIV**
Stefania Mihale, Romania
- PE30/22 **Health-related quality of life in a single center cohort of people living with chronic diseases: comparison between HIV and other clinical conditions**
Antonella Cingolani, Italy
- PE30/23 **Experiences of Dutch obstetric healthcare providers with HIV-positive pregnant women: a qualitative study**
Carlijn Damsté, Netherlands

Scientific Programme

- PE30/24 **Evaluation of knowledge, attitudes and practices among HIV positive pregnant women and their partners in four healthcare facilities in Malawi**
Isotta Triulzi, Italy
- PE30/25 **Towards the 4th 90, measuring multi-dimensional quality of life in people living with HIV in Aquitaine, France: psychometric properties of the French version of the WHOQOL-HIV BREF**
Diana Barger, France
- PE30/26 **Body size modifies the relationship between internalized HIV stigma and pain in people with HIV in the Southeastern USA**
Kaylee Crockett, United States

ePosters
09:00 - 16:00

Exhibition hall

Treatment in resource-constrained settings

- PE34/2 **Optimizing clients linkage into ART using family-centered differentiated approach (FCDA) in Kebbi state, northwestern Nigeria: successes and challenges**
Johnson Okolie, Nigeria
- PE34/3 **A multi-stakeholder evaluation of the early implementation experiences of differentiated anti-retroviral therapy (ART) delivery roll-out across Uganda: a qualitative analysis**
Henry Zakumumpa, Uganda
- PE34/5 **Evaluation of the financial cost of treating people living with human immunodeficiency virus in the United Kingdom versus matched HIV-negative controls in 2004, 2010 and 2017**
Scott Francis, United Kingdom
- PE34/6 **Continuous quality improvement across the viral load testing spectrum at the Infectious Diseases Institute, Uganda**
Harriet Tibakabikoba, Uganda
- PE34/7 **Pediatric HIV viral load suppression: qualitative insights of barriers and facilitators among caregivers of children on ART in high volume sites in Kisumu County, Kenya**
Nicollate Okoko, Kenya
- PE34/8 **Boosting economic affordability of HIV medicines while considering safety and effectiveness within transition from donor funding. Enabling access to TAF regime with better safety profile in Ukraine through advocacy campaign of community organization**
Zoia Zamikhovska, Ukraine

ePosters
09:00 - 16:00

Exhibition hall

Vulnerable groups

- PE39/1 **Boys having sex with boys: CD4 count as parameter to estimate the time of infection among HIV seropositive men having sex with men and its societal implications in the Philippines**
Patrick Eustaquio, Philippines
- PE39/2 **Evaluating factors increasing the vulnerability of adolescent girls and young women to HIV/AIDS infection in selected communities, Akwa Ibom State**
Jessie Inyang, Nigeria

Scientific Programme

- PE39/3 **Men's perspectives on HIV self-testing in sub-Saharan Africa: a systematic review and meta-synthesis**
Mbuzeleni Hlongwa, South Africa
- PE39/4 **Molecular-biological methods of diagnostics in the investigation of the case of transmission of HIV-infection**
Diana Valutite, Russian Federation
- PE39/5 **Implementation of demedicalized and decentralized HIV testing project in Brussels: action test, project for vulnerable populations at high HIV risk in Brussels, including Subsaharan African Migrants (SAM)**
Tresors Kouadio, Belgium
- PE39/6 **HIV prevalence, risk-taking behavior and self-testing potential among men who have sex with men and transgender people**
Evgeniy Pisemskiy, Russian Federation
- PE39/7 **Political commitment matters in the elimination of the threat of HIV and HCV and TB among people who use drugs**
Gefra Fulane, Portugal
- PE39/8 **Challenges in health and social care for migrant HIV patients in the Czech Republic**
Elena Tulupova, Czech Republic
- PE39/9 **Integration of hepatitis C cure in housing facility Soleil Evant: health cost implications**
Erika Castro, Switzerland
- PE39/10 **The role of sexual partners of people who inject drugs in better uptake of retention in HIV services**
Marine Gogia, Georgia
- PE39/11 **Male sex workers and ICT: anthropological approach of male sex workers and the different practices online: bareback, PrEP and chemsex**
Maxime Maes, Belgium
- PE39/12 **Portuguese League Against AIDS - mobile screening unit**
Maria Eugénia Saraiva, Portugal
- PE39/13 **Detectable viraemia in the era of successful antiretroviral therapy; engagement with multi-disciplinary services**
Shimu Khamlich, United Kingdom
- PE39/14 **Optimal HIV self-testing, potential strategies to increase HIV diagnosis in Tanzania**
Neema Makyao, Tanzania, United Republic of

ePosters
09:00 - 16:00

Exhibition hall

Clinical case

- PE7/1 **Disseminated histoplasmosis in HIV, a key point of interest in Latin America**
Nelson Delgado, Ecuador
- PE7/2 **H-ART to Heart: a 43 year old body builder with HIV on anti-retroviral therapy with recurrent myocardial infarctions (5 heart attacks)**
Gavin Paul Raphael Manmathan, United Kingdom

Scientific Programme

- PE7/3 **Immune reconstitution inflammatory syndrome presenting as toxoplasma macular retinochoroiditis of eyes**
Dombu Guiafaing Reine Charlye, Cameroon
- PE7/4 **Invasive pulmonary aspergillosis and pulmonary tuberculosis in newly HIV diagnosed patients without prior ART exposure: differential diagnosis difficulties, treatment strategy**
Katerina Lytvin, Ukraine
- PE7/5 **Pseudotumor mimicking lung malignancy as a clinical presentation of Mycobacterium Avium infection in AIDS patient**
Luka Jovanovic, Serbia
- PE7/6 **Use of ibalizumab in a heavily treatment-experienced HIV-1-infected subject harbouring a multidrug-resistant virus**
Diana Canetti, Italy
- PE7/7 **Successful use of long-acting injectable cabotegravir and rilpivirine combination therapy in a patient with HIV-1 infection unable to absorb oral medication**
Razan Saman, United Kingdom
- PE7/8 **Cutaneous malignancy in a Romanian HIV-infected patient: diagnosis and treatment challenges**
Irina Cristiana Ianache, Romania
- PE7/9 **Autoantibodies, drugs and a failing liver**
Sonia Raffe, United Kingdom

ePosters
09:00 - 16:00

Exhibition hall

Novel consultations, remote care - telemedicine, mobile applications

- PE23/1 **Harnessing mobile technology for health worker capacity building to improve quality of care in resource-constrained settings**
Walter Joseph Arinaitwe, Uganda
- PE23/2 **Feasibility, uptake and acceptability of the EmERGE mHealth app in individuals living with stable HIV in five European countries**
Jenny Whetham, United Kingdom
- PE23/3 **Attracting people who use drugs to HIV prevention and care programs via darknet and messengers: evidence from St. Petersburg, Russia**
Aleksey Lakhov, Russian Federation
- PE23/4 **People living with HIV (PLHIV) and their doctors: adopters and sceptics, and those opened to e-health**
Christine Jacomet, France
- PE23/5 **Fitness tracking wearable devices and a dedicated smart phone app (MySAwH App) to predict quality of life in PLWH: a multi-centre prospective study**
Giovanni Guaraldi, Italy
- PE23/6 **The efficiency of introducing the EmERGE Pathway of care for stable Croatian PLHIV**
Eduard J. Beck, United Kingdom

Scientific Programme

- PE23/7 **'The 4th 90': a preliminary assessment of change in quality of life over 1 year of the EmERGE study: PROQOL-HIV and EQ-5D-5L, a descriptive analysis**
Christopher Jones, United Kingdom
- PE23/8 **Measuring empowerment in EmERGE mHealth platform users: a descriptive analysis of interim data**
Stephen Bremner, United Kingdom

ePosters
09:00 - 16:00

Exhibition hall

PrEP

- PE28/1 **Establishment of the service system of HIV pre-exposure prophylaxis/post exposure prophylaxis (PrEP/PEP) in a certain area of Southern Taiwan**
Kuei Ying Wang, Taiwan, Republic of China
- PE28/2 **Systematic review of post-migration HIV acquisition within Europe: the case for PrEP interventions for migrants**
Simran Mann, United Kingdom
- PE28/3 **Self-reported STI history and associated factors among German PrEP users**
Uwe Koppe, Germany
- PE28/4 **PrEP implementation among MSM in Ukraine: results of pilot project in Kyiv**
Roman Marchenko, Ukraine
- PE28/5 **Emergency post-exposure prophylaxis (PEP) seeking behaviors among men who have sex with men (MSM) with recent HIV risk exposure in Thailand**
Tarandeep Anand, Thailand
- PE28/6 **The back side: Lymphogranuloma venereum in PrEP-users and PLWH**
Sven Schellberg, Germany
- PE28/7 **Awareness and interest in pre-exposure prophylaxis (PrEP) among MSM population in Serbia**
Vanja Subotic, Serbia
- PE28/8 **PrEP reimbursement and access in Europe: 2019 update**
Krzysztof Tronczyński, Poland
- PE28/9 **Users' perspective of an ideal service model for delivering pre-exposure prophylaxis (PrEP) to men who have sex with men**
Shui Shan Lee, Hong Kong
- PE28/10 **Assessment of the trough concentrations of tenofovir in HIV-negative subjects on pre-exposure prophylaxis: a single center, real-life experience**
Dario Cattaneo, Italy
- PE28/11 **No new HIV infections, but high incidence of syphilis among Pre-exposure Prophylaxis (PrEP) users in Georgia**
Ekaterine Karkashadze, Georgia
- PE28/12 **Feasibility and acceptability of an oral pre-exposure prophylaxis (PrEP) program against HIV targeting female sex workers in Belgium**
Florence Deneumoustier, Belgium

Scientific Programme

- PE28/13 **First results after 52 weeks of informal PrEP use in a cohort of MSM in Southern Spain**
Alejandro Berto Moran, Spain
- PE28/14 **Clinical outcomes of pre-exposure prophylaxis from clinical center in Warsaw, Poland**
Iwona Cielniak, Poland
- PE28/15 **Where are we with PrEP use in Central and Eastern Europe? - data from the ECEE Network Group**
Josip Begovac, Croatia
- PE28/16 **Sexual risk and HIV preventative behaviours among men who have sex in men in London in the era of HIV pre-exposure prophylaxis, 2019**
Fiona Burns, United Kingdom
- PE28/17 **Chemsex and mood disorders under HIV pre-exposure prophylaxis**
Helene Peyriere, France
- PE28/18 **Pre-exposure prophylaxis one year after implementation in Portugal - the reality of a central hospital**
Diogo Guerra, Portugal
- PE28/19 **DISCOVER in Europe: a sub-analysis of the phase 3 randomized, controlled trial of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP)**
Frank Post, United States
- PE28/20 **The Good and Bad of PrEP: a 14 month follow up on awareness, adherence, efficacy and sexually transmitted diseases at Hospital de Curry Cabral**
Marta Leal dos Santos, Portugal
- PE28/21 **PrEP for life: new challenges and barriers in PrEP uptake among men who have sex with men (MSM) and transgender people (TG) in Kyiv, Ukraine**
Dzmitry Filippau, Ukraine
- PE28/22 **Analysis of the need for pre-exposure prophylaxis of HIV among people that have high risk to be infected**
Vitaliy Andres, Ukraine
- PE28/23 **Lesson learnt from a combined HIV prevention using HIV self-testing and oral pre-exposure prophylaxis (PrEP) demonstration project in the United Republic of Tanzania**
Neema Makyao, Tanzania, United Republic of

Scientific Programme

Parallel session
10:00 - 12:00

Event Hall

PS8, Antiretroviral therapy: Today and in the future

Session interpreted in Russian

Access to the webcasted session:

[PS8/1](http://resourcelibrary.eacs.cyim.com?mediald=78726)
[PS8/2](http://resourcelibrary.eacs.cyim.com?mediald=78727)
[PS8/3](http://resourcelibrary.eacs.cyim.com?mediald=78728)
[PS8/4](http://resourcelibrary.eacs.cyim.com?mediald=78729)
[PS8/5](http://resourcelibrary.eacs.cyim.com?mediald=78730)

[ML1](http://resourcelibrary.eacs.cyim.com?mediald=78746)

[PS8/7](http://resourcelibrary.eacs.cyim.com?mediald=78747)

Chairs:

Jose Arribas, Spain
Alexandra Calmy, Switzerland

PS8/1	Adherence and clinical outcomes in asymptomatic patients starting ART: the Swiss HIV Cohort Study Tracy R Glass, Switzerland	10:00 - 10:15
PS8/2	Assessments of very low level HIV replication for dolutegravir+lamivudine (DTG+3TC) vs dolutegravir+tenofovir disoproxil/emtricitabine (DTG+TDF/FTC) in the GEMINI 1&2 studies through week 96 Mark Underwood, United States	10:15 - 10:30
PS8/3	Dolutegravir/emtricitabine dual therapy is non-inferior to standard combination antiretroviral therapy in maintaining HIV suppression throughout 48 weeks (SIMPL'HIV study) Delphine Sculier, Switzerland	10:30 - 10:45
PS8/4	Risk of failure in dual therapy versus triple therapy in naïve HIV-patients: a meta-analysis Antonio Russo, Italy	10:45 - 11:00
PS8/5	Shorter time to treatment failure in PLHIV switched to dolutegravir plus either rilpivirine or lamivudine compared to integrase inhibitor-based triple therapy in a large Spanish cohort - VACH Ramón Teira, Spain	11:00 - 11:15
PS8/6	Five-year follow-up of patients enrolled in NEAT001/ANRS 143 randomized clinical trial (NEAT001 LONG TERM (NLT) study) Francois Raffi, France	11:15 - 11:30
ML1	Panel discussion: Controversies in antiretroviral therapy Jacques Reynes, France Hans-Jürgen Stellbrink, Germany	11:30 - 11:45
PS8/7	Uptake and discontinuation of Integrase Inhibitors (INSTIs) in a large cohort setting Lauren Greenberg, United Kingdom	11:45 - 11:55

Scientific Programme

Parallel session
10:00 - 12:00

San Francisco

PS9, Emerging issues in public health and epidemiology of HIV in Europe

Access to the webcasted session:

[ML1](http://resourcelibrary.eacs.cyim.com?mediald=78732)
[ML2](http://resourcelibrary.eacs.cyim.com?mediald=78733)
[PS9/1](http://resourcelibrary.eacs.cyim.com?mediald=78734)
[PS9/4](http://resourcelibrary.eacs.cyim.com?mediald=78748)
[PS9/6](http://resourcelibrary.eacs.cyim.com?mediald=78752)

Chairs:

Akaki Abutidze, Georgia
Teymur Noori, Sweden

ML1	Epidemiology of HIV in Central and Eastern Europe Antons Mozalevskis, Denmark	10:00 - 10:15
ML2	Euroguidelines in Central and Eastern Europe ECEE network/Euroguidelines group Arjan Harxhi, Albania	10:15 - 10:30
PS9/1	Current trends in HIV/AIDS epidemic in Russia Natalia Ladnaya, Russian Federation	10:30 - 10:45
PS9/2	A simple tool to evaluate the effectiveness of HIV care for settings with gaps in data availability Dorthe Raben, Denmark	10:45 - 11:00
PS9/3	HIV continuum of care: bridging cross-sectional and longitudinal analyses Giota Touloumi, Greece	11:00 - 11:15
PS9/4	Reaching the second and third UNAIDS 90-90-90 targets is accompanied by a dramatic reduction in primary HIV infection and in recent HIV infections in a large French nationwide HIV cohort Adrien Le Guillou, France	11:15 - 11:30
PS9/5	Similar but different: using combined phylogenies of Austria and Switzerland reveals differences in transmission patterns of the local HIV-1 epidemics Katharina Kusejko, Switzerland	11:30 - 11:45
PS9/6	‘Chems4EU’ a study describing chemsex use across 4 European countries in MSM attending HIV services Katie Conway, United Kingdom	11:45 - 12:00

Scientific Programme

Parallel session
10:00 - 12:00

Boston 1-3

PS10, Severe infections co-organised with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

Access to the webcasted session:

ML1
ML3
PS10/1
PS10/2

PS10/3

PS10/4

Chairs:

Nathalie de Castro, France
Winfried Kern, Germany

ML1	The burden of histoplasmosis and HIV: Connecting the dots Mathieu Nacher, French Guiana	10:00 - 10:15
ML2	Hemophagocytic syndrome during HIV infection: How to sail to weather the storm? Lionel Galicier, France	10:15 - 10:30
ML3	Tuberculosis and HIV: recent advances and perspectives Nathalie de Castro, France	10:30 - 10:45
PS10/1	Frequency, presentation and predictors of strongyloidiasis in HIV-infected migrants at the Institute of Tropical Medicine Antwerp (ITM), Belgium Caroline Theunissen, Belgium	10:45 - 11:00
PS10/2	Diagnosing tuberculosis in people living with HIV in a rural district of Mozambique: yield of TB-LAM, digital chest X ray and Xpert®Ultra Santiago Izco, Spain	11:00 - 11:15
PS10/3	A New Health Care Index independently predicts 12-month mortality among HIV positive individuals diagnosed with tuberculosis Ashley Roen, United Kingdom	11:15 - 11:30
PS10/4	Comparison of TB drug susceptibility, treatment regimens and outcome among TB/HIV-patients in a setting with high prevalence of resistant TB: results from a national and supranational reference laboratories Daria Podlekareva, Denmark	11:30 - 11:45
PS10/5	Influence of vitamin D deficiency on development of opportunistic infection in people living with HIV/AIDS (PWAH) Shinwon Lee, Korea, Republic of	11:45 - 12:00

Scientific Programme

Industry sponsored session
12:15 - 13:45

San Francisco

Industry sponsored session

(For more details, please visit the [conference website](https://eacs-conference2019.com/index.php?article_id=166))

Special session
12:45 - 13:45

Shanghai 3

EACS General Assembly

Chair: Jürgen Rockstroh, EACS President

Special session
12:45 - 13:45

Shanghai 1-2

Best poster discussion I - Antiretroviral (ARV)

Access to the webcasted session:

[BPD1/1](http://resourcelibrary.eacs.cyim.com?mediald=78753)
[BPD1/4](http://resourcelibrary.eacs.cyim.com?mediald=78761)
[BPD1/5](http://resourcelibrary.eacs.cyim.com?mediald=78762)

Chairs:

Christine Katlama, France
Vadim Rassokhin, Russian Federation

BPD1/1	Causes of treatment failure in independent and industry-funded clinical trials of dolutegravir for HIV, and outcomes of unsuppressed patients continued on treatment in the ADVANCE study Toby Pepperrell, United Kingdom	12:45 - 12:55
BPD1/2	Evolution of drug interactions with antiretroviral medications in HIV-infected patients Majdouline El Moussaoui, Belgium	12:55 - 13:05
BPD1/3	Drug interaction profiles for first line antiretroviral therapy and selected fixed-dose antiretroviral combinations over 20 years of the Liverpool Drug Interaction website Best Poster Sara Gibbons, United Kingdom	13:05 - 13:15
BPD1/4	Retrospective analysis of co-medication patterns among patients treated for HIV, and potential interactions with antiviral treatment, in Norway during 2012-2018 using the Norwegian population-based prescription database Lars Heggelund, Norway	13:15 - 13:25
BPD1/5	TDF/FTC is a cost-saving maintenance option in HIV-infected people with low reservoir Thierry Prazuck, France	13:25 - 13:35

Scientific Programme

Special session
12:45 - 13:45

Boston 1-3

Best poster discussion II - Ageing: Long-term complications

Access to the webcasted session:

[BDP2/2](http://resourcelibrary.eacs.cyim.com?mediald=78763)
[BDP2/3](http://resourcelibrary.eacs.cyim.com?mediald=78764)

[BDP2/4](http://resourcelibrary.eacs.cyim.com?mediald=78765)

[BDP2/5](http://resourcelibrary.eacs.cyim.com?mediald=78766)

Chairs:

Antonella d'Arminio Monforte, Italy
Serhat Ünal, Turkey

BPD2/1	DXA Scan vs. FRAX score for the evaluation of fracture risk in a cohort of elderly people living with HIV Maria Mazzitelli, United Kingdom	12:45 - 12:57
BPD2/2	Prevalence of and risk factors for low bone mineral density assessed by central quantitative computed tomography in people living with HIV and uninfected controls Best poster Magda Teresa Thomsen, Denmark	12:57 - 13:09
BPD2/3	Restless legs syndrome and health-related quality of life in HIV: results from the POPPY sleep substudy Ken Kunisaki, United States	13:09 - 13:21
BPD2/4	Depression and kynurenine/tryptophan ratio in people living with HIV Ninna Drivsholm, Denmark	13:21 - 13:33
BPD2/5	Antiretroviral therapy and clearance of oncogenic HPVs in HIV positive MSM Carmen Hidalgo-Tenorio, Spain	13:33 - 13:45

Special session
12:45 - 13:45

Darwin

Best poster discussion III - Hot topics

Access to the webcasted session:

[BDP3/2](http://resourcelibrary.eacs.cyim.com?mediald=78768)

[BDP3/3](http://resourcelibrary.eacs.cyim.com?mediald=78769)

Chairs:

Marta Vasylyev, Ukraine
Casper Rokx, Netherlands

BPD3/4	Novel highly potent CD4bs bNAbs with restricted pathway to HIV-1 escape Best poster Philipp Schommers, Germany	12:45 - 12:52
--------	---	---------------

Scientific Programme

BPD3/2	Harnessing big data on Indonesian MSM and transgender individuals using temanteman.org platforms to assess their vulnerabilities, HIV support seeking patterns and immediate HIV prevention needs Tarandeep Anand, Thailand	12:52 - 12:59
BPD3/3	Prescription of antimicrobials in primary health care as a marker to identify people living with undiagnosed HIV infection Raquel Martin-Iguacel, Denmark	12:59 - 13:06
BPD3/1	HIV infection in individuals seeking post-exposure prophylaxis (PEP): a retrospective data linkage study Frédérique Hovaguimian, Switzerland	13:06 - 13:13
BPD3/5	Effect of noresthisterone, combined contraceptive vaginal ring (CCVR) and COCPs on HIV cervical target cells in adolescent girls: a randomized crossover study Iyaloo Konstantinus, South Africa	13:13 - 13:20

Parallel session
14:00 - 16:00

San Francisco

PS11, Where do we stand with HIV prevention today?

Session interpreted in Russian

Access to the webcasted session:

[ML1](http://resourcelibrary.eacs.cyim.com?mediald=78772)
[PS11/1](http://resourcelibrary.eacs.cyim.com?mediald=78774)
[PS11/2](http://resourcelibrary.eacs.cyim.com?mediald=78775)

[PS11/5](http://resourcelibrary.eacs.cyim.com?mediald=78786)

[PS11/7](http://resourcelibrary.eacs.cyim.com?mediald=78813)

Chairs:

Diane Ponscarne, France
Ann Sullivan, United Kingdom

ML1	Combination prevention - The overview of what is being done in Europe Claudia Estcourt, United Kingdom	14:00 - 14:15
PS11/1	PrEP persistence and associated factors: an analysis from the ANRS Prevenir study Dominique Costagliola, France	14:15 - 14:30
PS11/2	Monitoring PrEP implementation in Belgium: national surveillance results, 2017-2018 Jessika Deblonde, Belgium	14:30 - 14:45
PS11/3	Awareness gaps on pre-exposure prophylaxis among late adolescents and young adults in the region characterised by high HIV prevalence and sexual violence Eyitayo Omolara Owolabi, South Africa	14:45 - 15:00
PS11/4	Risk factors for inadequate HIV and STI testing among German PrEP users Janna Seifried, Germany	15:00 - 15:15

Scientific Programme

PS11/5	Changes in bone mineral density over 2 years in men who have sex with men on tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis: longitudinal cohort data Andrew Carr, Australia	15:15 - 15:30
PS11/6	Can HIV epidemics be eliminated using PrEP? Sofia Jijon, France	15:30 - 15:45
PS11/7	Drop in HIV diagnoses among MSM in Paris: combined effect of PrEP, testing and political support to the communities Eve Plenel, France	15:45 - 16:00

Parallel session
14:00 - 16:00

Shanghai 1-2

PS12, Viral co-infection and liver disease

Access to the webcasted session:

[ML1](http://resourcelibrary.eacs.cyim.com?mediald=78776)
[PS12/1](http://resourcelibrary.eacs.cyim.com?mediald=78777)
[PS12/2](http://resourcelibrary.eacs.cyim.com?mediald=78778)
[PS12/3](http://resourcelibrary.eacs.cyim.com?mediald=78787)
[PS12/4](http://resourcelibrary.eacs.cyim.com?mediald=78788)

[PS12/5](http://resourcelibrary.eacs.cyim.com?mediald=78789)

[PS12/7](http://resourcelibrary.eacs.cyim.com?mediald=78815)

Chairs:

Sanjay Bhagani, United Kingdom
Milesz Parczewski, Poland

ML1	Micro-elimination of HCV - A reality? Graham Cooke, United Kingdom	14:00 - 14:15
PS12/1	"Giving HepC a place and letting it go again": response to a sexual risk reduction intervention in HIV/HCV co-infected men who have sex with men Patrizia Künzler-Heule, Switzerland	14:15 - 14:30
PS12/2	Impairment of CD8 T cell memory in DAA treated HCV/HIV co-infected patients Matthias Hoffmann, Switzerland	14:30 - 14:45
PS12/3	Evolution of non-invasive markers of liver fibrosis in HIV-hepatitis C virus (HCV) co-infection before and after sustained virologic response (SVR): results from the Canadian co-infection cohort Marina Klein, Canada	14:45 - 15:00
PS12/4	HIV/HBV coinfection in Spain: prevalence and clinical characteristics Juan Berenguer, Spain	15:00 - 15:15
PS12/5	Outcomes after switching from TDF to TAF in HIV/HBV-coinfected individuals with renal impairment: a nationwide cohort study Bernard Surial, Switzerland	15:15 - 15:30

Scientific Programme

PS12/6	Hepatic steatosis in HIV monoinfected individuals: which impact has baseline BMI and treatment with integrase inhibitors? Jenny Bischoff, Germany	15:30 - 15:45
PS12/7	Evolutive NAFLD predicts frailty in people living with HIV (PLWH) Jovana Milic, Italy	15:45 - 16:00

Parallel session
14:00 - 16:00

Boston 1-3

PS13, Liverpool/EACS pharmacology workshop - Pharmacology today and tomorrow

Access to the webcasted session:

[ML1](http://resourcelibrary.eacs.cyim.com?mediald=78780)
[ML2](http://resourcelibrary.eacs.cyim.com?mediald=78781)
[ML3](http://resourcelibrary.eacs.cyim.com?mediald=78782)
[ML4](http://resourcelibrary.eacs.cyim.com?mediald=78790)
[ML5](http://resourcelibrary.eacs.cyim.com?mediald=78791)
[PS13/1](http://resourcelibrary.eacs.cyim.com?mediald=78792)

[PS13/2](http://resourcelibrary.eacs.cyim.com?mediald=78816)

[PS13/3](http://resourcelibrary.eacs.cyim.com?mediald=78817)

Chairs:

Saye Khoo, United Kingdom
Catia Marzolini, Switzerland

ML1	Introduction Saye Khoo, United Kingdom Catia Marzolini, Switzerland	14:00 - 14:05
ML2	Long-acting antiretroviral drugs Marta Boffito, United Kingdom	14:05 - 14:30
ML3	Clinical case 1 - Complex DDIs José Moltó, Spain	14:30 - 14:50
ML4	Clinical case 2 - Administration of drugs through feeding tube & absorption/DDIs issues Ales Chrdle, Czech Republic	14:50 - 15:10
ML5	Clinical case 3 - Cancer drugs DDIs Caroline Solas, France	15:10 - 15:30
PS13/1	Safety and PK of subcutaneous GS-6207, a novel HIV-1 capsid inhibitor Rebecca Begley, United States	15:30 - 15:40
PS13/2	A multicentred randomised controlled open study of the utility and acceptability of a medicines optimisation review (MOR) toolkit compared to standard pharmaceutical care in HIV outpatients Jaime Vera, United Kingdom	15:40 - 15:50
PS13/3	Prevalence of potential drug-drug interactions in patients of the Swiss HIV cohort study in the era of HIV integrase inhibitors Elisabeth Deutschmann, Switzerland	15:50 - 16:00

Scientific Programme

Industry sponsored session
16:15 - 17:45

San Francisco

Industry sponsored session

(For more details, please visit the [conference website](https://eacs-conference2019.com/index.php?article_id=166))

Workshop/Symposium
17:45 - 19:15

Sydney

YING symposium - Growing your research

Convener: EACS
Session interpreted in Russian

Chairs:

Nathan Clumeck, Belgium
Annemarie Wensing, Netherlands

YING intro and how (not) to network	17:45 - 18:05
Casper Rokx, Netherlands	
Developing a good research question; how to search and some common pitfalls	18:05 - 18:25
Christoph Spinner, Germany	
	18:25 - 18:45
Anca Streinu-Cercel, Romania	
What's happening in clinical research on HIV/AIDS in Europe	18:45 - 18:55
Agnès Libois, Belgium	
Roundtable and discussion	18:55 - 19:15

Scientific Programme

Saturday, 09 November 2019

Meet-the-expert/Clinical cases
07:30 - 08:30

Montreal

Clinical cases II

Session interpreted in Russian

Chairs:

Hansjakob Furrer, Switzerland
David Jilich, Czech Republic

CC2/1	A case of rash in MSM patient - overlapping epidemics in Central and Eastern Europe can challenge a doctor Justyna Kowalska, Poland	07:30 - 07:50
CC2/2	Intestinal talaromycosis in an AIDS patient: a very rare presentation Sireethorn Nimitvilai, Thailand	07:50 - 08:10
CC2/3	Failure of daily PrEP with low peak levels of TDF/FTC with identification of the 184I mutation Benjamin Hampel, Switzerland	08:10 - 08:30

Roundtable discussion
08:30 - 09:45

Montreal

Roundtable discussion: UNAIDS goals after 2020 - What next?

Session interpreted in Russian

Access to the webcasted session:

[UNAIDS goals after 2020 - What next?](http://resourcelibrary.eacs.cyim.com?mediald=78820)

[Roundtable discussion: UNAIDS goals after 2020 - What next?](http://resourcelibrary.eacs.cyim.com?mediald=78821)

Chairs:

Valerie Delpech, United Kingdom

UNAIDS goals after 2020 - What next? Peter Ghys, Switzerland	08:30 - 08:40
Roundtable discussion: UNAIDS goals after 2020 - What next ? Nikos Dedes, Greece Peter Ghys, Switzerland Jean-Michel Molina, France Teymur Noori, Sweden Nicole Seguy, Denmark Liliya Ten, Kyrgyzstan Marco Vitoria, Switzerland	08:40 - 09:45

Scientific Programme

Workshop/Symposium
10:00 - 10:45

Montreal

Fast-track cities. Calculus for success: Fast-track cities on a pathway from 90-90-90 to getting to zero

Convener: IAPAC
Session interpreted in Russian

Access to the webcasted session:

[Equity-based data to support a strategic focus of HIV resource and programme prioritization](http://resourcelibrary.eacs.cyim.com?mediald=78823)

[Community engagement to generate demand for and deliver HIV and supportive services](http://resourcelibrary.eacs.cyim.com?mediald=78824)

[Addressing HIV and intersectional stigma as enemies of public health and barriers to progress](http://resourcelibrary.eacs.cyim.com?mediald=78825)
Question & answer period

Chairs:

Bertrand Audoin, France

Equity-based data to support a strategic focus of HIV resource and programme prioritization Philippe Bouvet de la Maisonneuve, France	10:00 - 10:06
Community engagement to generate demand for and deliver HIV and supportive services Olga Rudnieva, Ukraine	10:06 - 10:12
Addressing HIV and intersectional stigma as enemies of public health and barriers to progress Jorge Garrido, Spain	10:12 - 10:18
Mobilizing financial resources for sustained urban AIDS responses to support getting to zero Helen Corkin, United Kingdom	10:18 - 10:24
Question & answer period	10:24 - 10:44

Scientific Programme

Special session
11:00 - 12:45

Montreal

Status report and standard of care co-organised with the European Centre for Disease Prevention and Control (ECDC) and the British HIV Association (BHIVA)

Session interpreted in Russian

Access to the webcasted session:

[Tuberculosis](http://resourcelibrary.eacs.cyim.com?mediald=78829)

[Hepatitis](http://resourcelibrary.eacs.cyim.com?mediald=78830)

[BHIVA late presentation audit: What can we learn?](http://resourcelibrary.eacs.cyim.com?mediald=78831)

[Results of the European pilot audit on Hepatitis screening, prevention and management in people living with HIV](http://resourcelibrary.eacs.cyim.com?mediald=78832)

Chairs:

Nikoloz Chkhartishvili, Georgia

Cristiana Oprea, Romania

Chloe Orkin, United Kingdom

Tuberculosis	11:00 - 11:15
Cristiana Oprea, Romania	
Hepatitis	11:15 - 11:30
Mojca Maticic, Slovenia	
BHIVA late presentation audit: What can we learn?	11:30 - 11:45
David Chadwick, United Kingdom	
Pilot TB audit: Where are we?	11:45 - 11:55
Georg Behrens, Germany	
Results of the European pilot audit on Hepatitis screening, prevention and management in people living with HIV	11:55 - 12:05
Ann Sullivan, United Kingdom	
Panel discussion	12:05 - 12:35
Georg Behrens, Germany	
Nikoloz Chkhartishvili, Georgia	
Cristiana Oprea, Romania	
Chloe Orkin, United Kingdom	
Anastasia Pharris, Sweden	
Ann Sullivan, United Kingdom	
Elena Vovc, Denmark	

Ceremony
12:45 - 13:00

Montreal

Closing remarks

Session interpreted in Russian

Manuel Battegay, Local Conference Co-Chair

Jürgen Rockstroh, EACS President and Conference Co-Chair